<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001909.pub2" GROUP_ID="EPILEPSY" ID="772299081609544256" MERGED_FROM="" MODIFIED="2017-04-27 10:52:07 +0100" MODIFIED_BY="Ellen Dougan" REVIEW_NO="0011" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="14.0">
<COVER_SHEET MODIFIED="2017-04-26 16:25:09 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Lamotrigine add-on for drug-resistant partial epilepsy</TITLE>
<CONTACT>
<PERSON ID="4928" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sridharan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ramaratnam</LAST_NAME>
<SUFFIX/>
<POSITION>Director &amp; Senior Consultant</POSITION>
<EMAIL_1>rsridharan52@gmail.com</EMAIL_1>
<EMAIL_2>rsridharan@vsnl.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>The Nerve Centre</ORGANISATION>
<ADDRESS_1>5/1 Rajachar Street</ADDRESS_1>
<ADDRESS_2>T Nagar</ADDRESS_2>
<CITY>Chennai</CITY>
<ZIP>600017</ZIP>
<REGION>Tamil Nadu</REGION>
<COUNTRY CODE="IN">India</COUNTRY>
<PHONE_1>+91 44 28152265</PHONE_1>
<PHONE_2>+91 44 2815335</PHONE_2>
<FAX_1>+91 44 28153335</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-04-26 16:24:55 +0100" MODIFIED_BY="Rachael Kelly">
<PERSON ID="4928" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sridharan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ramaratnam</LAST_NAME>
<SUFFIX/>
<POSITION>Director &amp; Senior Consultant</POSITION>
<EMAIL_1>rsridharan52@gmail.com</EMAIL_1>
<EMAIL_2>rsridharan@vsnl.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>The Nerve Centre</ORGANISATION>
<ADDRESS_1>5/1 Rajachar Street</ADDRESS_1>
<ADDRESS_2>T Nagar</ADDRESS_2>
<CITY>Chennai</CITY>
<ZIP>600017</ZIP>
<REGION>Tamil Nadu</REGION>
<COUNTRY CODE="IN">India</COUNTRY>
<PHONE_1>+91 44 28152265</PHONE_1>
<PHONE_2>+91 44 2815335</PHONE_2>
<FAX_1>+91 44 28153335</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1309171501399297216125627086891" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Mariangela</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Panebianco</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>m.panebianco@liverpool.ac.uk</EMAIL_1>
<EMAIL_2>dott_mariangela@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Molecular and Clinical Pharmacology</DEPARTMENT>
<ORGANISATION>Institute of Translational Medicine, University of Liverpool</ORGANISATION>
<ADDRESS_1>Clinical Sciences Centre for Research and Education, Lower Lane</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L9 7LJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="555BA85182E26AA20187B7968786091D" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Anthony</FIRST_NAME>
<MIDDLE_INITIALS>G</MIDDLE_INITIALS>
<LAST_NAME>Marson</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Neurology</POSITION>
<EMAIL_1>a.g.marson@liverpool.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Molecular and Clinical Pharmacology</DEPARTMENT>
<ORGANISATION>Institute of Translational Medicine, University of Liverpool</ORGANISATION>
<ADDRESS_1>Clinical Sciences Centre for Research and Education, Lower Lane</ADDRESS_1>
<ADDRESS_2>Fazakerley</ADDRESS_2>
<CITY>Liverpool</CITY>
<ZIP>L9 7LJ</ZIP>
<REGION>Merseyside</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 151 529 5405</PHONE_1>
<PHONE_2>+44 151 529 5462</PHONE_2>
<FAX_1>+44 151 529 5465</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-12-09 11:04:51 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="28" MONTH="5" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="28" MONTH="5" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="5" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2017-04-26 16:25:09 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-04-26 16:25:09 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="4" YEAR="2017"/>
<DESCRIPTION>
<P>Declarations of interest section updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-04-26 16:11:00 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-04-26 16:11:00 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>Searches updated 28 May 2015. No new relevant studies were identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-04-26 16:10:57 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>Conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-10-24 12:07:40 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="1" YEAR="2010"/>
<DESCRIPTION>
<P>Searches updated 6th January 2010. Two new studies have been included (<A HREF="http://www.archie.cochrane.org/sections/documents/view?version=63636045659062352151100414113349&amp;format=REVMAN#STD-Naritoku-2007">Naritoku 2007</A> and <A HREF="http://www.archie.cochrane.org/sections/documents/view?version=63636045659062352151100414113349&amp;format=REVMAN#STD-Pi_x00f1_a_x002d_Garza-2008">Piña-Garza 2008</A>); the conclusions are unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-24 12:10:11 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-04-13 11:10:18 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="4" YEAR="2007"/>
<DESCRIPTION>
<P>Searches updated 25th April 2007. One new conference abstract (<LINK REF="STD-Carignani-2006" TYPE="STUDY">Carignani 2006</LINK>) has been added to the 'Studies Awaiting Classification' section. This will be assessed for inclusion at a later date.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-24 12:14:05 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="11" YEAR="2005"/>
<DESCRIPTION>
<P>We re-ran our search on 31 March 2005. One new study (<LINK REF="STD-Carignani-2004" TYPE="STUDY">Carignani 2004</LINK>) has been added to the 'studies awaiting assessment' section. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-12-09 11:01:45 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2015-12-09 11:01:45 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-12-09 11:01:45 +0000" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This review update was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Epilepsy Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-04-26 16:26:02 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-06-02 11:23:21 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-05-19 09:12:05 +0100" MODIFIED_BY="[Empty name]">Adding lamotrigine for drug-resistant partial epilepsy</TITLE>
<SUMMARY_BODY MODIFIED="2016-06-02 11:23:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>Epilepsy is a disorder in which unexpected electrical discharges from the brain cause seizures. Approximately one-third of patients with epilepsy continue to have seizures, despite treatment with presently used (older) antiepileptic drugs (AEDs). In addition, the older AEDs have a lot of adverse effects.</P>
<P>Therefore, the development of effective new therapies for the treatment of refractory seizures is of considerable importance. As a result, a range of new AEDs has been developed as 'add-on' treatments. Lamotrigine is one of these.</P>
<P>
<B>Aims of the review</B>
</P>
<P>This review aimed to determine the effects of lamotrigine on seizures, adverse effects, cognition (ability to learn and understand) and quality of life compared to placebo controls, when used as an add-on treatment for people with partial epilepsy that would not respond to existing AEDs.</P>
<P>For this update, we did not identify any new studies to add, and thus, the conclusions remain unchanged. The review included 14 randomised controlled trials with a total number of 1958 participants.</P>
<P>
<B>Results</B>
</P>
<P>Lamotrigine, used in combination with other AEDs in patients who have drug-resistant partial epilepsy can decrease the frequency of seizures further. However, adding lamotrigine to the usual treatment is more often associated with an increase in adverse effects such as unsteadiness (ataxia), dizziness, double vision (diplopia), and nausea.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>We assessed the trials with regards to risk of bias. Overall, we rated the quality of the evidence as high.</P>
<P>
<B>Conclusions</B>
</P>
<P>Further high-quality research is needed to fully evaluate the efficacy and tolerability of lamotrigine and compare it with other newer AEDs.</P>
<P>The evidence is current to 28 May 2015.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-06-08 12:13:09 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-05-19 09:10:48 +0100" MODIFIED_BY="[Empty name]">
<P>This is an updated version of the Cochrane review published in <I>The Cochrane Library</I> 2010, Issue 1.</P>
<P>Epilepsy is a common neurological disorder, affecting almost 0.5% to 1% of the population. For nearly 30% of these people, their epilepsy is refractory to currently available drugs. Pharmacological treatment remains the first choice to control epilepsy. Lamotrigine is one of the newer antiepileptic drugs and is the topic of this review. Lamotrigine in combination with other antiepileptic drugs (add-on) can reduce seizures, but with some adverse effects. The aim of this systematic review was to overview the current evidence for the efficacy and tolerability of lamotrigine when used as an adjunctive treatment for people with refractory partial epilepsy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-05-19 09:10:49 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the effects of lamotrigine on (1) seizures, (2) adverse effect profile, and (3) cognition and quality of life, compared to placebo controls, when used as an add-on treatment for people with refractory partial epilepsy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-05-19 09:10:52 +0100" MODIFIED_BY="[Empty name]">
<P>For the previous version of the review, the authors searched the Cochrane Epilepsy Group Specialized Register (January 2010), the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I> 2010, Issue 1), MEDLINE (1950 to January 2010), and reference lists of articles.</P>
<P>For this update, we searched the Cochrane Epilepsy Group Specialized Register (28 May 2015), CENTRAL (<I>The Cochrane Library</I> 2015, Issue 4), MEDLINE (Ovid, 1946 to May 2015), and reference lists of articles. We also contacted the manufacturers of lamotrigine (GlaxoSmithKline). No language restrictions were imposed.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-05-19 09:11:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised placebo-controlled trials of people with drug-resistant partial epilepsy of any age, in which an adequate method of concealment of randomisation was used. The studies were double-, single- or unblinded. For cross-over studies, the first treatment period was treated as a parallel trial. Eligible participants were adults or children with drug-resistant partial epilepsy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-05-19 09:11:32 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, two review authors independently assessed the trials for inclusion, and extracted data. Outcomes included 50% or greater reduction in seizure frequency, treatment withdrawal (any reason), adverse effects, effects on cognition and quality of life. Primary analyses were by intention-to-treat. Sensitivity best and worse case analyses were undertaken to account for missing outcome data. Pooled Risk Ratios (RR) with 95% confidence intervals (95% Cl) were estimated for the primary outcomes of seizure frequency and treatment withdrawal. For adverse effects, pooled RRs and 99% Cls were calculated.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-06-08 12:13:09 +0100" MODIFIED_BY="[Empty name]">
<P>We did not identify any new studies for this update, therefore, the results are unchanged.</P>
<P>For the previous version of the review, the authors found five parallel add-on studies and eight cross-over studies in adults or children with refractory focal epilepsy, and one parallel add-on study with a responder-enriched design in infants. In total, these 14 studies included 1958 participants (38 infants, 199 children, and 1721 adults). Baseline phases ranged from 4 to 12 weeks; treatment phases from 8 to 36 weeks. Overall, eleven studies (n = 1243 participants) were rated as having a low risk of bias, and three (n = 715 participants) had un unclear risk of bias due to lack of reported information around study design. Effective blinding of studies was reported in three studies (n = 504 participants). The overall risk ratio (RR) for 50% or greater reduction in seizure frequency was 1.80 (95% CI 1.45 to 2.23; 12 RCTs) for twelve studies (n = 1322 participants, adults and children) indicating that lamotrigine was significantly more effective than placebo in reducing seizure frequency. The overall RR for treatment withdrawal (for any reason) was 1.11 (95% CI 0.90 to 1.36; 14 RCTs) for fourteen studies (n = 1958 participants). The adverse events significantly associated with lamotrigine were: ataxia, dizziness, diplopia, and nausea. The RR of these adverse effects were as follows: ataxia 3.34 (99% Cl 2.01 to 5.55; 12 RCTs; n = 1524); dizziness 2.00 (99% Cl 1.51 to 2.64;13 RCTs; n = 1767); diplopia 3.79 (99% Cl 2.15 to 6.68; 3 RCTs; n = 943); nausea 1.81 (99% Cl 1.22 to 2.68; 12 RCTs; n = 1486). The limited data available precluded any conclusions about effects on cognition and quality of life. No important heterogeneity between studies was found for any of the outcomes. Overall, we assessed the evidence as high to moderate quality, due to incomplete data for some outcomes.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-05-19 09:12:03 +0100" MODIFIED_BY="[Empty name]">
<P>Lamotrigine as an add-on treatment for partial seizures appears to be effective in reducing seizure frequency, and seems to be fairly well tolerated. However, the trials were of relatively short duration and provided no evidence for the long-term. Further trials are needed to assess the long-term effects of lamotrigine, and to compare it with other add-on drugs.</P>
<P>Since we did not find any new studies, our conclusions remain unchanged.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-06-08 12:32:06 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-06-08 12:32:06 +0100" MODIFIED_BY="[Empty name]">
<P>This review is an update of a previously published review in <I>The Cochrane Library</I> 2010, Issue 1. </P>
<CONDITION MODIFIED="2016-06-08 11:39:42 +0100" MODIFIED_BY="[Empty name]">
<P>Epilepsy is characterised by recurrent and unprovoked seizures, constituting a transient sign and symptom of abnormal, excessive electrical activity in the cerebral cortex (<LINK REF="REF-Fisher-2005" TYPE="REFERENCE">Fisher 2005</LINK>). Epilepsy is one the most common serious neurological conditions worldwide, with significant psychosocial and physical morbidity. Its management requires expertise and good pharmacological knowledge of the available options (<LINK REF="REF-Lyer-2014" TYPE="REFERENCE">Lyer 2014</LINK>). The condition affects approximately 50 million people worldwide. The total annual cost in Europe is approximately 15.5 billion Euros (<LINK REF="REF-Mula-2013" TYPE="REFERENCE">Mula 2013</LINK>). Between 2% and 3% of the population will be given a diagnosis of epilepsy at some time in their lives (<LINK REF="REF-Hauser-1993" TYPE="REFERENCE">Hauser 1993</LINK>), the majority of whom will become seizure free. However, up to 30% will continue to have seizures, refractory to treatment with adequate doses of antiepileptic drugs (AEDs), which are often given in combination (<LINK REF="REF-Cockerell-1995" TYPE="REFERENCE">Cockerell 1995</LINK>). There is no internationally accepted definition of "drug-resistant". For the purposes of this review, people will be considered to be drug-resistant if they have failed to respond to a minimum of two AEDs, given as monotherapy. The majority of drug-resistant people have partial onset (also called focal or localization related) seizures. In other words, seizures start in one part of the brain and during the course of the seizure, the abnormal electrical activity remains localised or spreads to other parts of the brain. Partial seizures can be divided into three types: simple partial; complex partial, and secondarily generalized tonic-clonic seizures (<LINK REF="REF-Commission-1989" TYPE="REFERENCE">Commission 1989</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-06-08 11:41:33 +0100" MODIFIED_BY="[Empty name]">
<P>Although more than a dozen new antiepileptic drugs (AEDs) have entered the market since 1993, up to 30% of patients remain refractory to current treatments. Thus, a concerted effort continues to identify and develop new therapies that will help these patients (<LINK REF="REF-Barker_x002d_Haliski-2014" TYPE="REFERENCE">Barker-Haliski 2014</LINK>). Pharmacological treatment remains the first choice for controlling epilepsy (<LINK REF="REF-Loscher-2002" TYPE="REFERENCE">Loscher 2002</LINK>), although recent decades have seen advances in vagal stimulation (<LINK REF="REF-Panebianco-2015" TYPE="REFERENCE">Panebianco 2015</LINK>), and surgery (<LINK REF="REF-West-2015" TYPE="REFERENCE">West 2015</LINK>). Given that our standard drugs (e.g. carbamazepine, phenytoin, valproate) do not leave all people seizure free and are not without adverse effects, over the past 15 to 20 years, there has been renewed interest in the development of newer AEDs. One such drug is lamotrigine (LTG).</P>
<P>Lamotrigine is a novel AED, widely used in the treatment of epilepsy as adjunctive treatment for partial, secondarily generalised, and tonic-clonic seizures in patients with refractory epilepsy, and bipolar disorder (<LINK REF="STD-Yamamoto-2012" TYPE="STUDY">Yamamoto 2012</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-05-19 09:13:00 +0100" MODIFIED_BY="[Empty name]">
<P>Lamotrigine was approved by the Food and Drug Administration in the USA in 1994 for use in partial-onset seizures. It was ultimately approved for monotherapy in 1998. Lamotrigine is effective against a broad spectrum of seizure types and has a favourable metabolic profile. It has gained widespread use in the USA as both an immediate and an extended-release agent (<LINK REF="REF-Moore-2012" TYPE="REFERENCE">Moore 2012</LINK>). Lamictal (GlaxoSmithKline) is considered the reference drug (<LINK REF="STD-Girolineto-2012" TYPE="STUDY">Girolineto 2012</LINK>). In vitro pharmacological studies suggest that the main mechanism of action of lamotrigine is to inhibit voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory aminoacids, e.g. glutamate and aspartate (<LINK REF="REF-Leach-1995" TYPE="REFERENCE">Leach 1995</LINK>). Lamotrigine has been demonstrated to be effective as both an antiepileptic drug and a mood stabiliser (<LINK REF="REF-Vajda-2013" TYPE="REFERENCE">Vajda 2013</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-06-08 12:32:06 +0100" MODIFIED_BY="[Empty name]">
<P>In this review, we summarise evidence from randomised controlled trials where the efficacy and tolerability of lamotrigine for people with drug-resistant partial epilepsy have been investigated, in order to aid clinical decision-making when considering LTG as add-on treatment within this population.</P>
<P>Antiepileptic drugs may impair people's cognitive abilities, and in this review, we include outcomes that assess cognitive effects. In addition, we have chosen to include quality-of life outcomes, to assess the global impact of this drug on people's well-being.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-12-09 10:50:22 +0000" MODIFIED_BY="[Empty name]">
<P>To determine the effects of lamotrigine on (1) seizures, (2) adverse effect profile, and (3) cognition and quality of life, compared to controls, when used as an add-on treatment for people with refractory partial epilepsy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-06-08 11:50:03 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-05-29 13:56:18 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-05-19 09:13:14 +0100" MODIFIED_BY="[Empty name]">
<P>We included trials that met all the following criteria:</P>
<OL>
<LI>Randomised controlled trials, in which an adequate method of concealment of randomisation was used (e.g. allocation of sequentially sealed packages of medication, sealed opaque envelopes, telephone randomisation);</LI>
<LI>Double-, single-blind trials and unblinded trials;</LI>
<LI>Placebo-controlled trials;</LI>
<LI>Parallel group and cross-over studies. For cross-over studies, the first treatment period was treated as a parallel trial, for the purposes of analysis of efficacy and safety data (i.e. only data from the first treatment period was used).</LI>
</OL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-05-19 09:13:15 +0100" MODIFIED_BY="[Empty name]">
<P>Individuals of any age with partial epilepsy (i.e. experiencing simple partial, complex partial, or secondarily generalized tonic-clonic seizures) who had failed to respond to at least one AED (drug-resistant epilepsy).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-05-19 09:13:19 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>The treatment group received lamotrigine in addition to conventional antiepileptic drug (AED) treatment.</LI>
<LI>The control group received conventional AED treatment plus a matched placebo, or 'no treatment' control.</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-05-29 13:56:18 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">
<I>Primary outcome</I>
</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Greater than 50% reduction in seizure frequency</HEADING>
<P>The primary outcome was the proportion of participants with a 50% or greater reduction in seizure frequency during the treatment period, compared to the pre-randomisation baseline frequency. We chose this outcome as it is commonly reported in this type of study and can be calculated for studies that do not report this outcome, provided that baseline seizure data were recorded.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Secondary outcomes</I>
</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Treatment withdrawal</HEADING>
<P>The proportion of participants who had treatment withdrawn during the course of the treatment period was chosen as a measure of global effectiveness. Treatment may be withdrawn due to adverse effects, lack of efficacy, or a combination, and this is an outcome to which the individual makes a direct contribution. However, in studies of relatively short duration, such as studies that would be included in this review, adverse effects were likely to be the main reason for treatment withdrawal.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>(a) The proportion of participants experiencing any of the following adverse effects, which we considered to be the most common and important adverse effects of AEDs:</P>
<OL>
<LI>ataxia;</LI>
<LI>dizziness;</LI>
<LI>fatigue;</LI>
<LI>nausea;</LI>
<LI>somnolence;</LI>
<LI>diplopia;</LI>
<LI>headache.</LI>
</OL>
<P>(b) The proportion of participants who experienced the five most common adverse effects in a study, if different from those stated above.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cognitive effects</HEADING>
<P>The difference between intervention and control group(s) means for cognitive assessments used in the individual studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>The difference between intervention and control group(s) means for quality of life (QOL) assessments used in the individual studies.</P>
</SUBSECTION>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-05-29 13:53:10 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2016-05-29 13:53:10 +0100" MODIFIED_BY="[Empty name]">
<P>For the previous version of the review, the authors searched the following databases for relevant studies (<LINK REF="REF-Ramaratnam-2001" TYPE="REFERENCE">Ramaratnam 2001</LINK>):</P>
<OL>
<LI>The Cochrane Epilepsy Group Specialized Register (January 2010).</LI>
<LI>The Cochrane Central Register of Controlled Trials (<I>The Cochrane Library</I> Issue 1, 2010).</LI>
<LI>MEDLINE (1950 to January 2010).</LI>
</OL>
<P>For this update, we searched the following databases for relevant studies:</P>
<OL>
<LI>The Cochrane Epilepsy Group Specialized Register (28 May 2015), using the strategy outlined in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I> 2015, Issue 4), using the strategy outlined in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</LI>
<LI>MEDLINE (Ovid, 1946 to 28 May 2015), using the strategy outlined in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</LI>
</OL>
<P>We imposed no language restrictions. We tailored searches to individual databases, and adapted from those used in the previous review.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-05-19 09:15:11 +0100" MODIFIED_BY="[Empty name]">
<P>For the original review and this update, we checked reference lists of reviews and retrieved articles for additional studies, and performed citation searches on key articles. We contacted experts in the field for unpublished and ongoing trials, and authors and manufacturers of lamotrigine (GlaxoSmithKline) for additional information.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-06-08 11:50:03 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-05-19 09:15:15 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, two review authors (SR and MP) independently assessed trials for inclusion. Any disagreements were resolved by discussion with a third author (AM). Two review authors (SR and MP) independently extracted data and assessed the risk of bias for included trials; again, disagreements were resolved by mutual discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-06-02 12:34:26 +0100" MODIFIED_BY="[Empty name]">
<P>We extracted the following data for each trial, using a data extraction form:</P>
<SUBSECTION>
<HEADING LEVEL="3">(1) Methods and trial design:</HEADING>
<P>(a) Method of randomisation.<BR/>(b) Method of allocation concealment.<BR/>(c) Method of blinding.<BR/>(d) Whether any participants had been excluded from reported analyses.<BR/>(e) Duration of baseline period.<BR/>(f) Duration of treatment period.<BR/>(g) Dose(s) of LTG tested.<BR/>(h) Information on Sponsorship and Funding.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(2) Participant and demographic information:</HEADING>
<P>(a) Total number of participants allocated to each treatment group.<BR/>(b) Age and sex.<BR/>(c) Number with partial and generalized epilepsy.<BR/>(d) Seizure types.<BR/>(e) Seizure frequency during the baseline period.<BR/>(f) Number of background drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>We recorded the number of participants who experienced each outcome (<I>see</I> <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>) per randomised group, and contacted authors of trials for any missing information.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-06-08 11:49:21 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (SR and MP) independently assessed the risk of bias for each trial, using the Cochrane 'Risk of bias' tool as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We discussed and resolved disagreements. We completed a 'Risk of bias' table for each included study in RevMan (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We rated all included studies as having a low, high or unclear risk of bias on six domains applicable to randomised controlled trials: randomisation method, allocation concealment, blinding methods, incomplete outcome data, selective outcome reporting, and other sources of bias. We created 'Summary of findings' tables, using GRADEpro and the GRADE approach for assessing the quality of evidence (<LINK REF="REF-GRADEpro-2014" TYPE="REFERENCE">GRADEpro 2014</LINK>)</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-06-08 11:50:03 +0100" MODIFIED_BY="[Empty name]">
<P>We analysed the primary outcome of seizure reduction as a binary outcome and presented it as a risk ratio. We also analysed secondary outcomes, including treatment withdrawal and adverse effects as binary outcomes and presented risk ratio. We had also planned to present cognitive effects and quality of life as continuous outcomes via mean differences if the same measurement scales were used or via standardised mean differences if different measurement scales were used to measure the same outcome. However, due to the limited amount of data available for these outcomes, we have presented these outcomes in a narrative discussion</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-05-19 09:15:38 +0100" MODIFIED_BY="[Empty name]">
<P>We included eight cross-over studies in the review. We analysed data from these studies from the first treatment period only; we analysed parallel and cross-over design studies in separate subgroups.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-05-19 09:15:39 +0100" MODIFIED_BY="[Empty name]">
<P>We sought missing data by contacting the study authors. We carried out intention-to-treat (ITT), best case and worst case analysis on the primary outcome to account for any missing data (see <LINK TAG="DATA_SYNTHESIS" TYPE="SECTION">Data synthesis</LINK>). We presented all analyses in the main report.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-05-24 15:39:19 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed clinical heterogeneity by comparing the distribution of important participant factors between trials (e.g. age, seizure type, duration of epilepsy, number of antiepileptic drugs taken at time of randomisation), and trial factors (e.g. randomisation concealment, blinding, losses to follow up). We examined statistical heterogeneity using a Chi² test and I² statistic. When we found no significant heterogeneity (P &lt; 0.10), we used a fixed-effect model. Had we found heterogeneity (&gt; 50%), we had planned to use a random-effects model for the analysis.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-05-19 09:15:50 +0100" MODIFIED_BY="[Empty name]">
<P>We requested protocols for all included studies to enable a comparison of outcomes of interest. If outcome reporting bias was suspected for any included study, we had planned to further investigate using the ORBIT matrix system (<LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>). We had planned an examination of asymmetry funnel plots to establish publication bias, but such an assessment was not possible due to the small number of studies included in the review.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-06-02 11:42:56 +0100" MODIFIED_BY="[Empty name]">
<P>We used a fixed-effect model meta-analysis to synthesise the data. We measured the effect of each comparison on our preset primary and secondary outcomes, if data were available. Comparisons we expected to carry out included:</P>
<OL>
<LI>usual treatment plus lamotrigine versus usual treatment plus placebo</LI>
<LI>usual treatment plus lamotrigine versus no treatment</LI>
<LI>usual treatment plus lamotrigine versus usual treatment</LI>
</OL>
<P>Our preferred estimator for all binary outcomes was the Mantel-Haenzsel Risk Ratio (RR). For the outcomes 50% or greater reduction in seizure frequency and treatment withdrawal, we used 95% confidence intervals (Cls). For individual adverse effects we used 99% Cls to make an allowance for multiple testing.<BR/>Our analyses included all participants in the treatment groups to which they had been allocated following randomisation.</P>
<P>For the efficacy outcome (50% or greater reduction in seizure frequency) we undertook three analyses:</P>
<P>(a) Primary (intention-to-treat) analysis<BR/>Participants not completing follow-up or with inadequate seizure data were assumed to be non-responders. To test the effect of this assumption, we undertook the following sensitivity analyses. Analysis by ITT was done where this was reported by the included studies.</P>
<P>(b) Worst case analysis<BR/>Participants not completing follow-up or with inadequate seizure data were assumed to be non-responders in the lamotrigine group, and responders in the placebo group.</P>
<P>(c) Best case analysis<BR/>Participants not completing follow-up or with inadequate seizure data were assumed to be responders in the lamotrigine group, and non-responders in the placebo group.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-05-19 09:16:48 +0100" MODIFIED_BY="[Empty name]">
<P>We considered adults and children and doses in our subgroup analyses. We performed a subgroup analysis for adverse events.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-05-19 09:16:48 +0100" MODIFIED_BY="[Empty name]">
<P>We had intended to carry out sensitivity analyses if peculiarities were found between study quality, characteristics of participants, interventions and outcomes.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-06-08 12:13:20 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-05-29 16:42:07 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2016-05-19 09:16:54 +0100" MODIFIED_BY="[Empty name]">
<P>The latest search (carried out 28 May 2015) identified 141 records from the databases outlined above. We screened 96 records after duplicates were removed for inclusion in the review. We excluded 82 at this point, and requested 14 full-text articles to assess for eligibility. We contacted authors of these trials for more information, providing their contact details were available. Following this, we excluded all 14 studies (please see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for reason of exclusion). Thus, no new studies were included in this review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-05-29 16:42:07 +0100" MODIFIED_BY="[Empty name]">
<P>We did not find any new studies for this update. </P>
<P>In the previous version of this review, the authors included 14 randomised controlled trials that investigated the use of add-on lamotrigine compared to placebo, in 1958 participants with uncontrolled partial seizures (38 infants, 199 children, and 1721 adults). Trial characteristics are summarised below. For further information on each trial, please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>The 14 studies included five parallel group studies (<LINK REF="STD-Baulac-2010" TYPE="STUDY">Baulac 2010</LINK>; <LINK REF="STD-Duchowny-1999" TYPE="STUDY">Duchowny 1999</LINK>; <LINK REF="STD-Matsuo-1993" TYPE="STUDY">Matsuo 1993</LINK>; <LINK REF="STD-Naritoku-2007" TYPE="STUDY">Naritoku 2007</LINK>; <LINK REF="STD-Schachter-1995" TYPE="STUDY">Schachter 1995</LINK>); one parallel group study in infants with a responder-enriched design, in which all patients received adjunctive lamotrigine during an open-label phase and those who had a 40% or greater reduction in the frequency of partial seizures during the last four weeks were randomly assigned to double-blind treatment for up to eight weeks with continued lamotrigine or placebo (<LINK REF="STD-Pi_x00f1_a_x002d_Garza-2008" TYPE="STUDY">Piña-Garza 2008</LINK>); and eight cross-over studies (<LINK REF="STD-Binnie-1989" TYPE="STUDY">Binnie 1989</LINK>; <LINK REF="STD-Boas-1996" TYPE="STUDY">Boas 1996</LINK>; <LINK REF="STD-Jawad-1989" TYPE="STUDY">Jawad 1989</LINK>; <LINK REF="STD-Loiseau-1990" TYPE="STUDY">Loiseau 1990</LINK>; <LINK REF="STD-Messenheimer-1994" TYPE="STUDY">Messenheimer 1994</LINK>; <LINK REF="STD-Schapel-1993" TYPE="STUDY">Schapel 1993</LINK>; <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>; <LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>). All the studies but two recruited adults; <LINK REF="STD-Duchowny-1999" TYPE="STUDY">Duchowny 1999</LINK> recruited only children, and <LINK REF="STD-Pi_x00f1_a_x002d_Garza-2008" TYPE="STUDY">Piña-Garza 2008</LINK> enrolled only infants aged one to 24 months of age. One trial used extended-release formulation of lamotrigine (<LINK REF="STD-Naritoku-2007" TYPE="STUDY">Naritoku 2007</LINK>), while the others used immediate-release formulations. In general, the individuals included in these studies had at least three to four partial seizures a month, despite therapy with a stable AED regime consisting of two or three AEDs, which were appropriate for the type of epilepsy, and were given in adequate doses. </P>
<P>Almost all studies excluded people with: intellectual disabilities, progressive neurological disease, major psychiatric problems, associated pseudo seizures, newly-diagnosed epilepsy, status epilepticus in the 24 weeks preceding the trial, associated systemic diseases, abnormal laboratory investigations not explained by enzyme induction by AEDs, a history of non-compliance, failure to keep reliable records of seizures or adverse effects, irregular clinic visits, recent use of any other investigational AED, abuse of alcohol or other prescription or non-prescription drugs; people receiving chronic medication, especially antipsychotic drugs, women who were pregnant or at risk of pregnancy, lactating women. For the cross-over studies, participants were not randomised to a single dose, but took a range of doses, depending on their clinical response and the concurrent administration of other AEDs. Use of valproate was not permitted in three studies (<LINK REF="STD-Matsuo-1993" TYPE="STUDY">Matsuo 1993</LINK>; <LINK REF="STD-Messenheimer-1994" TYPE="STUDY">Messenheimer 1994</LINK>; <LINK REF="STD-Schachter-1995" TYPE="STUDY">Schachter 1995</LINK>), two excluded people on valproate monotherapy (<LINK REF="STD-Schapel-1993" TYPE="STUDY">Schapel 1993</LINK>; <LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>), while others used lower dosages of lamotrigine for people on valproate. One parallel study tested doses of 300 mg and 500 mg of lamotrigine per day (<LINK REF="STD-Matsuo-1993" TYPE="STUDY">Matsuo 1993</LINK>), whereas the others tested a range of doses between 75 mg and 600 mg per day (median between 200 mg and 400 mg/day). The length of the treatment period varied from eight to 24 weeks.</P>
<P>All studies were published as full articles, except <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>, which was only published as an abstract. All studies, except <LINK REF="STD-Baulac-2010" TYPE="STUDY">Baulac 2010</LINK> (which was sponsored by Pfizer Inc), were sponsored by GlaxoSmithKline, manufacturers of lamotrigine, as part of their pre-licensing programme.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-05-19 09:17:36 +0100" MODIFIED_BY="[Empty name]">
<P>In this update, we excluded 14 studies for the following reasons: four studies were not randomised trials; five studies did not study an eligible population; study results were not available for three studies; one study did not include LTG as part of the add-on therapy; and one study was not a placebo-controlled trial. The details of these studies are given in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-06-08 12:13:20 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for a summary of the risk of bias in each included study. Each study was allocated an overall rating for risk of bias: low, high, or unclear. See below for specific domain ratings.</P>
<ALLOCATION MODIFIED="2016-06-08 12:13:20 +0100" MODIFIED_BY="[Empty name]">
<P>We rated the method by which allocation was randomised as having a low risk of bias in eleven trials (n = 1243 participants), because they used a computer-generated randomisation schedule or random number tables (<LINK REF="STD-Binnie-1989" TYPE="STUDY">Binnie 1989</LINK>; <LINK REF="STD-Boas-1996" TYPE="STUDY">Boas 1996</LINK>; <LINK REF="STD-Duchowny-1999" TYPE="STUDY">Duchowny 1999</LINK>; <LINK REF="STD-Jawad-1989" TYPE="STUDY">Jawad 1989</LINK>; <LINK REF="STD-Loiseau-1990" TYPE="STUDY">Loiseau 1990</LINK>; <LINK REF="STD-Matsuo-1993" TYPE="STUDY">Matsuo 1993</LINK>; <LINK REF="STD-Messenheimer-1994" TYPE="STUDY">Messenheimer 1994</LINK>; <LINK REF="STD-Schachter-1995" TYPE="STUDY">Schachter 1995</LINK>; <LINK REF="STD-Schapel-1993" TYPE="STUDY">Schapel 1993</LINK>; <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>; <LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>). The investigators did not provide clear methods In three trials (n = 715 participants), which were rated as unclear (<LINK REF="STD-Baulac-2010" TYPE="STUDY">Baulac 2010</LINK>; <LINK REF="STD-Naritoku-2007" TYPE="STUDY">Naritoku 2007</LINK>; <LINK REF="STD-Pi_x00f1_a_x002d_Garza-2008" TYPE="STUDY">Piña-Garza 2008</LINK>). For sequence generation, we rated the same 11 studies as having a low risk of bias because they dispensed sequentially numbered packages to each participant, and random permuted blocks were used to generate the allocation sequence. We rated three studies (n = 715 participants) as unclear due to a lack of details on the methods used (<LINK REF="STD-Baulac-2010" TYPE="STUDY">Baulac 2010</LINK>; <LINK REF="STD-Naritoku-2007" TYPE="STUDY">Naritoku 2007</LINK>; <LINK REF="STD-Pi_x00f1_a_x002d_Garza-2008" TYPE="STUDY">Piña-Garza 2008</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-06-08 12:12:49 +0100" MODIFIED_BY="[Empty name]">
<P>We rated three studies (n = 504 participants) as having a low risk of bias for this particular domain because participants, parents and investigators were blinded (<LINK REF="STD-Binnie-1989" TYPE="STUDY">Binnie 1989</LINK>; <LINK REF="STD-Jawad-1989" TYPE="STUDY">Jawad 1989</LINK>; <LINK REF="STD-Schachter-1995" TYPE="STUDY">Schachter 1995</LINK>). We judged blinding of participants as unclear in ten papers (n = 1373 participants) because no details of the method of blinding were provided (<LINK REF="STD-Baulac-2010" TYPE="STUDY">Baulac 2010</LINK>; <LINK REF="STD-Boas-1996" TYPE="STUDY">Boas 1996</LINK>; <LINK REF="STD-Duchowny-1999" TYPE="STUDY">Duchowny 1999</LINK>; <LINK REF="STD-Loiseau-1990" TYPE="STUDY">Loiseau 1990</LINK>; <LINK REF="STD-Matsuo-1993" TYPE="STUDY">Matsuo 1993</LINK>; <LINK REF="STD-Messenheimer-1994" TYPE="STUDY">Messenheimer 1994</LINK>; <LINK REF="STD-Naritoku-2007" TYPE="STUDY">Naritoku 2007</LINK>; <LINK REF="STD-Pi_x00f1_a_x002d_Garza-2008" TYPE="STUDY">Piña-Garza 2008</LINK>; <LINK REF="STD-Schapel-1993" TYPE="STUDY">Schapel 1993</LINK>; <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>). One study (n = 81 participants) was rated as high risk of bias because patients and investigators were able to identify the lamotrigine treatment (<LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-06-08 12:12:53 +0100" MODIFIED_BY="[Empty name]">
<P>We rated all the included studies, except one (<LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>) (n = 1877 participants), as having a low risk of bias for this domain as minimal missing data were reported; either intention-to-treat analysis was employed, or there were no concerns of missing data having an effect on the overall outcome estimate. <LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK> was rated as unclear risk of bias because participants who discontinued prematurely did not complete the HRQOL measure at the time of discontinuation.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-05-19 09:18:00 +0100" MODIFIED_BY="[Empty name]">
<P>We requested the protocols for all included studies to compare a priori methods and outcomes to the published report, but none of the protocols for the included studies were available. We rated all included studies as low risk of bias for this domain as there was no suspicion of selective outcome reporting bias. All expected outcomes were reported in each of the publications.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-05-19 09:18:02 +0100" MODIFIED_BY="[Empty name]">
<P>All these studies, except one (<LINK REF="STD-Baulac-2010" TYPE="STUDY">Baulac 2010</LINK>, which was sponsored by Pfizer Inc.), were sponsored by GlaxoSmithKline, the manufacturers of the LTG, and therefore, we rated all but one study as having an unclear risk of bias for this domain.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-06-08 12:13:03 +0100" MODIFIED_BY="[Empty name]">
<P>For the cross-over trials, we analysed data from the first treatment phase for the efficacy, treatment, withdrawal, and adverse effects. These data were unpublished and obtained from Glaxo Wellcome, the sponsors of all but one study (<LINK REF="STD-Baulac-2010" TYPE="STUDY">Baulac 2010</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary Outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Greater than 50% reduction in seizure frequency</HEADING>
<P>A Chi² test for responses to lamotrigine indicated no significant heterogeneity between trials (Chi² = 11.02; df = 11; P = 0.44; I² = 0%), so a fixed-effect model was used to measure efficacy.</P>
<P>For twelve studies (n = 1322 participants, adults and children), the RR was 1.80; 95% CI 1.45 to 2.23 for any dose of lamotrigine added to regular anti-epileptic drug therapy versus placebo. The RR from eight cross-over studies (N = 382 participants) was 2.58; 95% CI 1.44 to 4.61 (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).The RR for the best case and worst case scenarios were RR 2.88 (95% CI 2.36 to 3.50) and RR 0.97 (95% CI 0.82 to 1.15) respectively (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>The RR for a daily dose of 300 mg of lamotrigine was 1.23; 95% CI 0.57 to 2.67; the RR was 2.13; 95% CI 1.08 to 4.20 for lamotrigine 500 mg per day, compared to placebo (<LINK REF="STD-Matsuo-1993" TYPE="STUDY">Matsuo 1993</LINK>). For children, the RR was 2.64; 95% CI 1.59 to 4.38 (<LINK REF="STD-Duchowny-1999" TYPE="STUDY">Duchowny 1999</LINK>).</P>
<P>We could not calculate responder rates for <LINK REF="STD-Schachter-1995" TYPE="STUDY">Schachter 1995</LINK> because baseline seizure counts were not obtained, or for the infants in <LINK REF="STD-Pi_x00f1_a_x002d_Garza-2008" TYPE="STUDY">Piña-Garza 2008</LINK>, where the primary end point was exit due to treatment failure,</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Treatment withdrawal</HEADING>
<P>Fourteen studies (n = 1958 participants) were included in this analysis. The overall RR for treatment withdrawal for any reason was (RR 1.11; 95% CI 0.90 to 1.36); thus there was insufficient evidence to conclude that participants were more likely to discontinue lamotrigine than placebo (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>We obtained the following data: 186 participants withdrew from treatment and 77 participants withdrew from control groups in parallel studies in adults (<LINK REF="STD-Baulac-2010" TYPE="STUDY">Baulac 2010</LINK>, <LINK REF="STD-Matsuo-1993" TYPE="STUDY">Matsuo 1993</LINK>, <LINK REF="STD-Naritoku-2007" TYPE="STUDY">Naritoku 2007</LINK>, <LINK REF="STD-Schachter-1995" TYPE="STUDY">Schachter 1995</LINK>); 14 participants withdrew from treatment and 18 from control groups in a parallel study in children (<LINK REF="STD-Duchowny-1999" TYPE="STUDY">Duchowny 1999</LINK>); 19 participants withdrew from treatment and 10 participants withdrew from control groups in cross-over studies in adults (<LINK REF="STD-Binnie-1989" TYPE="STUDY">Binnie 1989</LINK>, <LINK REF="STD-Boas-1996" TYPE="STUDY">Boas 1996</LINK>, <LINK REF="STD-Jawad-1989" TYPE="STUDY">Jawad 1989</LINK>, <LINK REF="STD-Loiseau-1990" TYPE="STUDY">Loiseau 1990</LINK>, <LINK REF="STD-Messenheimer-1994" TYPE="STUDY">Messenheimer 1994</LINK>, <LINK REF="STD-Schapel-1993" TYPE="STUDY">Schapel 1993</LINK>, <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>, <LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>); 11 participants withdrew from treatment and 16 withdrew from control groups in a parallel study in infants (<LINK REF="STD-Pi_x00f1_a_x002d_Garza-2008" TYPE="STUDY">Piña-Garza 2008</LINK>).</P>
<P>Insufficient data were available to undertake the planned dose-response subgroup analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>In addition to reports of ataxia, dizziness, fatigue, and nausea, some studies reported somnolence, diplopia and headache among the five most common adverse effects and are included in the analysis. Ataxia, dizziness, diplopia, and nausea were significantly more likely with lamotrigine. The RR for individual adverse effects were:</P>
<OL>
<LI>ataxia - RR 3.34; (99% CI 2.01 to 5.55) (12 studies, 1524 participants, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>);</LI>
<LI>dizziness - RR 2.00 (99% CI 1.51 to 2.64) (13 studies, 1767 participants, <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>);</LI>
<LI>fatigue - RR 0.82 (99% CI 0.55 to 1.22) (12 studies, 1551 participants, <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>);</LI>
<LI>nausea - RR 1.81(99% CI 1.22 to 2.68) (12 studies, 1486 participants, <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>);</LI>
<LI>somnolence - RR 1.39 (99% CI 0.96 to 2.00) (13 studies, 1767 participants, <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>);</LI>
<LI>diplopia - RR 3.79 (99% CI 2.15 to 6.68) (3 studies, 943 participants, <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>); and</LI>
<LI>headache - RR 1.13 (99% CI 0.87 to 1.45) (5 studies, 1385 participants, <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cognitive effects and Quality of life</HEADING>
<P>Two studies incorporated measures of cognitive functions (<LINK REF="REF-Banks-1991" TYPE="REFERENCE">Banks 1991</LINK>; <LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>; n = 54 participants). No significant differences were found on any of the tests used. However, participants receiving lamotrigine showed a marginal (not significant) reduction in general cerebral efficiency as assessed by the third segment of the Stroop colour word test-a test of concentration and distractibility (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>We provided a narrative discussion for this outcome and more information in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Meta-analysis of the two studies was not possible due to the differences in cognitive function measured in the two studies.</P>
<P>The results of the health-related quality of life (HRQOL) assessments are given in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. <LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK> (n = 54 participants), incorporated an HRQOL measure containing previously validated measures of physical, social and psychological functioning and a novel measure of seizure severity. There were no significant differences for the physical and social components of the HRQOL measure. Participants also reported significant improvements on the seizure severity scale when comparing lamotrigine versus placebo.</P>
<P>We provided a narrative discussion for this outcome and more information in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. Meta-analysis was not possible as only a single study reported on this outcome.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-06-02 11:54:41 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-05-29 13:08:41 +0100" MODIFIED_BY="[Empty name]">
<P>Since publication of the previous version of this review, we found no new studies that met the selection criteria for this review.</P>
<P>The baseline phase in all but one trial ranged from 4 to 12 weeks, the treatment phase from 8 to 36 weeks (<LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>). Eleven of the fourteen included trials described adequate methods of concealment of randomisation, only four described adequate blinding. All but one trial was sponsored by the manufacturer of lamotrigine.</P>
<P>This meta-analysis suggested that lamotrigine was more effective than placebo in reducing seizure frequency, when added to conventionally used antiepileptic drugs in people suffering from refractory partial epilepsy. We were unable to examine dose effects in planned subgroup analyses, but the results from <LINK REF="STD-Matsuo-1993" TYPE="STUDY">Matsuo 1993</LINK> suggested increased efficacy with an increased dose. Only one study recruited children (<LINK REF="STD-Duchowny-1999" TYPE="STUDY">Duchowny 1999</LINK>), and one study recruited infants (<LINK REF="STD-Pi_x00f1_a_x002d_Garza-2008" TYPE="STUDY">Piña-Garza 2008</LINK>); we have no evidence from this review to indicate whether lamotrigine is more or less effective in infants and children than in adults. The use of 50% or more reduction in seizure frequency as a measure of efficacy could be criticized, given that seizure freedom would be a more relevant clinical measure. However, seizure freedom was rarely achieved in the studies involving people with refractory epilepsy.</P>
<P>For a drug to be an attractive option, it would need to have a favourable adverse effect profile, have little effect on cognition, and have positive effects on quality of life, in addition to reducing seizures. In our review, certain adverse effects (ataxia, dizziness, diplopia, and nausea) were significantly more likely to occur with lamotrigine. It was emphasized that researchers should routinely and regularly enquire about adverse effects, using a standardised check-list thesaurus, and should not record only those volunteered by the patient. More participants had lamotrigine withdrawn than placebo, but this was not statistically significant.<BR/>
</P>
<P>The results of this review apply only to add-on use of lamotrigine. Our results do not inform us how add-on lamotrigine compares with other drugs when used as add-ons, which is an extremely important issue for clinicians who are faced with an ever increasing number of antiepileptic drugs (AEDs) from which to choose, and who need to make an evidence-based choice between the AEDs. Indirect comparisons can be made using results of other reviews, but such indirect comparisons require cautious interpretation.<BR/>
</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-06-02 11:53:27 +0100" MODIFIED_BY="[Empty name]">
<P>Only two studies evaluated the effects of add-on lamotrigine therapy on cognition and quality of life. The results of these studies suggested that lamotrigine was probably not associated with any significant cognitive decline. Anyway, the limited data available and heterogenous measurement scales for quality of life outcome precluded us from drawing any conclusions about the effects on cognition and quality of life.</P>
<P>Caution is required when translating the results of clinical trials into everyday practice, since the individuals in trials are a highly selected population who may be better motivated, and are closely followed and monitored; participants who are uncooperative and non-compliant, who are likely to have adverse effects and fewer benefits, are excluded. The results of this review cannot be extrapolated to people with generalized epilepsies, about whom there is a great paucity of data. The safety of lamotrigine during pregnancy and lactation cannot be ascertained from this review. The duration of the studies included in this review was insufficient to detect changes in cognition, social problems, or long-term adverse effects. Trials that include a larger number of individuals, preferably who are using lamotrigine as monotherapy, and which are using reliable, validated measures and longer follow-up are warranted. This review did not have the sensitivity to detect rare but serious adverse effects, such as psychosis, Steven Johnson's syndrome, or aplastic anaemia which may be seen with AEDs. Rare phenomena such as habituation and tolerance may not be evident in short-term trials. The economic aspects of lamotrigine therapy also need to be examined.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-06-02 11:54:05 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, eleven studies were rated as having low risk of bias and three had an unclear risk of bias, due to lack of reported information around study design. Effective blinding of studies of lamotrigine was only reported in three studies. We rated all the included studies as low risk of bias for incomplete outcome data due to the intention-to-treat analyses undertaken by the study authors. The GRADE approach was used to rate the quality of evidence for each outcome and is presented in a 'Summary of findings' table (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). For the main outcome of greater than 50% reduction in seizure frequency, the quality of evidence was rated as high (all studies contributed to the analysis). Tolerability outcomes (withdrawal and adverse effects) were judged as high to moderate quality due to the incomplete outcome data from some studies contributing to the analysis and a wide confidence intervals.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-06-02 11:54:41 +0100" MODIFIED_BY="[Empty name]">
<P>Although all protocols were requested, the time frame in which the majority of the studies were conducted made retrieval of all of these difficult. This could lead to potential bias through omitted information to which we did not have access. All studies but one were sponsored by GlaxoSmithKline, the manufacturers of lamotrigine and this could be a potential source of bias.</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-05-29 18:17:33 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-05-29 18:17:33 +0100" MODIFIED_BY="[Empty name]">
<P>In people with drug-resistant partial epilepsy, lamotrigine when used as an add-on treatment was effective in reducing the seizure frequency. The lowest daily dose tested in the trials included in this review was 75 mg for people on sodium valproate monotherapy, 100 mg in the balanced group receiving enzyme inducing AEDs and valproate, and 200 mg in people receiving enzyme inducing AEDs. However, the trials reviewed were of relatively short duration.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-05-19 09:20:01 +0100" MODIFIED_BY="[Empty name]">
<P>Further evaluation of lamotrigine is required to assess the following effects in the long term:</P>
<OL>
<LI>effects on seizures;</LI>
<LI>adverse effects;</LI>
<LI>effects on cognition;</LI>
<LI>effects on quality of life;</LI>
<LI>health economic effects.</LI>
</OL>
<P>In the following scenarios:</P>
<OL>
<LI>lamotrigine compared to other add-on treatments in drug-resistant partial epilepsy;</LI>
<LI>lamotrigine for childhood and generalized epilepsies;</LI>
<LI>lamotrigine compared with standard AEDs such as:</LI>
<OL>
<LI>lamotrigine as monotherapy in partial epilepsy;</LI>
<LI>lamotrigine as monotherapy in generalized epilepsy.</LI>
</OL>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-05-19 09:20:01 +0100" MODIFIED_BY="[Empty name]">
<P>We acknowledge Professor Gus Baker for his contribution to the original publication of this review.</P>
<P>GlaxoSmithKline provided unpublished data for the first treatment phase of cross-over trials.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-04-26 16:26:02 +0100" MODIFIED_BY="[Empty name]">
<P>SR: none known.</P>
<P>MP: none known.</P>
<P>AGM: A consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management in Hospitals (NASH) through grants paid to University of Liverpool. Professor Tony Marson is Theme Leader for Managing Complex Needs at NIHR CLAHRC NWC.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-05-19 09:20:05 +0100" MODIFIED_BY="[Empty name]">
<P>Sridharan Ramaratnam was primarily responsible for the writing of this update and completed data extraction and 'Risk of bias' assessments. Mariangela Panebianco assessed the studies for eligibility, extracted data, and assessed risk of bias. The assessment and interpretation of psychological data was done by Gus Baker in the original version of this review. Anthony Marson provided guidance and manuscript feedback during the update process.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-12-09 10:59:49 +0000" MODIFIED_BY="[Empty name]">
<P>No differences between protocol and review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-04-27 10:52:07 +0100" MODIFIED_BY="Ellen Dougan">
<STUDIES MODIFIED="2016-06-08 12:14:04 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-06-08 12:14:04 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baulac-2010" MODIFIED="2016-06-08 12:14:04 +0100" MODIFIED_BY="[Empty name]" NAME="Baulac 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-06-08 12:14:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Baulac M, Leon T, O'Brien TJ, Whalen E, Barrett J</AU>
<TI>A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures</TI>
<SO>Epilepsy Research</SO>
<YR>2010</YR>
<VL>91</VL>
<NO>1</NO>
<PG>10-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711243"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711242"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Binnie-1989" MODIFIED="2016-05-16 18:09:29 +0100" MODIFIED_BY="[Empty name]" NAME="Binnie 1989" YEAR="1989">
<REFERENCE MODIFIED="2016-05-16 18:09:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Binnie CD, Debets RMC, Engelsman M, Meijer JWA, Meinardi H, Overweg J, et al</AU>
<TI>Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy</TI>
<SO>Epilepsy Research</SO>
<YR>1989</YR>
<VL>4</VL>
<PG>222-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711245"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711244"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Boas-1996" NAME="Boas 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Boas J, Dam M, Friis ML, Kristensen O, Pedersen B, Gallagher J</AU>
<TI>Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1996</YR>
<VL>94</VL>
<PG>247-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711247"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711246"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duchowny-1999" MODIFIED="2016-05-19 09:23:13 +0100" MODIFIED_BY="[Empty name]" NAME="Duchowny 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-05-19 09:23:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Duchowny M, Pellock JM, Graf WD, Billard C, Gilman J, Casale E, et al</AU>
<TI>A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>8</NO>
<PG>1724-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711249"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711248"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jawad-1989" NAME="Jawad 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jawad S, Richens A, Goodwin G, Yuen WC</AU>
<TI>Controlled trial of lamotrigine (lamictal) for refractory partial seizures</TI>
<SO>Epilepsia</SO>
<YR>1989</YR>
<VL>30</VL>
<NO>3</NO>
<PG>356-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711251"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711250"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loiseau-1990" MODIFIED="2016-05-16 18:11:56 +0100" MODIFIED_BY="[Empty name]" NAME="Loiseau 1990" YEAR="1990">
<REFERENCE MODIFIED="2016-05-16 18:11:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Loiseau P, Yuen AWC, Duche B, Menager T, Arne-Bes MC</AU>
<TI>A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures</TI>
<SO>Epilepsy Research</SO>
<YR>1990</YR>
<VL>7</VL>
<PG>136-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711253"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711252"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsuo-1993" MODIFIED="2016-05-19 09:23:29 +0100" MODIFIED_BY="[Empty name]" NAME="Matsuo 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-05-19 09:23:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, et al</AU>
<TI>Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. US Lamotrigine Protocol 0.5 Clinical Trial Group</TI>
<SO>Neurology</SO>
<YR>1993</YR>
<VL>43</VL>
<PG>2284-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711255"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711254"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Messenheimer-1994" MODIFIED="2016-05-19 09:23:44 +0100" MODIFIED_BY="[Empty name]" NAME="Messenheimer 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-05-19 09:23:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Messenheimer J, Ramsay RE, Willmore LJ, Leroy RF, Zielinski JJ, Mattson R, et al</AU>
<TI>Lamotrigine therapy for partial seizures: A multicenter, placebo-controlled, double-blind, cross-over trial</TI>
<SO>Epilepsia</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>1</NO>
<PG>113-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711257"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711256"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naritoku-2007" MODIFIED="2016-05-19 09:23:50 +0100" MODIFIED_BY="[Empty name]" NAME="Naritoku 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-05-19 09:23:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naritoku DK, Warnock CR, Messenheimer JA, Borgohain R, Evers S, Guekht AB, et al</AU>
<TI>Lamotrigine extended-release as adjunctive therapy for partial seizures</TI>
<SO>Neurology</SO>
<YR>2007</YR>
<VL>69</VL>
<PG>1610-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711259"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711258"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pi_x00f1_a_x002d_Garza-2008" MODIFIED="2016-05-19 09:23:56 +0100" MODIFIED_BY="[Empty name]" NAME="Piña-Garza 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-05-19 09:23:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piña-Garza JE, Levisohn P, Gucuyener K, Mikati MA, Warnock CR, Conklin HS, et al</AU>
<TI>Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months</TI>
<SO>Neurology</SO>
<YR>2008</YR>
<VL>70</VL>
<PG>2099-108</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711261"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711260"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Schachter-1995" MODIFIED="2016-05-19 09:24:06 +0100" MODIFIED_BY="[Empty name]" NAME="Schachter 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-05-19 09:24:06 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;\par Schachter SC, Leppik IE, Matsuo F, Messenheimer JA, Faught E, Moore EL, Risner ME. Lamotrigine: A six-month, placebo-controlled, safety and tolerance study. Journal of Epilepsy 1995; 8: 201-9.&lt;/p&gt;" NOTES_MODIFIED="2016-05-19 09:24:06 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schachter SC, Leppik IE, Matsuo F, Messenheimer JA, Faught E, Moore EL, et al</AU>
<TI>Lamotrigine: a six-month, placebo-controlled, safety and tolerance study</TI>
<SO>Journal of Epilepsy</SO>
<YR>1995</YR>
<VL>8</VL>
<PG>201-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711263"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711262"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Schapel-1993" MODIFIED="2016-05-19 09:24:12 +0100" MODIFIED_BY="[Empty name]" NAME="Schapel 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-05-19 09:24:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schapel GJ, Beran RG, Vajda FJE, Berkovic SF, Mashford ML, Dunagan FM, et al</AU>
<TI>Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1993</YR>
<VL>56</VL>
<PG>448-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711265"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711264"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Schmidt-1993" NAME="Schmidt 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;\par Schmidt D, Ried S, Rapp P. Add-on treatment with lamotrigine for intractable partial epilepsy: A placebo-controlled, cross-over trial. Epilepsia 1993; 34(Suppl2): 66&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt D, Ried S, Rapp P</AU>
<TI>Add-on treatment with lamotrigine for intractable partial epilepsy: a placebo-controlled, cross-over trial</TI>
<SO>Epilepsia</SO>
<YR>1993</YR>
<VL>34 Suppl</VL>
<NO>2</NO>
<PG>66</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711267"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711266"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Smith-1993" NAME="Smith 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smith D, Baker GA, Davies G, Dewey M, Chadwick DW</AU>
<TI>Outcomes of add-on treatment with lamotrigine in partial epilepsy</TI>
<SO>Epilepsia</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>2</NO>
<PG>312-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711269"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711268"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-05-19 09:25:18 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Biton-2010" MODIFIED="2012-08-19 13:13:11 +0100" MODIFIED_BY="[Empty name]" NAME="Biton 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-19 13:13:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Biton V, Di Memmo J, Shukla R, Lee YY, Poverennova I, Demchenko V, et al</AU>
<TI>Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study</TI>
<SO>Epilepsy &amp; Behavior</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>3</NO>
<PG>352-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711271"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711270"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biton-2013" MODIFIED="2015-09-24 15:23:45 +0100" MODIFIED_BY="[Empty name]" NAME="Biton 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-24 15:23:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biton V, Shneker BF, Naritoku D, Hammer AE, Vuong A, Caldwell PT, et al</AU>
<TI>Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2013</YR>
<VL>33</VL>
<NO>5</NO>
<PG>359-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711273"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-09-24 15:13:41 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711272"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brzakovic-2012" MODIFIED="2016-05-19 09:24:28 +0100" MODIFIED_BY="[Empty name]" NAME="Brzakovic 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-05-19 09:24:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brzakovic BB, Vezmar Kovacevic SD, Vucicevic KM, Miljkovic BR, Martinovic ZJ, Pokrajac MV, et al</AU>
<TI>Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics</TI>
<SO>Journal of Clinical Pharmacy &amp; Therapeutics</SO>
<YR>2012</YR>
<VL>37</VL>
<NO>6</NO>
<PG>693-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711275"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711274"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carignani-2004" MODIFIED="2010-04-13 13:22:07 +0100" MODIFIED_BY="[Empty name]" NAME="Carignani 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-04-13 13:22:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carignani MAC, Matassa JCM</AU>
<TI>Controlled trial of lamotrigine for the treatment of refractory partial seizures</TI>
<SO>Epilepsia</SO>
<YR>2004</YR>
<VL>45 Suppl 3</VL>
<PG>135-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711277"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711276"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carignani-2006" MODIFIED="2010-04-13 13:20:51 +0100" MODIFIED_BY="[Empty name]" NAME="Carignani 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-04-13 13:20:51 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Abstract: Conference proceedings: 7th European Congress on Epileptology, Helsinki, Finland. 2-6 July 2006. Abstract p475.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-04-13 13:20:51 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carignani M, Matassa J, Rosso D</AU>
<TI>Controlled trial of lamotrigine for the treatment of refractory partial seizures</TI>
<SO>Epilepsia</SO>
<YR>2006</YR>
<VL>47 Suppl 3</VL>
<PG>124</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711279"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711278"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cramer-2013" MODIFIED="2015-09-24 15:45:09 +0100" MODIFIED_BY="[Empty name]" NAME="Cramer 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-24 15:45:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cramer JA, Sapin C, Francois C</AU>
<TI>Indirect comparison of clobazam and other therapies for Lennox-Gastaut Syndrome</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2013</YR>
<VL>128</VL>
<NO>2</NO>
<PG>91-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711281"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711280"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-French-2012" MODIFIED="2015-09-24 15:52:42 +0100" MODIFIED_BY="[Empty name]" NAME="French 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-09-24 15:52:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>French JA, Hammer AE, Vuong A, Messenheimer JA</AU>
<TI>Analysis of three lamotrigine extended-release clinical trials: comparison of pragmatic ITT and LOCF methodologies</TI>
<SO>Epilepsy Research</SO>
<YR>2012</YR>
<VL>101</VL>
<NO>1-2</NO>
<PG>141-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711283"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711282"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Girolineto-2012" MODIFIED="2015-09-24 16:08:03 +0100" MODIFIED_BY="[Empty name]" NAME="Girolineto 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-09-24 16:08:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Girolineto BM, Alexandre Junior V, Sakamoto AC, Pereira LR</AU>
<TI>Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life</TI>
<SO>Brazilian Journal of Pharmaceutical Sciences</SO>
<YR>2012</YR>
<VL>48</VL>
<NO>1</NO>
<PG>95-102</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711285"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711284"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hammer-2008" MODIFIED="2015-09-24 15:58:07 +0100" MODIFIED_BY="[Empty name]" NAME="Hammer 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-09-24 15:58:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hammer AE, Vuong A, Kustra R, Messenheimer JA</AU>
<TI>Pragmatic intent-to-treat analysis for lamotrigine extended release adjunctive therapy in patients with intractable partial seizures</TI>
<SO>Epilepsia</SO>
<YR>2008</YR>
<VL>49</VL>
<NO>Suppl 7</NO>
<PG>100</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711287"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711286"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartung-2012" MODIFIED="2015-09-28 09:07:20 +0100" MODIFIED_BY="[Empty name]" NAME="Hartung 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-09-28 09:07:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartung DM, Middleton L, Svoboda L, McGregor JC</AU>
<TI>Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study</TI>
<SO>CNS Drugs</SO>
<YR>2012</YR>
<VL>26</VL>
<NO>8</NO>
<PG>707-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711289"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711288"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Helmstaedter-2013" MODIFIED="2016-05-19 09:25:07 +0100" MODIFIED_BY="[Empty name]" NAME="Helmstaedter 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-05-19 09:25:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Helmstaedter C, Witt J-A</AU>
<TI>The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting</TI>
<SO>Epilepsy &amp; Behaviour</SO>
<YR>2013</YR>
<VL>26</VL>
<NO>2</NO>
<PG>182-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711291"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711290"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kang-2012" MODIFIED="2016-05-19 09:25:14 +0100" MODIFIED_BY="[Empty name]" NAME="Kang 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-05-19 09:25:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kang HC, Hu Q, Liu XY, Xu F, Li X, Liu ZG, et al</AU>
<TI>Efficacy and safety of the combined therapy of valproic acid and lamotrigine for epileptics</TI>
<SO>Zhonghua yi xue za zhi</SO>
<YR>2012</YR>
<VL>92</VL>
<NO>17</NO>
<PG>1174-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711293"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711292"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montouris-2007" MODIFIED="2016-05-19 09:25:18 +0100" MODIFIED_BY="[Empty name]" NAME="Montouris 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-05-19 09:25:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montouris G, Alok A, Vuong A, VanLandingham K</AU>
<TI>An analysis of the efficacy of lamotrigine extended-release adjunctive therapy in subjects with partial epilepsy by number of concomitant AEDs</TI>
<SO>Epilepsia</SO>
<YR>2007</YR>
<VL>48</VL>
<NO>Suppl 6</NO>
<PG>369</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711295"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711294"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohtahara-2007" MODIFIED="2012-08-19 13:16:15 +0100" MODIFIED_BY="[Empty name]" NAME="Ohtahara 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-19 13:16:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CODEN: CCT&lt;/p&gt;" NOTES_MODIFIED="2012-08-19 13:16:15 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohtahara S, Iinuma K, Fujiwara T, Yamatogi Y</AU>
<TI>[Single-blind and controlled comparative study of lamotrigine with zonisamide for refractory pediatric epilepsy]</TI>
<SO>Journal of the Japan Epilepsy Society</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>4</NO>
<PG>425-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711297"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711296"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sander-1990" NAME="Sander 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Sander JWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Research 1990; 6: 221-6&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sander JWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC</AU>
<TI>A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy</TI>
<SO>Epilepsy Research</SO>
<YR>1990</YR>
<VL>6</VL>
<PG>221-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711299"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711298"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Semah-2014" MODIFIED="2015-09-28 18:19:42 +0100" MODIFIED_BY="[Empty name]" NAME="Semah 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-09-28 18:19:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Semah F, Thomas P, Coulbaut S, Derambure P</AU>
<TI>Early add-on treatment vs alternative monotherapy in patients with partial epilepsy</TI>
<SO>Epileptic disorders</SO>
<YR>2014</YR>
<VL>16</VL>
<NO>2</NO>
<PG>165-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711301"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711300"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stolarek-1994" NAME="Stolarek 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stolarek I, Blacklaw J, Forrest G, Brodie MJ</AU>
<TI>Vigabatrin and lamotrigine in refractory epilepsy</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1994</YR>
<VL>57</VL>
<PG>921-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711303"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711302"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomson-2012" MODIFIED="2015-09-28 09:40:15 +0100" MODIFIED_BY="[Empty name]" NAME="Tomson 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-09-28 09:40:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tomson T, Hirsch L, Friedman D, Bester N, Hammer A, Irizarry M, et al</AU>
<TI>Evaluation of sudden unexpected death in epilepsy (SUDEP) occurring in lamotrigine (LTG) clinical trials</TI>
<SO>Epilepsia</SO>
<YR>2012</YR>
<VL>53</VL>
<NO>Suppl 5</NO>
<PG>118</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711305"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711304"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomson-2013" MODIFIED="2015-09-28 09:54:34 +0100" MODIFIED_BY="[Empty name]" NAME="Tomson 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-28 09:54:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tomson T, Hirsch LJ, Friedman D, Bester N, Hammer A, Irizarry M, et al</AU>
<TI>Sudden unexpected death in epilepsy in lamotrigine randomized-controlled trials</TI>
<SO>Epilepsia</SO>
<YR>2013</YR>
<VL>54</VL>
<NO>1</NO>
<PG>135-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711307"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711306"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veendrick-2000" MODIFIED="2010-03-14 14:44:57 +0000" MODIFIED_BY="[Empty name]" NAME="Veendrick 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-03-14 14:44:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veendrick-Meekes MJBM, Beun AM, Carpay JA, Arends LR, Schlosser A</AU>
<TI>Use of lamotrigine as adjunctive therapy in patients with mental retardation and epilepsy. An interim analysis of a double blind study with evaluation of behavioural effects</TI>
<SO>Epilepsia</SO>
<YR>2000</YR>
<VL>41(Suppl Florence)</VL>
<PG>97</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711309"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711308"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamamoto-2012" MODIFIED="2015-09-28 10:03:55 +0100" MODIFIED_BY="[Empty name]" NAME="Yamamoto 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-09-28 10:03:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamamoto Y, Inoue Y, Matsuda K, Takahashi Y, Kagawa Y</AU>
<TI>Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients</TI>
<SO>Biological &amp; Pharmaceutical Bulletin</SO>
<YR>2012</YR>
<VL>35</VL>
<NO>4</NO>
<PG>487-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2711311"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2711310"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-03-14 14:44:57 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-06-08 11:39:42 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-06-08 11:39:42 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Banks-1991" MODIFIED="2015-11-18 15:23:15 +0000" MODIFIED_BY="[Empty name]" NAME="Banks 1991" TYPE="JOURNAL_ARTICLE">
<AU>Banks GK, Beran RG</AU>
<TI>Neuropsychological assessment in lamotrigine treated epileptic patients</TI>
<SO>Clinical and Experimental Neurology</SO>
<YR>1991</YR>
<VL>28</VL>
<PG>230-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barker_x002d_Haliski-2014" MODIFIED="2015-10-15 16:03:58 +0100" MODIFIED_BY="[Empty name]" NAME="Barker-Haliski 2014" TYPE="JOURNAL_ARTICLE">
<AU>Barker-Haliski M, Sills GJ, White HS</AU>
<TI>What are the arguments for and against rational therapy for epilepsy?</TI>
<SO>Advances in Experimental Medicine &amp; Biology</SO>
<YR>2014</YR>
<VL>813</VL>
<PG>295-308</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cockerell-1995" NAME="Cockerell 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD</AU>
<TI>Remission of epilepsy: results from the national general practice study of epilepsy</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>346</VL>
<PG>140-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Commission-1989" NAME="Commission 1989" TYPE="JOURNAL_ARTICLE">
<AU>Commission on Classification and Terminology of the International League Against Epilepsy</AU>
<TI>Proposal for revised classification of epilepsies and epileptic syndromes</TI>
<SO>Epilepsia</SO>
<YR>1989</YR>
<VL>30</VL>
<NO>4</NO>
<PG>389-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fisher-2005" MODIFIED="2016-05-19 09:25:46 +0100" MODIFIED_BY="[Empty name]" NAME="Fisher 2005" TYPE="JOURNAL_ARTICLE">
<AU>Fisher RS, Van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al</AU>
<TI>Epileptic seizures and epilepsy: definitions proposed by the International League A Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)</TI>
<SO>Epilepsia</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>4</NO>
<PG>470-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2014" MODIFIED="2016-05-19 09:25:51 +0100" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro. [Computer program on www.gradepro.org]. Version [insert date of use]</TI>
<YR>2014</YR>
<PB>McMaster University</PB>
<CY>Hamilton, Canada</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hauser-1993" MODIFIED="2010-04-13 13:24:31 +0100" MODIFIED_BY="[Empty name]" NAME="Hauser 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hauser WA, Annegers JF, Kurland LT</AU>
<TI>Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935 -1984</TI>
<SO>Epilepsia</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>3</NO>
<PG>453-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-05-19 09:25:56 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirkham-2010" MODIFIED="2016-06-08 10:44:37 +0100" MODIFIED_BY="[Empty name]" NAME="Kirkham 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al</AU>
<TI>The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c365</PG>
<IDENTIFIERS MODIFIED="2016-05-16 18:23:40 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-05-16 18:23:40 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=" 10.1136/bmj.c365"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leach-1995" NAME="Leach 1995" TYPE="BOOK_SECTION">
<AU>Leach LJ, Lees G, Riddall DR</AU>
<TI>Lamotrigine</TI>
<SO>Mechanisms of action in antiepileptic drugs</SO>
<YR>1995</YR>
<EN>4th</EN>
<ED>Levy RH, Mattson RH, Medlrum BS</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2015-06-02 17:16:25 +0100" MODIFIED_BY="Graham Chan" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from http://handbook.cochrane.org/</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loscher-2002" MODIFIED="2016-05-19 09:26:09 +0100" MODIFIED_BY="[Empty name]" NAME="Loscher 2002" TYPE="JOURNAL_ARTICLE">
<AU>Loscher W</AU>
<TI>Current status and future directions in the pharmacotherapy of epilepsy</TI>
<SO>Trends in Pharmacological Sciences</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>3</NO>
<PG>113-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lyer-2014" MODIFIED="2016-06-08 11:39:42 +0100" MODIFIED_BY="[Empty name]" NAME="Lyer 2014" TYPE="JOURNAL_ARTICLE">
<AU>Lyer A, Marson A</AU>
<TI>Pharmacotherapy of focal epilepsy</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2014</YR>
<VL>15</VL>
<NO>11</NO>
<PG>1543-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2012" MODIFIED="2015-10-15 16:06:02 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 2012" TYPE="JOURNAL_ARTICLE">
<AU>Moore JL, Aggarwal P</AU>
<TI>Lamotrigine use in pregnancy</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2012</YR>
<VL>13</VL>
<NO>8</NO>
<PG>1213-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mula-2013" MODIFIED="2015-10-15 16:07:19 +0100" MODIFIED_BY="[Empty name]" NAME="Mula 2013" TYPE="JOURNAL_ARTICLE">
<AU>Mula M</AU>
<TI>Emerging drugs for focal epilepsy</TI>
<SO>Expert Opinion on Emerging Drugs</SO>
<YR>2013</YR>
<VL>18</VL>
<NO>1</NO>
<PG>87-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Panebianco-2015" MODIFIED="2016-03-29 13:45:48 +0100" MODIFIED_BY="[Empty name]" NAME="Panebianco 2015" TYPE="COCHRANE_REVIEW">
<AU>Panebianco M, Rigby A, Weston J, Marson AG</AU>
<TI>Vagus nerve stimulation for partial seizures</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-03-29 13:45:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-29 13:45:48 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002896.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-12-09 11:07:10 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<PB>5.3. The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vajda-2013" MODIFIED="2015-10-15 16:09:29 +0100" MODIFIED_BY="[Empty name]" NAME="Vajda 2013" TYPE="JOURNAL_ARTICLE">
<AU>Vajda FJE, Dodd S, Horgan D</AU>
<TI>Lamotrigine in epilepsy, pregnancy and psychiatry - a drug for all seasons?</TI>
<SO>Journal of Clinical Neuroscience</SO>
<YR>2013</YR>
<VL>20</VL>
<NO>1</NO>
<PG>13-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-West-2015" MODIFIED="2016-05-19 09:26:17 +0100" MODIFIED_BY="[Empty name]" NAME="West 2015" TYPE="COCHRANE_REVIEW">
<AU>West S, Nolan SJ, Cotton J, Gandhi S, Weston J, Sudan A, et al</AU>
<TI>Surgery for epilepsy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2016-03-29 13:41:59 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-29 13:41:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD010541.pub2"/></IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-10-15 16:01:21 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ramaratnam-2001" MODIFIED="2013-06-12 14:12:01 +0100" MODIFIED_BY="[Empty name]" NAME="Ramaratnam 2001" TYPE="COCHRANE_REVIEW">
<AU>Ramaratnam S, Marson AG, Baker GA</AU>
<TI>Lamotrigine add-on for drug-resistant partial epilepsy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-06-12 14:12:01 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-06-12 14:12:01 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001909"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2015-06-02 17:17:35 +0100" MODIFIED_BY="Graham Chan"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-06-08 11:57:15 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-06-08 11:57:15 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-06-08 11:56:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baulac-2010">
<CHAR_METHODS MODIFIED="2016-05-19 09:20:09 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled, randomised, parallel-group study.</P>
<P>Three arms: 1 placebo, 1 lamotrigine, and 1 pregabalin.</P>
<P>Baseline period = 6 weeks; double-blind treatment period = 17 weeks, which included initial 5 weeks dosage titration for lamotrigine and 6 weeks maintenance at 300 mg/day and additional treatment period of 6 weeks with dose escalation to 400 mg/day for those with continuing seizures. Double-blind treatment period was followed by an open-label study or a 2-week taper phase.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 09:20:10 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>97 centres in Europe, Canada, and Australia.</LI>
</UL>
<UL>
<LI>Adults over the age of 18 years and body weight &#8805;40 kg, with a diagnosis of partial seizures (as defined by the International League Against Epilepsy Classification of Seizures).</LI>
</UL>
<UL>
<LI>546 persons screened, 434 randomised. M:F ratio 39.3:60.7 for placebo and 54.6:45.4 for lamotrigine. Mean age 39.1 in placebo group and 39.4 in Lamotrigine group. Minimum seizure frequency of 4 partial seizures during the 6-week baseline period and no 28-day period free of partial seizure, despite treatment with at least three AEDs from at least two different AED classes, each at or above the lowest recommended dose or the lowest adequate plasma concentration given for a minimum of 3 months; were allowed to take one to three AEDs concurrently, one of which had to be an enzyme inducer.</LI>
</UL>
<P>Exclusion Criteria:</P>
<UL>
<LI>previous treatment with pregabalin;</LI>
<LI>previous treatment with lamotrigine within 6 months before entering baseline;</LI>
<LI>history of rash with lamotrigine;</LI>
<LI>previous treatment with valproic acid products within 2 months of baseline; and</LI>
<LI>previous treatment with gabapentin, felbamate, or vigabatrin &lt; 6 weeks prior to screening.</LI>
<LI>history of status epilepticus in the last 1 year, significant psychiatric disorder, or use of concomitant medication that could interfere with response to study medications or affect seizure frequency.</LI>
<LI>pregnant or planning to conceive, lactation.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-08 11:56:42 +0100" MODIFIED_BY="[Empty name]">
<P>Group I (n = 141): received placebo.</P>
<P>Group II (n = 141): received lamotrigine 300 mg/day after dose titration over 5 weeks, and if seizures occurred during 6-week maintenance, further dose escalation to 400 mg/day from week 12 to 17.</P>
<P>Group III (n = 152): received pregabalin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-17 11:35:14 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Seizure frequency.</P>
<P>(2) Adverse events, including changes in physical and neurologic examinations, 12-lead electrocardiograms (ECGs), and clinical laboratory tests (hematology, blood chemistry, pregnancy, and urinalysis).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-11-17 11:36:44 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-19 09:20:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Binnie-1989">
<CHAR_METHODS MODIFIED="2016-05-19 09:20:17 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, cross-over study.</P>
<P>Two treatment arms: 1 placebo, and 1 lamotrigine.</P>
<P>Baseline period = 8 weeks.Treatment I and II = 12 weeks each. Washout = 6 weeks, including taper period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 09:20:17 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Single centre study from Netherlands.</LI>
</UL>
<UL>
<LI>34 adults aged between 16 to 51 years (mean 37.1 +/- 10.26). 16 were randomised to lamotrigine and 18 to placebo during the first treatment phase. All had drug-resistant partial seizures. The age of onset of epilepsy ranged from 1 to 40 (mean 14.3 +/- 10.7), the duration of epilepsy was 6 to 49.5 (mean 22.8 +/- 11) years.</LI>
<LI>Maximum number of other AEDs = 4.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-18 18:26:02 +0100" MODIFIED_BY="[Empty name]">
<P>Add-on lamotrigine, or placebo. Median daily dose of lamotrigine was 200 mg. Participants on valproate received lower doses.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) 50% responder rates.<BR/>(2) Withdrawal from study for any reason.<BR/>(3) Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-11-17 11:53:13 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-08 11:57:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boas-1996">
<CHAR_METHODS MODIFIED="2016-06-08 11:57:15 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, cross-over study.</P>
<P>Two treatment arms: 1 placebo, 1 lamotrigine.<BR/>Five phases: baseline period = 12 weeks; treatment I = 12 weeks; washout I = 4 weeks; treatment II = 12 weeks; washout II = 4 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-18 18:32:05 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>4 centre study from Denmark.</LI>
</UL>
<UL>
<LI>56 adults with refractory drug-resistant partial seizures, aged from 16 to 65 years. 30 were allocated to lamotrigine and 26 to placebo during the first treatment phase. There were 27 men and 29 women. </LI>
<LI>Maximum number of other AEDs = 3.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-17 12:08:36 +0000" MODIFIED_BY="[Empty name]">
<P>Lamotrigine or placebo was added to the patients' existing AEDs. The dose of lamotrigine varied from 75 to 400 mg. Participants on valproate received lower doses. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) 50% responder rates.<BR/>(2) Withdrawal from study for any reason.<BR/>(3) Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-11-17 12:08:52 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-19 09:20:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Duchowny-1999">
<CHAR_METHODS MODIFIED="2016-05-19 09:20:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double blind, parallel group, multi-centre study.<BR/>Two treatment arms: 1 placebo, 1 lamotrigine.<BR/>Pre-randomization baseline period = 8 weeks. Treatment phase = 18 weeks (including 6-week titration). Taper and follow-up = 1 to 6 weeks, including 1-week taper.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-18 18:35:41 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>40 centres from USA and France: </LI>
<LI>199 children with refractory drug-resistant partial seizures, aged from 2 to 16 years (27% were less than 6 years old, 60% aged between 6 to 12 years and 11% were over 12 years age). </LI>
<LI>98 were allocated to lamotrigine and 101 to placebo. There were 103 boys and 96 girls. </LI>
<LI>Maximum number of other AEDs = 2.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-17 12:19:52 +0000" MODIFIED_BY="[Empty name]">
<P>Add-on lamotrigine or placebo. Median dose ranged from 2.7 to 12.9 mg/kg/day depending upon concurrent use of other AEDs. Participants on valproate received lower doses. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) 50% responder rates.<BR/>(2) Withdrawal from study for any reason.<BR/>(3) Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-11-17 12:20:26 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-19 09:20:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jawad-1989">
<CHAR_METHODS MODIFIED="2016-05-19 09:20:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, cross-over study.</P>
<P>Two treatment arms: 1 placebo, 1 lamotrigine.</P>
<P>Five phases: baseline period = 8 weeks; Treatment I = 12 weeks; Washout I = 6 weeks; treatment II = 12 weeks; Washout II = 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-18 18:39:07 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Single centre study from UK.</LI>
<LI>24 adults with refractory drug-resistant partial seizures, aged between 16 to 60 years. </LI>
<LI>12 were allocated to lamotrigine and 12 to placebo in the first treatment phase. </LI>
<LI>Maximum number of other AEDs = 2.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-17 12:30:41 +0000" MODIFIED_BY="[Empty name]">
<P>Add-on lamotrigine or placebo. The median daily dose of lamotrigine was 250 mg. Participants on valproate received lower doses. Unblinded investigator wrote prescriptions based on plasma concentration. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) 50% responder rates.<BR/>(2) Withdrawal from study for any reason.<BR/>(3) Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-11-17 12:31:06 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-19 09:20:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loiseau-1990">
<CHAR_METHODS MODIFIED="2016-05-19 09:20:58 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, cross-over study.</P>
<P>Two treatment arms: 1 placebo, 1 lamotrigine.<BR/>Five phases: Pre-randomisation baseline = 4 weeks. Treatment I = 8 weeks. Washout I = 4 weeks. Treatment II = 8 weeks. Washout II = 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-18 18:43:22 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Single centre study from France.</LI>
<LI>25 adults, aged between 20 to 54 (mean 34.2 +/- 12.41) years. All had drug-resistant partial epilepsy. </LI>
<LI>11 were randomised to lamotrigine and 14 to placebo in the first treatment phase. </LI>
<LI>The duration of epilepsy ranged from 3 to 45 years (mean 17.4 +/- 10.81). </LI>
<LI>Maximum number of other AEDs = 2.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-17 12:38:00 +0000" MODIFIED_BY="[Empty name]">
<P>Add-on lamotrigine or placebo. The median daily lamotrigine dose was 300 mg. Participants on valproate received lower doses.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) 50% responder rates.<BR/>(2) Withdrawal from study for any reason.<BR/>(3) Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-11-17 12:36:34 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-19 09:21:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matsuo-1993">
<CHAR_METHODS MODIFIED="2016-05-19 09:21:04 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, parallel group, multi-centre study.<BR/>Three treatment arms: 1 placebo, 1 lamotrigine 300 mg and 1 lamotrigine 500 mg.</P>
<P>Pre-randomisation baseline = 12 weeks. Treatment phase = 24 weeks. Taper and follow-up = 3 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-18 18:47:15 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Multicentre US study with 216 participants (67 males and 149 females) with a mean age of 33 (range 18 to 63) years. All had drug-resistant partial epilepsy.</LI>
<LI>73 were randomised to receive placebo, while 71 received lamotrigine 300 mg per day and 72 received lamotrigine 500 mg per day. </LI>
<LI>The mean duration of epilepsy was 21.9 years and the mean age at onset 11 years.</LI>
<LI>Maximum number of other AEDs = 3. People receiving valproate were excluded.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-17 12:45:04 +0000" MODIFIED_BY="[Empty name]">
<P>Add-on lamotrigine 300 mg or lamotrigine 500 mg or placebo. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) 50% responder rates.<BR/>(2) Withdrawal from study for any reason.<BR/>(3) Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-11-17 12:45:15 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-19 09:21:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Messenheimer-1994">
<CHAR_METHODS MODIFIED="2016-05-19 09:21:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, cross-over study.</P>
<P>Two treatment arms: 1 placebo, 1 lamotrigine.</P>
<P>Total study duration was 43 weeks. Pre-randomisation baseline = 8 weeks. Treatment A = 14 weeks (including 2 weeks blinded tapering). Follow-up period = 3 weeks. Treatment B = 14 weeks (including 2 weeks blinded tapering). Washout = 4 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 09:21:10 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Multi-centre US study with 98 participants (46 men and 52 women) with drug-resistant partial epilepsy.</LI>
<LI>46 were randomised to receive lamotrigine and 52 to placebo in the first treatment phase.</LI>
<LI>Age range 18 to 64 years with a mean of 35.</LI>
<LI>Age at onset of epilepsy was 12 years; mean duration 23.1 years.</LI>
<LI>Up to 3 other AEDs were permitted. Concomitant use of valproate was not allowed.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-17 19:36:05 +0000" MODIFIED_BY="[Empty name]">
<P>Add-on lamotrigine or placebo. Median lamotrigine dose 400 mg/day. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) 50% responder rates.<BR/>(2) Withdrawal from study for any reason.<BR/>(3) Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-11-17 19:36:25 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-19 09:21:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naritoku-2007">
<CHAR_METHODS MODIFIED="2016-05-19 09:21:14 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised, parallel-group, placebo-controlled multi-centre global study.</P>
<P>Screening phase of up to 2 weeks during which eligibility was determined; an 8-week baseline phase serving to exclude from randomisation patients who did not meet the minimum seizure frequency criterion; a 7-week, double-blind escalation phase during which lamotrigine XR (Extended Release) was introduced and titrated to its target dose; and a 12-week, double-blind maintenance phase during which dosage of study medication and concomitant AED were maintained.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 09:21:30 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>International multi-centre study from North and South America, Europe, and Asia.</LI>
</UL>
<UL>
<LI>Uncontrolled partial seizures (at least 8 partial seizures in 8 weeks with at least one partial seizure during each 4-week period of the baseline phase).</LI>
<LI>Male and female patients 12 years of age or older with partial seizures with or without generalisation who were treated with a stable regimen of one or two AEDs for at least 4 weeks before starting the baseline phase. </LI>
<LI>Total number enrolled = 243; (121 to treatment arm; 123 to placebo arm); </LI>
<LI>93% were aged between 16 and 65 years; mean age in lamotrigine group = 35.8 (12.7) and in placebo group = 37.5 (14.4) years. </LI>
<LI>Males constituted 47% of participants in lamotrigine group and 53% of participants in placebo group.</LI>
</UL>
<P>Exclusion criteria included: presence of primary generalized seizures, status epilepticus during or within 24 weeks before the start of the baseline phase, chronic treatment with three or more AEDs, current or previous use of lamotrigine, current use of felbamate or adherence to a ketogenic diet, and pregnancy or planned pregnancy during the study or within 3 weeks after the last dose of study medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 09:21:31 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group received lamotrigine XR (Extended Release); other group received identical placebo.</P>
<P>Dosage of lamotrigine XR was escalated gradually up to 200 mg/day in those receiving valproate, 300 mg/day in those receiving valproate and an enzyme inducing AED, and up to 500 mg/day in those receiving enzyme inducing AEDs without valproate.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-17 19:49:16 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Seizure frequency.</P>
<P>(2) Adverse events</P>
<P>(3) Withdrawals from study.</P>
<P>US subjects had following additional assessments: Profile of Mood States (POMS), Center for Epidemiologic Studies-Depression Scale (CES-D), research version of the Neurological Disorders Depression Inventory-Epilepsy (NDDI-E), Quality of Life in Epilepsy-31-P (QOLIE-31-P), Liverpool Adverse Experience Profile (AEP), Seizure Severity Questionnaire (SSQ), and Epworth Sleepiness Scale (ESS).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-11-17 19:49:29 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-29 16:06:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pi_x00f1_a_x002d_Garza-2008">
<CHAR_METHODS MODIFIED="2016-05-19 09:21:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, multi-centre placebo-controlled trial.</P>
<P>Responder-enriched design in which all patients received adjunctive lamotrigine during an open-label phase (wherein dose was escalated to achieve optimal response); those who had a 40% or greater reduction in the frequency of partial seizures during the last 4 weeks of the optimisation period were randomly assigned to double-blind treatment for up to 8 weeks with continued lamotrigine or placebo.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-29 16:06:54 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Total number enrolled = 38. Male or female infants aged 1 month to 24 months with at least 4 partial seizures (with or without generalisation) per month, uncontrolled by 1 AED and who showed 40% or greater reduction in seizure frequency during an initial open label phase.</LI>
<LI>There were 19 subjects in each arm; median age was 13.5 months in lamotrigine arm and 14.2 months in placebo arm;</LI>
<LI>median age of onset of epilepsy was 3 months and median duration of epilepsy was 9.1 months in lamotrigine arm and 8.5 months in placebo arm.</LI>
</UL>
<P>Exclusion Criteria: subjects with progressive myoclonic epilepsy; progressive neurologic disease, seizures unrelated to epilepsy or resulting from drug withdrawal; use of felbamate, adrenocorticotropic hormone, previous use of lamotrigine, two AEDs as maintenance treatment, presence of hepatic dysfunction, having a functioning vagus nerve stimulator; or being on a ketogenic diet.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-05-19 09:21:42 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention group was continued on lamotrigine. Control group subjects had their lamotrigine dose tapered and changed to placebo. The maximum maintenance dose was 5.1 mg/kg/day for those on non&#8211;enzyme-inducing AEDs or valproate and 15.6 mg/kg/day for those on enzyme-inducing AEDs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-19 09:21:44 +0100" MODIFIED_BY="[Empty name]">
<P>(1) Percentage of patients who had treatment failures during the double-blind phase.</P>
<P>(2) Cumulative percentage of patients who met escape criteria as a function of days on double-blind study medication.</P>
<P>Subjects were withdrawn from study if they met one of the following criteria:</P>
<UL>
<LI>50% increase in monthly partial seizure frequency compared with seizure frequency during the last 4 weeks of the open-label optimisation period;</LI>
<LI>a doubling of the highest consecutive 2-day partial seizure count observed during the open-label optimisation period;</LI>
<LI>onset of a new and more severe seizure type;</LI>
<LI>clinically significant worsening of non-partial seizures that were also observed during the historical baseline phase or the open-label optimisation period;</LI>
<LI>the need to use any therapeutic intervention in addition to study medication to control seizures; or</LI>
<LI>status epilepticus.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-19 09:21:45 +0100" MODIFIED_BY="[Empty name]">
<P>The protocol was amended midway through the study to randomly assign all patients with at least 40% reduction in seizure frequency, instead of planned inclusion of subjects with 40% to 80% reduction in seizure frequency. 43 subjects who had more than 80% reduction in seizure frequency before the protocol amendment were not included in the double-blind study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-19 09:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schachter-1995">
<CHAR_METHODS MODIFIED="2016-05-19 09:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, parallel-group study.<BR/>Two treatment arms: 1 placebo, 1 lamotrigine.<BR/>Patients were randomised to lamotrigine or placebo in a ratio of 3:1.</P>
<P>Pre-randomisation baseline = 4 weeks. Treatment phase = 24 weeks. Taper and follow-up = 3 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 09:21:50 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>A 34 centre US study with 446 participants with refractory drug-resistant partial seizures:</LI>
<LI>334 were randomised to lamotrigine and 112 to placebo.</LI>
<LI>There were 236 men and 210 women.</LI>
<LI>The mean age was 35 years (range 18 to 64).</LI>
<LI>The mean duration of epilepsy was 21 years, median age at onset: 12 years in the lamotrigine group and 11.5 in the placebo group.</LI>
<LI>Maximum number of other AEDs = 3.</LI>
<LI>Concomitant valproate therapy was not permitted.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-17 20:06:55 +0000" MODIFIED_BY="[Empty name]">
<P>Add-on lamotrigine or placebo.<BR/>Lamotrigine dose up to 500 mg/day. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Withdrawals from treatment.<BR/>(2) Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-11-17 20:07:04 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-29 12:47:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schapel-1993">
<CHAR_METHODS MODIFIED="2016-05-19 09:21:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, cross-over study.</P>
<P>Two treatment arms: 1 placebo, 1 lamotrigine.<BR/>Pre-randomization baseline = 12 weeks. Treatment I and II = 12 weeks each. Washout I and II = 4 weeks each, including 1 week taper.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 09:21:59 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Multicentre Australian study.</LI>
</UL>
<UL>
<LI>41 participants (21 males and 20 females) with drug-resistant partial seizures </LI>
<LI>20 were randomised to receive placebo and 21 to lamotrigine.</LI>
<LI>The age ranged from 17 to 63 (median 28) years. The mean age at onset was 10.4 +/-9.6 years.</LI>
<LI>Maximum number of other AEDs permitted = 3.</LI>
<LI>People receiving valproate monotherapy were excluded.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-17 20:12:30 +0000" MODIFIED_BY="[Empty name]">
<P>Add-on lamotrigine or placebo. Median daily dose of lamotrigine was 300 mg. Participants receiving valproate received lower doses. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) 50% responder rates.<BR/>(2) Withdrawal from study for any reason.<BR/>(3) Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-29 12:47:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="REF-Banks-1991" TYPE="REFERENCE">Banks 1991</LINK> is linked to this study and investigated cognitive functions (concentration and attention; general cerebral efficiency; mnestic function).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-19 09:22:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmidt-1993">
<CHAR_METHODS MODIFIED="2016-05-19 09:22:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, cross-over study.</P>
<P>Two treatment arms: 1 placebo, 1 lamotrigine.</P>
<P>Pre-randomisation baseline not known. Treatment I and II = 12 weeks each, including 2-week tapering period.</P>
<P>Washout = 2 weeks .<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-18 19:18:19 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Single centre German study. </LI>
<LI>23 adults (11 men and 12 women) with drug-resistant partial seizures. </LI>
<LI>11 were randomised to receive lamotrigine and 12 to placebo in the initial treatment phase. </LI>
<LI>Age of participants ranged from 16 to 62 years.</LI>
<LI>Maximum number of other AEDs permitted was 2.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-17 20:36:41 +0000" MODIFIED_BY="[Empty name]">
<P>Add-on lamotrigine or placebo. Dosage varied from 50 mg to 450 mg (median dose was 300 mg).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) 50% responder rates.<BR/>(2) Withdrawal from study for any reason.<BR/>(3) Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-11-17 20:28:34 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-05-29 11:38:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1993">
<CHAR_METHODS MODIFIED="2016-05-19 09:22:13 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, cross-over study.</P>
<P>Two treatment arms: 1 placebo, 1 lamotrigine.</P>
<P>Pre-randomisation baseline = 4 weeks. Treatment I and II = 18 weeks each. Washout = 6 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-19 09:22:14 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Single centre UK study.</LI>
<LI>81 participants with drug-resistant partial epilepsy (33 men and 48 women).</LI>
<LI>41 were randomised to lamotrigine and 40 to placebo in the initial treatment phase.</LI>
<LI>The age range was 15 to 67 years (mean 33.7);</LI>
<LI>duration of epilepsy ranged from 4 to 45 years (mean 21).</LI>
<LI>The mean age at onset was 11.8 years (&lt;1 to 52 years).</LI>
<LI>Maximum number of other AEDS permitted was 2.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-17 20:38:35 +0000" MODIFIED_BY="[Empty name]">
<P>Add-on lamotrigine or placebo. Lamotrigine dose up to 400 mg/day. Median daily dose was 300 mg. Participants on valproate received lower doses. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-29 11:37:31 +0100" MODIFIED_BY="[Empty name]">
<P>(1) 50% responder rates.<BR/>(2) Withdrawal from study for any reason.<BR/>(3) Adverse effects.<BR/>(4) Health-related quality of life (HRQL).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-29 11:38:21 +0100" MODIFIED_BY="[Empty name]">
<P>HRQL model was completed by 40 to 54 of 81 participants.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AED: antiepileptic drug</P>
<P>LTG: lamotrigine</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-05-29 17:52:06 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-05-19 09:22:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biton-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 09:22:20 +0100" MODIFIED_BY="[Empty name]">
<P>Ineligible population: subjects included had primary generalized epilepsy and not partial seizures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-24 10:05:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biton-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-24 10:05:02 +0000" MODIFIED_BY="[Empty name]">
<P>Inelegible population: subjects included in the study had uncontrolled partial epilepsy and generalised tonic-clonic seizures.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-24 10:05:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brzakovic-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-24 10:05:03 +0000" MODIFIED_BY="[Empty name]">
<P>Inelegible population: subjects included in the study had uncontrolled partial epilepsy and generalised tonic-clonic seizures.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-13 16:10:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carignani-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-13 16:10:18 +0000" MODIFIED_BY="[Empty name]">
<P>Published as conference abstract: details of the methods and results are not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-13 16:10:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carignani-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-13 16:10:22 +0000" MODIFIED_BY="[Empty name]">
<P>Published as conference abstract: details of the methods and results are not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-13 16:14:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cramer-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-13 16:14:24 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-13 16:14:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-French-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-13 16:14:37 +0000" MODIFIED_BY="[Empty name]">
<P>No randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 09:22:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Girolineto-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 09:22:21 +0100" MODIFIED_BY="[Empty name]">
<P>Comparative study among therapeutic equivalents of lamotrigine. Not placebo controlled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-13 16:22:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hammer-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-13 16:22:25 +0000" MODIFIED_BY="[Empty name]">
<P>Published as conference abstract: details of the methods and results are not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-24 10:05:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hartung-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-24 10:05:16 +0000" MODIFIED_BY="[Empty name]">
<P>Inelegible population: subjects included in the study had epilepsy, migraine, pain, psychiatric disorders.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 09:22:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Helmstaedter-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 09:22:23 +0100" MODIFIED_BY="[Empty name]">
<P>Subjects included in the study had all epileptic types. Lacosamide as add-on for epilepsy and in comparison with lamotrigine and topiramate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-13 16:11:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kang-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-13 16:11:16 +0000" MODIFIED_BY="[Empty name]">
<P>Inelegible population: subjects included in the study had all epileptic types.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-13 16:11:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montouris-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-13 16:11:23 +0000" MODIFIED_BY="[Empty name]">
<P>Published as conference abstract: details of the methods and results are not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-13 16:11:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ohtahara-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-13 16:11:33 +0000" MODIFIED_BY="[Empty name]">
<P>Comparative study of lamotrigine and zonisamide. Not placebo controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-24 10:05:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sander-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-24 10:05:22 +0000" MODIFIED_BY="[Empty name]">
<P>Study of institutionalised people with severe epilepsy. Subjects included in the study had all epileptic types.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 09:22:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Semah-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 09:22:23 +0100" MODIFIED_BY="[Empty name]">
<P>No LTG add-on.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-29 17:52:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stolarek-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-29 17:52:06 +0100" MODIFIED_BY="[Empty name]">
<P>Details of the results are not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-13 16:13:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tomson-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-13 16:13:37 +0000" MODIFIED_BY="[Empty name]">
<P>Published as conference abstract: details of the methods and results are not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 09:22:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tomson-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 09:22:23 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-13 16:13:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Veendrick-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-13 16:13:48 +0000" MODIFIED_BY="[Empty name]">
<P>Published as conference abstract: details of the methods and results are not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-19 09:22:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamamoto-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-19 09:22:26 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>AED: antiepileptic drug</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-03-14 14:44:57 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-05-29 11:39:37 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-05-19 09:22:09 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 11:38:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baulac-2010">
<DESCRIPTION>
<P>Method of randomisation not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Binnie-1989">
<DESCRIPTION>
<P>Computer-generated random permuted blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boas-1996">
<DESCRIPTION>
<P>Computer-generated random permuted blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duchowny-1999">
<DESCRIPTION>
<P>Computer-generated random permuted blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jawad-1989">
<DESCRIPTION>
<P>Computer-generated random permuted blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loiseau-1990">
<DESCRIPTION>
<P>Computer-generated random permuted blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matsuo-1993">
<DESCRIPTION>
<P>Computer-generated random permuted blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Messenheimer-1994">
<DESCRIPTION>
<P>Computer-generated random permuted blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 19:51:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Naritoku-2007">
<DESCRIPTION>
<P>Method of randomisation not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 19:54:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pi_x00f1_a_x002d_Garza-2008">
<DESCRIPTION>
<P>Method of randomisation not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schachter-1995">
<DESCRIPTION>
<P>Computer-generated random permuted blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:22:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schapel-1993">
<DESCRIPTION>
<P>Computer-generated random permuted blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:22:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmidt-1993">
<DESCRIPTION>
<P>Computer-generated random permuted blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 20:40:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1993">
<DESCRIPTION>
<P>Computer generated random permuted blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-05-19 09:22:11 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 12:16:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baulac-2010">
<DESCRIPTION>
<P>The details were not mentioned in the publication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Binnie-1989">
<DESCRIPTION>
<P>Participants were allocated sequentially-numbered sealed packages containing either lamotrigine or placebo.<BR/>
<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boas-1996">
<DESCRIPTION>
<P>Partcipants were allocated sequentially-numbered, sealed packages containing either lamotrigine or placebo.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duchowny-1999">
<DESCRIPTION>
<P>Patients were randomised with a blocked randomisation scheme to treatment with add-on lamotrigine or matched placebo in bottles labelled with pre-generated participant numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jawad-1989">
<DESCRIPTION>
<P>Partcipants were allocated by sequentially numbered, sealed packages containing either lamotrigine or placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loiseau-1990">
<DESCRIPTION>
<P>Participants were allocated by sequentially numbered, sealed packages containing either lamotrigine or placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matsuo-1993">
<DESCRIPTION>
<P>Randomisation concealment: allocated sequentially numbered, sealed packages containing either lamotrigine or placebo.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Messenheimer-1994">
<DESCRIPTION>
<P>Participants were allocated by sequentially numbered, sealed packages containing either lamotrigine or placebo.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Naritoku-2007">
<DESCRIPTION>
<P>Details not reported in the publication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pi_x00f1_a_x002d_Garza-2008">
<DESCRIPTION>
<P>Details not reported in the publication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schachter-1995">
<DESCRIPTION>
<P>Participants were allocated by sequentially numbered, sealed packages containing either lamotrigine or placebo.<BR/>
<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:22:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schapel-1993">
<DESCRIPTION>
<P>Participants were allocated by sequentially numbered, sealed packages containing either lamotrigine or placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:22:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmidt-1993">
<DESCRIPTION>
<P>Participants were allocated by sequentially numbered, sealed packages containing either lamotrigine or placebo.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 20:40:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1993">
<DESCRIPTION>
<P>Partecipants were allocated sequentially numbered, sealed packages containing either lamotrigine or placebo.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-05-19 09:22:03 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-05-19 09:20:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baulac-2010">
<DESCRIPTION>
<P>No details provided regarding blinding of participants, study personnel, and outcome assessors.</P>
<P>Regarding the medications, blinding was maintained by administering the same numbers of capsules per day per group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-02-24 10:03:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Binnie-1989">
<DESCRIPTION>
<P>Participants and parents were blinded. An unblinded investigator with knowledge of the medication and plasma concentrations instructed the blinded investigators about dispensing the trial medications.</P>
<P>Identical tablets and packaging used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-02-24 10:03:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boas-1996">
<DESCRIPTION>
<P>No details provided regarding blinding of participants, study personnel, and outcome assessors.</P>
<P>All treatments (tablets) and packaging were identical. Prepacked coded medication was dispensed by pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-05-19 09:20:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duchowny-1999">
<DESCRIPTION>
<P>Treatment assignments were unknown to all study-site personnel, patients and sponsors. Lamotrigine and matching placebo were provided as berry-flavoured, chewable, dispersible caplets or tablets in strengths of 5, 25, and 100 mg.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-02-24 10:04:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jawad-1989">
<DESCRIPTION>
<P>No details provided regarding blinding of participants, study personnel, and outcome assessors.</P>
<P>Identical tablets and packaging used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-05-19 09:21:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loiseau-1990">
<DESCRIPTION>
<P>Neurologists, participants and parents were blinded. Investigators were blinded.</P>
<P>All treatments (tablets) and packaging were identical. Pre-packed coded medication dispensed by pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-02-24 10:04:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matsuo-1993">
<DESCRIPTION>
<P>No details provided regarding blinding of participants, study personnel, and outcome assessors.</P>
<P>Identical tablets and packaging used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-05-19 09:21:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Messenheimer-1994">
<DESCRIPTION>
<P>Investigators were blinded. No more information provided regarding blinding of neurologists, participants, and parents.</P>
<P>All treatments (tablets) and packaging were identical. Pre-packed coded medication dispensed by pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-05-19 09:21:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Naritoku-2007">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-05-19 09:21:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pi_x00f1_a_x002d_Garza-2008">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-02-24 10:04:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schachter-1995">
<DESCRIPTION>
<P>Neurologists, participants and parents were blinded. Investigators were blinded.</P>
<P>Identical tablets and packaging used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-05-19 09:22:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schapel-1993">
<DESCRIPTION>
<P>No details provided regarding blinding of participants, study personnel, and outcome assessors.</P>
<P>All treatments and packaging were identical. Pre-packed coded medication dispensed by pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-02-24 10:04:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-1993">
<DESCRIPTION>
<P>No details provided regarding blinding of participants and parents. Unblinded investigator wrote prescriptions based on plasma concentration.</P>
<P>Identical tablets and packaging were used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-02-24 10:04:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-1993">
<DESCRIPTION>
<P>Patients (46/73) and investigators (52/73) were able to identify lamotrigine treatment.</P>
<P>Identical tablets and packaging were used. Prepacked coded medication dispensed by pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-11-17 11:18:47 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-11-17 11:18:47 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-05-29 11:39:31 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME/>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-11-17 12:15:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baulac-2010">
<DESCRIPTION>
<P>35 withdrew from placebo group and 40 from lamotrigine group. The reasons for exclusion were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-11-17 11:53:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Binnie-1989">
<DESCRIPTION>
<P>No participants were excluded from analysis. No participant withdrew from the study during the first treatment phase.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-05-19 09:20:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boas-1996">
<DESCRIPTION>
<P>No participants were excluded from analysis. 10 participants withdrew from the study; 8 randomised to lamotrigine and 2 to placebo. The reasons for exclusion were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-05-16 19:08:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duchowny-1999">
<DESCRIPTION>
<P>No participants were excluded from analysis. 2 enrolled participants withdrew before randomisation. 14 participants allocated to lamotrigine and 18 participants allocated to placebo withdrew during treatment phase. The reasons for exclusion were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-05-19 09:20:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jawad-1989">
<DESCRIPTION>
<P>No participants were excluded from analysis. One participant who was allocated to lamotrigine withdrew from the study (the reason for exclusion was reported) and none withdrew from the placebo group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-11-18 16:04:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loiseau-1990">
<DESCRIPTION>
<P>No participants were excluded from analysis. 2 participants withdrew from the study; 1 receiving lamotrigine and 1 receiving placebo. The reasons for exclusion were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-11-17 12:45:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matsuo-1993">
<DESCRIPTION>
<P>No participants were excluded from analysis. 25 participants withdrew from the study; 7 receiving lamotrigine 300 mg, 12 receiving lamotrigine 500 mg and 6 receiving placebo. The reasons for exclusion were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-11-18 16:04:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Messenheimer-1994">
<DESCRIPTION>
<P>No participants were excluded from analysis. 6 participants withdrew from the study; 2 receiving lamotrigine and 4 receiving placebo. The reasons for exclusion were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-05-19 09:21:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naritoku-2007">
<DESCRIPTION>
<P>24 subjects withdrew from treatment group and 16 from placebo group. The reasons for exclusion were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-11-17 22:16:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pi_x00f1_a_x002d_Garza-2008">
<DESCRIPTION>
<P>11 patients (8 in the lamotrigine group and 3 in placebo group) completed the double-blind phase, 25 (9 in the lamotrigine group and 16 in placebo group) met escape criteria, and 2 (both in the lamotrigine group) prematurely withdrew because of protocol violations. The reasons for exclusion were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-11-17 20:08:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schachter-1995">
<DESCRIPTION>
<P>No participants were excluded from analysis. 73 participants withdrew from the study; 53 receiving lamotrigine and 20 receiving placebo. The reasons for exclusion were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-11-17 20:13:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schapel-1993">
<DESCRIPTION>
<P>No participants were excluded from analysis. None withdrew from the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-11-17 20:29:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmidt-1993">
<DESCRIPTION>
<P>No participants were excluded from analysis. 1 participant receiving lamotrigine and 9 receiving placebo withdrew from the study. The reasons for exclusion were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-05-29 11:39:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1993">
<DESCRIPTION>
<P>No participants were excluded from analysis. 9 people withdrew from the study; 6 receiving lamotrigine and 3 receiving placebo. The reasons for exclusion were reported.</P>
<P>Patients who discontinued prematurely did not complete the HRQOL measure at the time of discontinuation, the exclusion of treatment failures may introduce a bias in favour of lamotrigine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-05-19 09:21:54 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baulac-2010">
<DESCRIPTION>
<P>Protocol unavailable to check a priori outcomes, but appears all expected and pre-specified outcomes are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-19 16:14:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Binnie-1989">
<DESCRIPTION>
<P>All outcomes stated in methods section of paper were reported in the results. There was no protocol available to check to priori outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boas-1996">
<DESCRIPTION>
<P>All outcomes stated in methods section of paper were reported in the results. There was no protocol available to check a priori outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duchowny-1999">
<DESCRIPTION>
<P>All outcomes stated in methods section of paper were reported in the results.</P>
<P>There was no protocol available to check a priori outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jawad-1989">
<DESCRIPTION>
<P>All outcomes stated in methods section of paper were reported in the results.</P>
<P>There was no protocol available to check a priori outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loiseau-1990">
<DESCRIPTION>
<P>All outcomes stated in methods section of paper were reported in the results.</P>
<P>There was no protocol available to check a priori outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matsuo-1993">
<DESCRIPTION>
<P>Protocol unavailable to check a priori outcomes, but appears all expected and pre-specified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Messenheimer-1994">
<DESCRIPTION>
<P>All outcomes stated in methods section of paper were reported in the results.</P>
<P>There was no protocol available to check a priori outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naritoku-2007">
<DESCRIPTION>
<P>There was no protocol available to check a priori outcomes,but appears all expected and pre-specified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-19 16:17:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pi_x00f1_a_x002d_Garza-2008">
<DESCRIPTION>
<P>All expected and pre-specified outcomes were reported. Protocol was not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schachter-1995">
<DESCRIPTION>
<P>All outcomes stated in methods section of paper were reported in the results.</P>
<P>There was no protocol available to check a priori outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-19 16:18:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schapel-1993">
<DESCRIPTION>
<P>Protocol unavailable, but appears all expected and pre-specified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-19 16:18:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmidt-1993">
<DESCRIPTION>
<P>Protocol unavailable, but appears all expected and pre-specified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-19 16:16:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1993">
<DESCRIPTION>
<P>Protocol unavailable, but appears all expected and pre-specified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-05-29 11:39:37 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 11:36:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baulac-2010">
<DESCRIPTION>
<P>Responder rates were mentioned as percentages and actual numbers were not given. Author has been contacted regarding actual number of responders in each group.</P>
<P>This study was sponsored by Pfizer Inc.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Binnie-1989">
<DESCRIPTION>
<P>This study was sponsored by GlaxoSmithKline, the manufactures of LTG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boas-1996">
<DESCRIPTION>
<P>This study was sponsored by GlaxoSmithKline, the manufactures of LTG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duchowny-1999">
<DESCRIPTION>
<P>This study was sponsored by GlaxoSmithKline, the manufactures of LTG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:20:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jawad-1989">
<DESCRIPTION>
<P>This study was sponsored by GlaxoSmithKline, the manufactures of LTG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loiseau-1990">
<DESCRIPTION>
<P>This study was sponsored by GlaxoSmithKline, the manufactures of LTG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matsuo-1993">
<DESCRIPTION>
<P>This study was sponsored by GlaxoSmithKline, the manufactures of LTG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Messenheimer-1994">
<DESCRIPTION>
<P>This study was sponsored by GlaxoSmithKline, the manufactures of LTG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Naritoku-2007">
<DESCRIPTION>
<P>This study was sponsored by GlaxoSmithKline, the manufactures of LTG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pi_x00f1_a_x002d_Garza-2008">
<DESCRIPTION>
<P>This study was sponsored by GlaxoSmithKline, the manufactures of LTG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:21:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schachter-1995">
<DESCRIPTION>
<P>This study was sponsored by GlaxoSmithKline, the manufactures of LTG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:22:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schapel-1993">
<DESCRIPTION>
<P>This study was sponsored by GlaxoSmithKline, the manufactures of LTG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-19 09:22:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-1993">
<DESCRIPTION>
<P>This study was sponsored by GlaxoSmithKline, the manufactures of LTG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-29 11:39:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1993">
<DESCRIPTION>
<P> This study was sponsored by GlaxoSmithKline, the manufactures of LTG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-06-08 12:00:04 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-06-08 12:00:04 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-11-19 16:27:18 +0000" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Lamotrigine versus placebo for drug-resistant partial epilepsy </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>participants with drug-resistant partial epilepsy</P>
<P>
<B>Settings: </B>outpatient setting</P>
<P>
<B>Intervention: </B>Lamotrigine versus placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>
</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Placebo</P>
</TH>
<TH VALIGN="TOP">
<P>Lamotrigine</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>50% or greater reduction in seizure frequency - ITT analysis</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>157 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>283 per 1000</B>
<BR/>(223 to 350)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.80 </B>
</P>
<P>(95% CI 1.45 to 2.23)</P>
</TD>
<TD VALIGN="TOP">
<P>1322<BR/>(12 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high<SUP>1</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>RR &gt;1 indicates outcome is more likely in Lamotrigine group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Treatment withdrawal </B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>159 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>176 per 1000</B>
<BR/>(143 to 216)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.11</B>
</P>
<P>(95% CI 0.90 to 1.36)</P>
</TD>
<TD VALIGN="TOP">
<P>1805<BR/>(14 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high<SUP>2</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>RR &gt;1 indicates outcome is more likely in Lamotrigine group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Ataxia</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>45 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 per 1000</B>
<BR/>(90 to 250)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 3.34 </B>
</P>
<P>(99% CI 2.01 to 5.55)</P>
</TD>
<TD VALIGN="TOP">
<P>1524<BR/>(12 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>3</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>RR &gt;1 indicates outcome is more likely in Lamotrigine group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dizziness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>128 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>256 per 1000</B>
<BR/>(193 to 338)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 2.00</B>
</P>
<P>(99% CI 1.51 to 2.64)</P>
</TD>
<TD VALIGN="TOP">
<P>1767<BR/>(13 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high<SUP>1</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>RR &gt;1 indicates outcome is more likely in Lamotrigine group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Fatigue</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>113 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>93 per 1000</B>
<BR/>(62 to 138)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.82 </B>
</P>
<P>(99% CI 0.55 to 1.22)</P>
</TD>
<TD VALIGN="TOP">
<P>1551</P>
<P>(12 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high<SUP>1</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>RR &gt;1 indicates outcome is more likely in Lamotrigine group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Nausea</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>83 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 per 1000</B>
<BR/>(101 to 222)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.81 </B>
</P>
<P>(99% CI 1.22 to 2.68)</P>
</TD>
<TD VALIGN="TOP">
<P>1486<BR/>(12 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high<SUP>1</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>RR &gt;1 indicates outcome is more likely in Lamotrigine group</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes<SUP>4</SUP>. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk Ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1 </SUP>One or two studies do not contribute to the analysis, but no other bias.</P>
<P>
<SUP>2</SUP> All studies contributed to the analysis.</P>
<P>
<SUP>3 </SUP>Wide confidence intervals.</P>
<P>
<SUP>4</SUP>Assumed risk is calculated as the event rate in the control group per 1000 people (number of events divided by the number of participants receiving control treatment).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-05-29 13:44:13 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-05-29 13:44:13 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-05-29 13:44:13 +0100" MODIFIED_BY="[Empty name]">Cognitive outcomes</TITLE>
<TABLE COLS="5" ROWS="13">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Number tested</P>
</TH>
<TH>
<P>Lamotrigine mean</P>
</TH>
<TH>
<P>Placebo mean</P>
</TH>
</TR>
<TR>
<TD>
<P>Stroop time</P>
</TD>
<TD>
<P>
<LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>
</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>93.98</P>
</TD>
<TD>
<P>98.39</P>
</TD>
</TR>
<TR>
<TD>
<P>Stroop error</P>
</TD>
<TD>
<P>
<LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>
</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>2.18</P>
</TD>
<TD>
<P>2.41</P>
</TD>
</TR>
<TR>
<TD>
<P>Stroop colour word (Total score)</P>
</TD>
<TD>
<P>
<LINK REF="REF-Banks-1991" TYPE="REFERENCE">Banks 1991</LINK>
</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>32.4+/-10.9</P>
</TD>
<TD>
<P>35.6+/-9.42</P>
</TD>
</TR>
<TR>
<TD>
<P>Number cancellation: AC</P>
</TD>
<TD>
<P>
<LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>
</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>51.36</P>
</TD>
<TD>
<P>49.7</P>
</TD>
</TR>
<TR>
<TD>
<P>Number cancellation: AE</P>
</TD>
<TD>
<P>
<LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>
</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>3.6</P>
</TD>
<TD>
<P>3.04</P>
</TD>
</TR>
<TR>
<TD>
<P>Number cancellation: BC</P>
</TD>
<TD>
<P>
<LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>
</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>48.21</P>
</TD>
<TD>
<P>48.54</P>
</TD>
</TR>
<TR>
<TD>
<P>Number cancellation: C</P>
</TD>
<TD>
<P>
<LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>
</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>38.19</P>
</TD>
<TD>
<P>39.29</P>
</TD>
</TR>
<TR>
<TD>
<P>Critical flicker fusion</P>
</TD>
<TD>
<P>
<LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>
</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>30.44</P>
</TD>
<TD>
<P>30.37</P>
</TD>
</TR>
<TR>
<TD>
<P>Choice reaction time</P>
</TD>
<TD>
<P>
<LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>
</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>0.675</P>
</TD>
<TD>
<P>0.669</P>
</TD>
</TR>
<TR>
<TD>
<P>Digit symbol (Scaled score)</P>
</TD>
<TD>
<P>
<LINK REF="REF-Banks-1991" TYPE="REFERENCE">Banks 1991</LINK>
</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>5 +/-2.45</P>
</TD>
<TD>
<P>6.6 +/- 2.71</P>
</TD>
</TR>
<TR>
<TD>
<P>Rey complex figure recall percentile</P>
</TD>
<TD>
<P>
<LINK REF="REF-Banks-1991" TYPE="REFERENCE">Banks 1991</LINK>
</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>22+/-17.51</P>
</TD>
<TD>
<P>30.5+/-27.33</P>
</TD>
</TR>
<TR>
<TD>
<P>Trail making part B percentile</P>
</TD>
<TD>
<P>
<LINK REF="REF-Banks-1991" TYPE="REFERENCE">Banks 1991</LINK>
</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>26+/-30.35</P>
</TD>
<TD>
<P>30.5+/-32.09</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2016-05-19 09:23:04 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-05-19 09:22:54 +0100" MODIFIED_BY="[Empty name]">Health related quality of life outcomes (Smith 1993)</TITLE>
<TABLE COLS="5" ROWS="19">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Number tested</P>
</TH>
<TH>
<P>Lamotrigine - Mean</P>
</TH>
<TH>
<P>Placebo - Mean </P>
</TH>
<TH>
<P>Clinical relevance</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>PSYCHOLOGICAL:</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Depression</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>4.24</P>
</TD>
<TD>
<P>4.26</P>
</TD>
<TD>
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Happiness</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P>3.8</P>
</TD>
<TD>
<P>1.96</P>
</TD>
<TD>
<P>Higher scores in LTG group; P = 0.003</P>
</TD>
</TR>
<TR>
<TD>
<P>Mood</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>24.36</P>
</TD>
<TD>
<P>26.8</P>
</TD>
<TD>
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Self-esteem</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>30.06</P>
</TD>
<TD>
<P>29.16</P>
</TD>
<TD>
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Mastery</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>20.02</P>
</TD>
<TD>
<P>18.78</P>
</TD>
<TD>
<P>Higher scores in LTG group; P = 0.003</P>
</TD>
</TR>
<TR>
<TD>
<P>Anxiety</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>6.87</P>
</TD>
<TD>
<P>6.83</P>
</TD>
<TD>
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>PHYSICAL (Nottingham Health Profile):</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Energy</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>0.68</P>
</TD>
<TD>
<P>0.68</P>
</TD>
<TD>
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Pain</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>0.6</P>
</TD>
<TD>
<P>0.69</P>
</TD>
<TD>
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Emotional reaction</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>1.96</P>
</TD>
<TD>
<P>1.96</P>
</TD>
<TD>
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Sleep</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>0.89</P>
</TD>
<TD>
<P>0.76</P>
</TD>
<TD>
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Social isolation</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>0.92</P>
</TD>
<TD>
<P>0.94</P>
</TD>
<TD>
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Physical mobility</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>0.96</P>
</TD>
<TD>
<P>0.91</P>
</TD>
<TD>
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>SEIZURE SEVERITY SCALE:</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Percept</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>25.19</P>
</TD>
<TD>
<P>25.47</P>
</TD>
<TD>
<P>No significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Ictal</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>19.47</P>
</TD>
<TD>
<P>20.53</P>
</TD>
<TD>
<P>Less severe seizures in LTG group; P = 0.017</P>
</TD>
</TR>
<TR>
<TD>
<P>Caregivers</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>20.35</P>
</TD>
<TD>
<P>21.80</P>
</TD>
<TD>
<P>Less severe seizures in LTG group; P = 0.035</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-06-02 12:38:55 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-06-02 12:38:55 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Efficacy of add-on lamotrigine versus placebo - 50% responders</NAME>
<DICH_OUTCOME CHI2="23.11869766071549" CI_END="2.08201759473788" CI_START="1.5445832713688255" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="RR" EFFECT_SIZE="1.79327899322099" ESTIMABLE="YES" EVENTS_1="384" EVENTS_2="208" I2="0.0" I2_Q="35.32684386457633" ID="CMP-001.01" LOG_CI_END="0.3184843953307537" LOG_CI_START="0.1888113268952367" LOG_EFFECT_SIZE="0.2536478611129952" METHOD="MH" MODIFIED="2016-06-02 12:38:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5128003069199043" P_Q="0.15856689384888523" P_Z="1.7524306431977264E-14" Q="9.277419502206106" RANDOM="NO" SCALE="19.094182003450054" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1380" TOTAL_2="1337" WEIGHT="700.0" Z="7.66760096811164">
<NAME>Intention-to-treat analysis</NAME>
<GROUP_LABEL_1>Lamotrigine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lamotrigine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.472942580561278" CI_END="4.609896570218054" CI_START="1.442141844591126" DF="7" EFFECT_SIZE="2.5783957693008595" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="14" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.6636911814661186" LOG_CI_START="0.15900797834014252" LOG_EFFECT_SIZE="0.4113495799031306" NO="1" P_CHI2="0.8380831287908088" P_Z="0.00139832866837541" STUDIES="8" TAU2="0.0" TOTAL_1="187" TOTAL_2="195" WEIGHT="99.99999999999997" Z="3.1949958178599047">
<NAME>Cross-over</NAME>
<DICH_DATA CI_END="16.55254127889542" CI_START="0.0764610689485897" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2188646796026918" LOG_CI_START="-1.1165596347079294" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="84667" O_E="0.0" SE="1.3718398027628607" STUDY_ID="STD-Binnie-1989" TOTAL_1="16" TOTAL_2="18" VAR="1.8819444444444444" WEIGHT="6.816923315957354"/>
<DICH_DATA CI_END="4.109775980002234" CI_START="0.41121462781021983" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6138181495401986" LOG_CI_START="-0.38593144492652504" LOG_EFFECT_SIZE="0.11394335230683679" ORDER="84668" O_E="0.0" SE="0.5872578606300599" STUDY_ID="STD-Boas-1996" TOTAL_1="30" TOTAL_2="26" VAR="0.34487179487179487" WEIGHT="31.041347242305807"/>
<DICH_DATA CI_END="42.59442830538803" CI_START="0.8451809645593047" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6293527935984997" LOG_CI_START="-0.07305029283121235" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="84669" O_E="0.0" SE="1.0" STUDY_ID="STD-Jawad-1989" TOTAL_1="12" TOTAL_2="12" VAR="1.0000000000000002" WEIGHT="7.242981023204688"/>
<DICH_DATA CI_END="24.56080078230795" CI_START="0.2638081266325207" EFFECT_SIZE="2.5454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3902425224719004" LOG_CI_START="-0.5787118301039119" LOG_EFFECT_SIZE="0.4057653461839942" ORDER="84670" O_E="0.0" SE="1.1565735331842666" STUDY_ID="STD-Loiseau-1990" TOTAL_1="11" TOTAL_2="14" VAR="1.3376623376623378" WEIGHT="6.373823300420126"/>
<DICH_DATA CI_END="8.401803281079848" CI_START="0.9506015814257203" EFFECT_SIZE="2.8260869565217392" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.9243725087966327" LOG_CI_START="-0.022001467546107163" LOG_EFFECT_SIZE="0.45118552062526274" ORDER="84671" O_E="0.0" SE="0.5559047583304609" STUDY_ID="STD-Messenheimer-1994" TOTAL_1="46" TOTAL_2="52" VAR="0.30903010033444817" WEIGHT="27.19813282182985"/>
<DICH_DATA CI_END="41.10291930513015" CI_START="0.6705728076243932" EFFECT_SIZE="5.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6138726684231326" LOG_CI_START="-0.17355406161121895" LOG_EFFECT_SIZE="0.7201593034059569" ORDER="84672" O_E="0.0" SE="1.049943309127189" STUDY_ID="STD-Schapel-1993" TOTAL_1="20" TOTAL_2="21" VAR="1.1023809523809522" WEIGHT="7.066322949467988"/>
<DICH_DATA CI_END="15.414774237929704" CI_START="0.077204026880898" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.187937168508564" LOG_CI_START="-1.1123600467297645" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="84673" O_E="0.0" SE="1.3512059708858513" STUDY_ID="STD-Schmidt-1993" TOTAL_1="11" TOTAL_2="12" VAR="1.825757575757576" WEIGHT="6.928068804804485"/>
<DICH_DATA CI_END="33.420856049740024" CI_START="0.4556744541916766" EFFECT_SIZE="3.902439024390244" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5240175698217917" LOG_CI_START="-0.34134531794941303" LOG_EFFECT_SIZE="0.5913361259361892" ORDER="84674" O_E="0.0" SE="1.0957233939720192" STUDY_ID="STD-Smith-1993" TOTAL_1="41" TOTAL_2="40" VAR="1.200609756097561" WEIGHT="7.332400542009685"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.672750319742935" CI_START="0.5695516635988138" DF="0" EFFECT_SIZE="1.2338028169014084" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.426958390173466" LOG_CI_START="-0.24446687527545516" LOG_EFFECT_SIZE="0.09124575744900541" NO="2" P_CHI2="1.0" P_Z="0.5942324440486266" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="73" WEIGHT="100.0" Z="0.532712745691972">
<NAME>Parallel group lamotrigine - 300 mg</NAME>
<DICH_DATA CI_END="2.672750319742935" CI_START="0.5695516635988138" EFFECT_SIZE="1.2338028169014084" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.426958390173466" LOG_CI_START="-0.24446687527545516" LOG_EFFECT_SIZE="0.09124575744900541" ORDER="84675" O_E="0.0" SE="0.3943985245333627" STUDY_ID="STD-Matsuo-1993" TOTAL_1="71" TOTAL_2="73" VAR="0.15555019615409352" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.19868463760525" CI_START="1.0797073573570592" DF="0" EFFECT_SIZE="2.129166666666667" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.6231132560879905" LOG_CI_START="0.03330606075822302" LOG_EFFECT_SIZE="0.32820965842310673" NO="3" P_CHI2="1.0" P_Z="0.029159757589977818" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="73" WEIGHT="100.0" Z="2.181319980431294">
<NAME>Parallel group lamotrigine - 500 mg</NAME>
<DICH_DATA CI_END="4.19868463760525" CI_START="1.0797073573570592" EFFECT_SIZE="2.129166666666667" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.6231132560879905" LOG_CI_START="0.03330606075822302" LOG_EFFECT_SIZE="0.32820965842310673" ORDER="84676" O_E="0.0" SE="0.34645566612940887" STUDY_ID="STD-Matsuo-1993" TOTAL_1="72" TOTAL_2="73" VAR="0.12003152859317243" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.38261899548691" CI_START="1.5914193251926387" DF="0" EFFECT_SIZE="2.6409438775510203" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="16" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.6417337167525394" LOG_CI_START="0.20178462755537738" LOG_EFFECT_SIZE="0.4217591721539584" NO="4" P_CHI2="1.0" P_Z="1.713750612326087E-4" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="101" WEIGHT="100.0" Z="3.757856569630191">
<NAME>Parallel group (children)</NAME>
<DICH_DATA CI_END="4.38261899548691" CI_START="1.5914193251926387" EFFECT_SIZE="2.6409438775510203" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="16" LOG_CI_END="0.6417337167525394" LOG_CI_START="0.20178462755537738" LOG_EFFECT_SIZE="0.4217591721539584" ORDER="84677" O_E="0.0" SE="0.25842827277752733" STUDY_ID="STD-Duchowny-1999" TOTAL_1="98" TOTAL_2="101" VAR="0.06678517217077606" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5017152325794267" CI_START="1.1601314815624844" DF="0" EFFECT_SIZE="1.7036192647477915" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="29" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="0.3982378729201957" LOG_CI_START="0.0645072120555158" LOG_EFFECT_SIZE="0.23137254248785574" MODIFIED="2010-03-14 14:33:02 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.006574700664731246" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="122" WEIGHT="100.0" Z="2.717651708193136">
<NAME>Parallel Group -Adults-Lamotrigine ER</NAME>
<DICH_DATA CI_END="2.5017152325794263" CI_START="1.1601314815624846" EFFECT_SIZE="1.7036192647477915" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="29" LOG_CI_END="0.3982378729201956" LOG_CI_START="0.06450721205551588" LOG_EFFECT_SIZE="0.23137254248785574" MODIFIED="2010-03-14 14:33:02 +0000" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.19603504218532716" STUDY_ID="STD-Naritoku-2007" TOTAL_1="121" TOTAL_2="122" VAR="0.038429737764603004" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7455513446129518" CI_START="0.7358388215897765" DF="0" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="30" I2="0.0" ID="CMP-001.01.06" LOG_CI_END="0.24193262791623849" LOG_CI_START="-0.13321730327105313" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2016-06-02 12:38:55 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.5700477131730566" STUDIES="1" TAU2="0.0" TOTAL_1="141" TOTAL_2="141" WEIGHT="100.0" Z="0.5679812340569641">
<NAME>Parallel Group 300 to 600mg</NAME>
<DICH_DATA CI_END="1.7455513446129518" CI_START="0.7358388215897765" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="30" LOG_CI_END="0.24193262791623849" LOG_CI_START="-0.13321730327105313" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2012-10-12 18:19:27 +0100" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.22036492660152415" STUDY_ID="STD-Baulac-2010" TOTAL_1="141" TOTAL_2="141" VAR="0.048560700876095125" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.015199772329364" CI_END="2.227864359902056" CI_START="1.4493513162784422" DF="11" EFFECT_SIZE="1.7969301996777374" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="99" I2="0.13798907549136272" ID="CMP-001.01.07" LOG_CI_END="0.34788874595443847" LOG_CI_START="0.16117366927236218" LOG_EFFECT_SIZE="0.25453120761340026" MODIFIED="2012-10-12 18:18:20 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.44199095703430025" P_Z="9.108266292222261E-8" STUDIES="12" TAU2="0.0" TOTAL_1="690" TOTAL_2="632" WEIGHT="100.00000000000001" Z="5.343671317053758">
<NAME>Any dose lamotrigine, adults or children</NAME>
<DICH_DATA CI_END="1.7455513446129518" CI_START="0.7358388215897765" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="30" LOG_CI_END="0.24193262791623849" LOG_CI_START="-0.13321730327105313" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2012-10-12 18:14:22 +0100" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.22036492660152415" STUDY_ID="STD-Baulac-2010" TOTAL_1="141" TOTAL_2="141" VAR="0.048560700876095125" WEIGHT="29.50239400140315"/>
<DICH_DATA CI_END="16.55254127889542" CI_START="0.0764610689485897" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2188646796026918" LOG_CI_START="-1.1165596347079294" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="84678" O_E="0.0" SE="1.3718398027628607" STUDY_ID="STD-Binnie-1989" TOTAL_1="16" TOTAL_2="18" VAR="1.8819444444444444" WEIGHT="0.9255653020048047"/>
<DICH_DATA CI_END="4.109775980002234" CI_START="0.41121462781021983" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6138181495401986" LOG_CI_START="-0.38593144492652504" LOG_EFFECT_SIZE="0.11394335230683679" ORDER="84679" O_E="0.0" SE="0.5872578606300599" STUDY_ID="STD-Boas-1996" TOTAL_1="30" TOTAL_2="26" VAR="0.34487179487179487" WEIGHT="4.214627714486165"/>
<DICH_DATA CI_END="4.38261899548691" CI_START="1.5914193251926387" EFFECT_SIZE="2.6409438775510203" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="16" LOG_CI_END="0.6417337167525394" LOG_CI_START="0.20178462755537738" LOG_EFFECT_SIZE="0.4217591721539584" ORDER="84680" O_E="0.0" SE="0.25842827277752733" STUDY_ID="STD-Duchowny-1999" TOTAL_1="98" TOTAL_2="101" VAR="0.06678517217077606" WEIGHT="15.497404956180953"/>
<DICH_DATA CI_END="42.59442830538803" CI_START="0.8451809645593047" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6293527935984997" LOG_CI_START="-0.07305029283121235" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="84681" O_E="0.0" SE="1.0" STUDY_ID="STD-Jawad-1989" TOTAL_1="12" TOTAL_2="12" VAR="1.0000000000000002" WEIGHT="0.983413133380105"/>
<DICH_DATA CI_END="24.56080078230795" CI_START="0.2638081266325207" EFFECT_SIZE="2.5454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3902425224719004" LOG_CI_START="-0.5787118301039119" LOG_EFFECT_SIZE="0.4057653461839942" ORDER="84682" O_E="0.0" SE="1.1565735331842666" STUDY_ID="STD-Loiseau-1990" TOTAL_1="11" TOTAL_2="14" VAR="1.3376623376623378" WEIGHT="0.8654035573744925"/>
<DICH_DATA CI_END="3.2233930231985104" CI_START="0.8804166831839881" EFFECT_SIZE="1.6846153846153846" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="10" LOG_CI_END="0.5083132615781438" LOG_CI_START="-0.055311736511580584" LOG_EFFECT_SIZE="0.22650076253328158" ORDER="84683" O_E="0.0" SE="0.331076113866641" STUDY_ID="STD-Matsuo-1993" TOTAL_1="143" TOTAL_2="73" VAR="0.10961139317303702" WEIGHT="13.021118340125465"/>
<DICH_DATA CI_END="8.401803281079848" CI_START="0.9506015814257203" EFFECT_SIZE="2.8260869565217392" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.9243725087966327" LOG_CI_START="-0.022001467546107163" LOG_EFFECT_SIZE="0.45118552062526274" ORDER="84684" O_E="0.0" SE="0.5559047583304609" STUDY_ID="STD-Messenheimer-1994" TOTAL_1="46" TOTAL_2="52" VAR="0.30903010033444817" WEIGHT="3.692816664121211"/>
<DICH_DATA CI_END="2.5017152325794263" CI_START="1.1601314815624846" EFFECT_SIZE="1.7036192647477915" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="29" LOG_CI_END="0.3982378729201956" LOG_CI_START="0.06450721205551588" LOG_EFFECT_SIZE="0.23137254248785574" MODIFIED="2010-03-14 14:33:26 +0000" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.19603504218532716" STUDY_ID="STD-Naritoku-2007" TOTAL_1="121" TOTAL_2="122" VAR="0.038429737764603004" WEIGHT="28.401618806837767"/>
<DICH_DATA CI_END="41.10291930513015" CI_START="0.6705728076243932" EFFECT_SIZE="5.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6138726684231326" LOG_CI_START="-0.17355406161121895" LOG_EFFECT_SIZE="0.7201593034059569" ORDER="84685" O_E="0.0" SE="1.049943309127189" STUDY_ID="STD-Schapel-1993" TOTAL_1="20" TOTAL_2="21" VAR="1.1023809523809522" WEIGHT="0.9594274472001024"/>
<DICH_DATA CI_END="15.414774237929704" CI_START="0.077204026880898" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.187937168508564" LOG_CI_START="-1.1123600467297645" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="84686" O_E="0.0" SE="1.3512059708858513" STUDY_ID="STD-Schmidt-1993" TOTAL_1="11" TOTAL_2="12" VAR="1.825757575757576" WEIGHT="0.9406560406244483"/>
<DICH_DATA CI_END="33.420856049740024" CI_START="0.4556744541916766" EFFECT_SIZE="3.902439024390244" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5240175698217917" LOG_CI_START="-0.34134531794941303" LOG_EFFECT_SIZE="0.5913361259361892" ORDER="84687" O_E="0.0" SE="1.0957233939720192" STUDY_ID="STD-Smith-1993" TOTAL_1="41" TOTAL_2="40" VAR="1.200609756097561" WEIGHT="0.995554036261341"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.7975700677461" CI_END="1.1504469170626694" CI_START="0.8201723412913139" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9713726069324086" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="184" I2="49.53565940693216" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.06086658462255176" LOG_CI_START="-0.0860948805339007" LOG_EFFECT_SIZE="-0.012614147955674487" METHOD="MH" MODIFIED="2012-10-12 18:26:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.025989267617194334" P_Q="1.0" P_Z="0.7365245404190067" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="690" TOTAL_2="632" WEIGHT="100.0" Z="0.336459297850108">
<NAME>Worst case scenario</NAME>
<GROUP_LABEL_1>Lamotrigine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lamotrigine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7370452803074362" CI_START="0.37122477379068675" EFFECT_SIZE="0.5230769230769231" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="65" LOG_CI_END="-0.13250583048072095" LOG_CI_START="-0.4303630487204799" LOG_EFFECT_SIZE="-0.28143443960060044" MODIFIED="2012-10-12 18:26:55 +0100" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.1749628044110438" STUDY_ID="STD-Baulac-2010" TOTAL_1="141" TOTAL_2="141" VAR="0.030611982927377168" WEIGHT="34.5544516143313"/>
<DICH_DATA CI_END="16.55254127889542" CI_START="0.0764610689485897" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2188646796026918" LOG_CI_START="-1.1165596347079294" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="84688" O_E="0.0" SE="1.3718398027628607" STUDY_ID="STD-Binnie-1989" TOTAL_1="16" TOTAL_2="18" VAR="1.8819444444444444" WEIGHT="0.5003359509767428"/>
<DICH_DATA CI_END="2.36136780417904" CI_START="0.31808306600175934" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.37316363760165305" LOG_CI_START="-0.49745945109934203" LOG_EFFECT_SIZE="-0.06214790674884446" ORDER="84689" O_E="0.0" SE="0.5114083119567587" STUDY_ID="STD-Boas-1996" TOTAL_1="30" TOTAL_2="26" VAR="0.2615384615384615" WEIGHT="3.4174732365822162"/>
<DICH_DATA CI_END="1.7809550895450215" CI_START="0.8672563882620573" EFFECT_SIZE="1.242797118847539" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="34" LOG_CI_END="0.2506529679704326" LOG_CI_START="-0.061852492435176404" LOG_EFFECT_SIZE="0.09440023776762811" ORDER="84690" O_E="0.0" SE="0.18356725436923224" STUDY_ID="STD-Duchowny-1999" TOTAL_1="98" TOTAL_2="101" VAR="0.033696936876658416" WEIGHT="17.802154275833303"/>
<DICH_DATA CI_END="42.59442830538803" CI_START="0.8451809645593047" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6293527935984997" LOG_CI_START="-0.07305029283121235" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="84691" O_E="0.0" SE="1.0" STUDY_ID="STD-Jawad-1989" TOTAL_1="12" TOTAL_2="12" VAR="1.0000000000000002" WEIGHT="0.5316069479127892"/>
<DICH_DATA CI_END="7.652232522549431" CI_START="0.21168132384510113" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8837881581307248" LOG_CI_START="-0.6743174570906989" LOG_EFFECT_SIZE="0.10473535052001298" ORDER="84692" O_E="0.0" SE="0.9152389511282492" STUDY_ID="STD-Loiseau-1990" TOTAL_1="11" TOTAL_2="14" VAR="0.8376623376623377" WEIGHT="0.9356282283265089"/>
<DICH_DATA CI_END="1.7822094254486784" CI_START="0.6220178153499124" EFFECT_SIZE="1.0528846153846154" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="16" LOG_CI_END="0.25095873616138853" LOG_CI_START="-0.20619717640667493" LOG_EFFECT_SIZE="0.022380779877356802" ORDER="84693" O_E="0.0" SE="0.2685356460007442" STUDY_ID="STD-Matsuo-1993" TOTAL_1="143" TOTAL_2="73" VAR="0.07211139317303701" WEIGHT="11.262191637263534"/>
<DICH_DATA CI_END="3.275745654254175" CI_START="0.609538127254323" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.5153101735394875" LOG_CI_START="-0.21499912361692441" LOG_EFFECT_SIZE="0.1501555249612815" ORDER="84694" O_E="0.0" SE="0.4289872962390007" STUDY_ID="STD-Messenheimer-1994" TOTAL_1="46" TOTAL_2="52" VAR="0.18403010033444817" WEIGHT="3.9924766700389065"/>
<DICH_DATA CI_END="1.5074955125417457" CI_START="0.799576506857614" EFFECT_SIZE="1.0978879706152433" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="45" LOG_CI_END="0.17825602802196786" LOG_CI_START="-0.0971399747990316" LOG_EFFECT_SIZE="0.04055802661146813" MODIFIED="2010-03-14 14:37:14 +0000" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.16176897528925493" STUDY_ID="STD-Naritoku-2007" TOTAL_1="121" TOTAL_2="122" VAR="0.026169201366135576" WEIGHT="23.823866924980553"/>
<DICH_DATA CI_END="41.10291930513015" CI_START="0.6705728076243932" EFFECT_SIZE="5.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6138726684231326" LOG_CI_START="-0.17355406161121895" LOG_EFFECT_SIZE="0.7201593034059569" ORDER="84695" O_E="0.0" SE="1.049943309127189" STUDY_ID="STD-Schapel-1993" TOTAL_1="20" TOTAL_2="21" VAR="1.1023809523809522" WEIGHT="0.5186409247929651"/>
<DICH_DATA CI_END="15.414774237929704" CI_START="0.077204026880898" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.187937168508564" LOG_CI_START="-1.1123600467297645" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="84696" O_E="0.0" SE="1.3512059708858513" STUDY_ID="STD-Schmidt-1993" TOTAL_1="11" TOTAL_2="12" VAR="1.825757575757576" WEIGHT="0.5084936023513635"/>
<DICH_DATA CI_END="3.6363545103743022" CI_START="0.26174961585215983" EFFECT_SIZE="0.975609756097561" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.560666216242497" LOG_CI_START="-0.5821139470260432" LOG_EFFECT_SIZE="-0.010723865391773113" ORDER="84697" O_E="0.0" SE="0.6712747247569812" STUDY_ID="STD-Smith-1993" TOTAL_1="41" TOTAL_2="40" VAR="0.45060975609756093" WEIGHT="2.152679986609813"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.256293983965288" CI_END="3.4996041376954463" CI_START="2.3645817823604434" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="2.876647387058046" ESTIMABLE="YES" EVENTS_1="308" EVENTS_2="99" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.5440189213395275" LOG_CI_START="0.373754339291871" LOG_EFFECT_SIZE="0.45888663031569926" METHOD="MH" MODIFIED="2012-10-12 18:25:58 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9181217313708847" P_Q="1.0" P_Z="4.3412945869239744E-26" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="690" TOTAL_2="632" WEIGHT="100.0" Z="10.564748787906785">
<NAME>Best case scenario</NAME>
<GROUP_LABEL_1>Lamotrigine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lamotrigine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.515167627534344" CI_START="1.7309116062588108" EFFECT_SIZE="2.466666666666667" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="30" LOG_CI_END="0.5459460400179639" LOG_CI_START="0.2382748900046636" LOG_EFFECT_SIZE="0.3921104650113138" MODIFIED="2012-10-12 18:25:58 +0100" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.18072755651456776" STUDY_ID="STD-Baulac-2010" TOTAL_1="141" TOTAL_2="141" VAR="0.03266244968372628" WEIGHT="29.502394001403154"/>
<DICH_DATA CI_END="16.55254127889542" CI_START="0.0764610689485897" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2188646796026918" LOG_CI_START="-1.1165596347079294" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="84698" O_E="0.0" SE="1.3718398027628607" STUDY_ID="STD-Binnie-1989" TOTAL_1="16" TOTAL_2="18" VAR="1.8819444444444444" WEIGHT="0.9255653020048048"/>
<DICH_DATA CI_END="8.076235967819605" CI_START="1.1392821046553943" EFFECT_SIZE="3.033333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.9072089994772538" LOG_CI_START="0.05663127572560871" LOG_EFFECT_SIZE="0.48192013760143115" ORDER="84699" O_E="0.0" SE="0.4996335653593537" STUDY_ID="STD-Boas-1996" TOTAL_1="30" TOTAL_2="26" VAR="0.2496336996336996" WEIGHT="4.214627714486165"/>
<DICH_DATA CI_END="5.739032110611916" CI_START="2.186942452834168" EFFECT_SIZE="3.5427295918367347" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="16" LOG_CI_END="0.7588386546864168" LOG_CI_START="0.3398373551705168" LOG_EFFECT_SIZE="0.5493380049284667" ORDER="84700" O_E="0.0" SE="0.24612343742552278" STUDY_ID="STD-Duchowny-1999" TOTAL_1="98" TOTAL_2="101" VAR="0.060576746450155226" WEIGHT="15.497404956180954"/>
<DICH_DATA CI_END="48.54060500398487" CI_START="1.0094641382400862" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.6861051850213529" LOG_CI_START="0.004090895007160764" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="84701" O_E="0.0" SE="0.9880235200593537" STUDY_ID="STD-Jawad-1989" TOTAL_1="12" TOTAL_2="12" VAR="0.9761904761904762" WEIGHT="0.9834131333801052"/>
<DICH_DATA CI_END="31.83930136142239" CI_START="0.4578778984880004" EFFECT_SIZE="3.8181818181818183" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5029635295993016" LOG_CI_START="-0.33925031911995085" LOG_EFFECT_SIZE="0.5818566052396754" ORDER="84702" O_E="0.0" SE="1.0821255338433111" STUDY_ID="STD-Loiseau-1990" TOTAL_1="11" TOTAL_2="14" VAR="1.170995670995671" WEIGHT="0.8654035573744926"/>
<DICH_DATA CI_END="4.91123098167689" CI_START="1.4347953896971755" EFFECT_SIZE="2.6545454545454548" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="10" LOG_CI_END="0.6911903600547774" LOG_CI_START="0.15678997252560908" LOG_EFFECT_SIZE="0.42399016629019326" ORDER="84703" O_E="0.0" SE="0.3139094329592151" STUDY_ID="STD-Matsuo-1993" TOTAL_1="143" TOTAL_2="73" VAR="0.09853913210077594" WEIGHT="13.021118340125467"/>
<DICH_DATA CI_END="9.786263532556713" CI_START="1.1752131077732626" EFFECT_SIZE="3.391304347826087" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.9906169066205429" LOG_CI_START="0.07011662672523224" LOG_EFFECT_SIZE="0.5303667666728875" ORDER="84704" O_E="0.0" SE="0.540706420960378" STUDY_ID="STD-Messenheimer-1994" TOTAL_1="46" TOTAL_2="52" VAR="0.2923634336677815" WEIGHT="3.6928166641212115"/>
<DICH_DATA CI_END="3.5983196329675837" CI_START="1.790189092829052" EFFECT_SIZE="2.5380450270732404" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="29" LOG_CI_END="0.5560997384060095" LOG_CI_START="0.25289890675358656" LOG_EFFECT_SIZE="0.404499322579798" MODIFIED="2010-03-14 14:38:16 +0000" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.1781016693809555" STUDY_ID="STD-Naritoku-2007" TOTAL_1="121" TOTAL_2="122" VAR="0.03172020463628319" WEIGHT="28.40161880683777"/>
<DICH_DATA CI_END="41.10291930513015" CI_START="0.6705728076243932" EFFECT_SIZE="5.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6138726684231326" LOG_CI_START="-0.17355406161121895" LOG_EFFECT_SIZE="0.7201593034059569" ORDER="84705" O_E="0.0" SE="1.049943309127189" STUDY_ID="STD-Schapel-1993" TOTAL_1="20" TOTAL_2="21" VAR="1.1023809523809522" WEIGHT="0.9594274472001025"/>
<DICH_DATA CI_END="20.8403581513736" CI_START="0.22841884692843634" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.318905178246906" LOG_CI_START="-0.6412680651401439" LOG_EFFECT_SIZE="0.33881855655338095" ORDER="84706" O_E="0.0" SE="1.151415466179596" STUDY_ID="STD-Schmidt-1993" TOTAL_1="11" TOTAL_2="12" VAR="1.325757575757576" WEIGHT="0.9406560406244484"/>
<DICH_DATA CI_END="72.73633039996456" CI_START="1.3085818200600423" EFFECT_SIZE="9.75609756097561" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.8617513868032842" LOG_CI_START="0.11680088241316931" LOG_EFFECT_SIZE="0.9892761346082268" ORDER="84707" O_E="0.0" SE="1.0249925639230566" STUDY_ID="STD-Smith-1993" TOTAL_1="41" TOTAL_2="40" VAR="1.0506097560975611" WEIGHT="0.9955540362613411"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-02-24 09:54:01 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Treatment withdrawal (global outcome)</NAME>
<DICH_OUTCOME CHI2="13.011532607093992" CI_END="1.3645805932729795" CI_START="0.9043886459827727" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1109055743331737" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="121" I2="15.45961315884716" I2_Q="58.890606460220084" ID="CMP-002.01" LOG_CI_END="0.13499919055931414" LOG_CI_START="-0.04364489858008546" LOG_EFFECT_SIZE="0.04567714598961433" METHOD="MH" MODIFIED="2016-02-24 09:54:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.292572520170696" P_Q="0.06299359541645866" P_Z="0.3162091374561007" Q="7.297602182082837" RANDOM="NO" SCALE="203.55365339191783" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1043" TOTAL_2="762" WEIGHT="100.00000000000001" Z="1.0022784575465429">
<NAME>Withdrawal from treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>More in controls</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More in Lamotrigine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.6191246644933504" CI_END="1.4986060020619978" CI_START="0.9018419020547883" DF="3" EFFECT_SIZE="1.1625427679575122" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="77" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.17568746765697463" LOG_CI_START="-0.04486959004474231" LOG_EFFECT_SIZE="0.06540893880611616" MODIFIED="2012-09-20 12:38:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4541466555875946" P_Z="0.24503106600005464" STUDIES="4" TAU2="0.0" TOTAL_1="739" TOTAL_2="447" WEIGHT="66.6444499454442" Z="1.1625033962898577">
<NAME>Parallel studies - adults</NAME>
<DICH_DATA CI_END="1.6738751850410856" CI_START="0.7692697746801882" EFFECT_SIZE="1.1347517730496455" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="35" LOG_CI_END="0.2237230710593577" LOG_CI_START="-0.11392133105826785" LOG_EFFECT_SIZE="0.05490087000054491" MODIFIED="2012-09-20 12:38:06 +0100" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.19833399317063918" STUDY_ID="STD-Baulac-2010" TOTAL_1="141" TOTAL_2="140" VAR="0.03933637284701115" WEIGHT="26.314085564622914"/>
<DICH_DATA CI_END="3.871949693628322" CI_START="0.6749143160662785" EFFECT_SIZE="1.6165501165501166" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.5879297060946328" LOG_CI_START="-0.17075135964547392" LOG_EFFECT_SIZE="0.20858917322457943" ORDER="84708" O_E="0.0" SE="0.4456530135475825" STUDY_ID="STD-Matsuo-1993" TOTAL_1="143" TOTAL_2="73" VAR="0.19860660848404177" WEIGHT="5.9516993146642045"/>
<DICH_DATA CI_END="2.7024023195486246" CI_START="0.8464112630920679" EFFECT_SIZE="1.512396694214876" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.43175000499437566" LOG_CI_START="-0.07241856616641683" LOG_EFFECT_SIZE="0.1796657194139794" MODIFIED="2010-03-14 14:21:06 +0000" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.2961511143745265" STUDY_ID="STD-Naritoku-2007" TOTAL_1="121" TOTAL_2="122" VAR="0.0877054825452739" WEIGHT="11.937311445936182"/>
<DICH_DATA CI_END="1.4185398875159083" CI_START="0.5566642198422838" EFFECT_SIZE="0.888622754491018" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="20" LOG_CI_END="0.15184155210543776" LOG_CI_START="-0.25440669251458775" LOG_EFFECT_SIZE="-0.05128257020457499" ORDER="84709" O_E="0.0" SE="0.23863222985104623" STUDY_ID="STD-Schachter-1995" TOTAL_1="334" TOTAL_2="112" VAR="0.05694534112368256" WEIGHT="22.441353620220887"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5213485364957233" CI_START="0.42235042572561604" DF="0" EFFECT_SIZE="0.8015873015873016" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.1822287210461525" LOG_CI_START="-0.3743270637159931" LOG_EFFECT_SIZE="-0.0960491713349203" NO="2" P_CHI2="1.0" P_Z="0.49872798915209715" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="101" WEIGHT="13.281678085477585" Z="0.6764925339579898">
<NAME>Parallel studies in children</NAME>
<DICH_DATA CI_END="1.5213485364957233" CI_START="0.42235042572561604" EFFECT_SIZE="0.8015873015873016" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.1822287210461525" LOG_CI_START="-0.3743270637159931" LOG_EFFECT_SIZE="-0.0960491713349203" ORDER="84710" O_E="0.0" SE="0.32692362296485095" STUDY_ID="STD-Duchowny-1999" TOTAL_1="98" TOTAL_2="101" VAR="0.10687905525246402" WEIGHT="13.281678085477585"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9931552715863" CI_END="3.7176157144251056" CI_START="0.8919132577142233" DF="5" EFFECT_SIZE="1.8209312844757446" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.5702644952448829" LOG_CI_START="-0.049677380520587636" LOG_EFFECT_SIZE="0.26029355736214754" NO="3" P_CHI2="0.7010413485334754" P_Z="0.09979442615294001" STUDIES="8" TAU2="0.0" TOTAL_1="187" TOTAL_2="195" WEIGHT="8.087232789894387" Z="1.6458510637233363">
<NAME>Cross-over studies</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="84711" O_E="0.0" SE="0.0" STUDY_ID="STD-Binnie-1989" TOTAL_1="16" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.894184564605663" CI_START="0.8068771892579241" EFFECT_SIZE="3.466666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.173016731197505" LOG_CI_START="-0.09319256203926927" LOG_EFFECT_SIZE="0.5399120845791179" ORDER="84712" O_E="0.0" SE="0.7437776066843692" STUDY_ID="STD-Boas-1996" TOTAL_1="30" TOTAL_2="26" VAR="0.5532051282051282" WEIGHT="1.6053534614978373"/>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="84713" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Jawad-1989" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="0.3745824743494954"/>
<DICH_DATA CI_END="18.13959594442618" CI_START="0.08929827961474163" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2586276090162232" LOG_CI_START="-1.049156907976197" LOG_EFFECT_SIZE="0.10473535052001298" ORDER="84714" O_E="0.0" SE="1.3556040489989463" STUDY_ID="STD-Loiseau-1990" TOTAL_1="11" TOTAL_2="14" VAR="1.8376623376623378" WEIGHT="0.6592651548551118"/>
<DICH_DATA CI_END="2.9441547004382738" CI_START="0.10851016061939107" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.46896062624342627" LOG_CI_START="-0.9645295936649384" LOG_EFFECT_SIZE="-0.24778448371075615" ORDER="84715" O_E="0.0" SE="0.842039251065203" STUDY_ID="STD-Messenheimer-1994" TOTAL_1="46" TOTAL_2="52" VAR="0.7090301003344481" WEIGHT="2.813190827767639"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="84716" O_E="0.0" SE="0.0" STUDY_ID="STD-Schapel-1993" TOTAL_1="20" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="72.35616493859207" CI_START="0.14597926809642672" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8594755400818401" LOG_CI_START="-0.8357088181240911" LOG_EFFECT_SIZE="0.5118833609788743" ORDER="84717" O_E="0.0" SE="1.583164633387904" STUDY_ID="STD-Schmidt-1993" TOTAL_1="11" TOTAL_2="12" VAR="2.506410256410256" WEIGHT="0.35959917537551556"/>
<DICH_DATA CI_END="7.272709020748604" CI_START="0.5234992317043197" EFFECT_SIZE="1.951219512195122" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8616962119064782" LOG_CI_START="-0.28108395136206205" LOG_EFFECT_SIZE="0.2903061302722081" ORDER="84718" O_E="0.0" SE="0.6712747247569812" STUDY_ID="STD-Smith-1993" TOTAL_1="41" TOTAL_2="40" VAR="0.45060975609756093" WEIGHT="2.275241696048787"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.056926751394905" CI_START="0.4471986818161243" DF="0" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" I2="0.0" ID="CMP-002.01.04" LOG_CI_END="0.02404489027119584" LOG_CI_START="-0.34949948526659524" LOG_EFFECT_SIZE="-0.16272729749769974" MODIFIED="2010-03-26 05:32:57 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.08770317774627008" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="11.986639179183852" Z="1.7076399125959243">
<NAME>Parallel Studies in Infants</NAME>
<DICH_DATA CI_END="1.056926751394905" CI_START="0.4471986818161243" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.02404489027119584" LOG_CI_START="-0.34949948526659524" LOG_EFFECT_SIZE="-0.16272729749769974" MODIFIED="2010-03-26 05:32:57 +0000" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.21942181526537893" STUDY_ID="STD-Pi_x00f1_a_x002d_Garza-2008" TOTAL_1="19" TOTAL_2="19" VAR="0.048145933014354075" WEIGHT="11.986639179183852"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-05-19 02:34:44 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Adverse effects</NAME>
<DICH_OUTCOME CHI2="4.152467528429671" CI_END="5.550153929230134" CI_START="2.010744705341706" CI_STUDY="99" CI_TOTAL="99" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="3.340650030612449" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.7443050281115442" LOG_CI_START="0.3033569337993424" LOG_EFFECT_SIZE="0.5238309809554433" METHOD="MH" MODIFIED="2012-10-11 17:25:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9010937843105146" P_Q="0.7889583179939192" P_Z="9.358062547264703E-10" Q="0.4740835940682153" RANDOM="NO" SCALE="28.52" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="903" TOTAL_2="621" WEIGHT="100.00000000000001" Z="6.119991029585724">
<NAME>Ataxia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>More in controls</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More in Lamotrigine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.772919636709161" CI_END="6.895262065698218" CI_START="1.6726822344913548" DF="2" EFFECT_SIZE="3.396112830789868" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="14" I2="27.873856367018437" ID="CMP-003.01.01" LOG_CI_END="0.8385507768967514" LOG_CI_START="0.2234134443009148" LOG_EFFECT_SIZE="0.5309821105988332" MODIFIED="2012-09-20 12:44:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.24995889642816216" P_Z="8.712867794938772E-6" STUDIES="3" TAU2="0.0" TOTAL_1="618" TOTAL_2="325" WEIGHT="56.750925432421255" Z="4.446874568217273">
<NAME>Parallel studies - adults</NAME>
<DICH_DATA CI_END="107.26118540578202" CI_START="0.4503719497505975" EFFECT_SIZE="6.950354609929078" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="2.0304425922946345" LOG_CI_START="-0.34642866622040447" LOG_EFFECT_SIZE="0.842006963037115" MODIFIED="2012-09-20 12:44:18 +0100" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="1.0623662678816217" STUDY_ID="STD-Baulac-2010" TOTAL_1="141" TOTAL_2="140" VAR="1.1286220871327255" WEIGHT="2.957266576635443"/>
<DICH_DATA CI_END="5.503049536494839" CI_START="0.7045335375033788" EFFECT_SIZE="1.969030969030969" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="7" LOG_CI_END="0.7406034221932268" LOG_CI_START="-0.1520983285929776" LOG_EFFECT_SIZE="0.2942525468001246" ORDER="84719" O_E="0.0" SE="0.39900193328377065" STUDY_ID="STD-Matsuo-1993" TOTAL_1="143" TOTAL_2="73" VAR="0.15920254276418658" WEIGHT="27.312283292047347"/>
<DICH_DATA CI_END="12.82021182121608" CI_START="1.559284579921455" EFFECT_SIZE="4.471057884231537" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="6" LOG_CI_END="1.1078952008478" LOG_CI_START="0.19292538408603424" LOG_EFFECT_SIZE="0.6504102924669171" ORDER="84720" O_E="0.0" SE="0.40895486702330286" STUDY_ID="STD-Schachter-1995" TOTAL_1="334" TOTAL_2="112" VAR="0.16724408326204734" WEIGHT="26.481375563738464"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="36.6387494218554" CI_START="0.724752902387561" DF="0" EFFECT_SIZE="5.153061224489796" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="1.5639406416209127" LOG_CI_START="-0.13981003676857978" LOG_EFFECT_SIZE="0.7120653024261665" NO="2" P_CHI2="1.0" P_Z="0.03131212274616076" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="101" WEIGHT="5.80471199881584" Z="2.1530834238769114">
<NAME>Parallel studies - children</NAME>
<DICH_DATA CI_END="36.6387494218554" CI_START="0.724752902387561" EFFECT_SIZE="5.153061224489796" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.5639406416209127" LOG_CI_START="-0.13981003676857978" LOG_EFFECT_SIZE="0.7120653024261665" ORDER="84721" O_E="0.0" SE="0.7615083244905055" STUDY_ID="STD-Duchowny-1999" TOTAL_1="98" TOTAL_2="101" VAR="0.579894928268337" WEIGHT="5.80471199881584"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9208692354290468" CI_END="6.4086166002144624" CI_START="1.3816320974413125" DF="5" EFFECT_SIZE="2.9756260509431494" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="12" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.8067642904026249" LOG_CI_START="0.14039241400621993" LOG_EFFECT_SIZE="0.4735783522044224" NO="3" P_CHI2="0.9686924391414434" P_Z="2.5104657428011695E-4" STUDIES="8" TAU2="0.0" TOTAL_1="187" TOTAL_2="195" WEIGHT="37.44436256876292" Z="3.661189916150953">
<NAME>Cross-over studies</NAME>
<DICH_DATA CI_END="38.52888421623976" CI_START="0.03284873221079536" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.5857864321703687" LOG_CI_START="-1.483481387275606" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="84722" O_E="0.0" SE="1.3718398027628607" STUDY_ID="STD-Binnie-1989" TOTAL_1="16" TOTAL_2="18" VAR="1.8819444444444444" WEIGHT="2.773439826565071"/>
<DICH_DATA CI_END="165.96251667518806" CI_START="0.04113738092313745" EFFECT_SIZE="2.6129032258064515" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.2200100118996438" LOG_CI_START="-1.3857633618108893" LOG_EFFECT_SIZE="0.41712332504437705" ORDER="84723" O_E="0.0" SE="1.6116363005074998" STUDY_ID="STD-Boas-1996" TOTAL_1="30" TOTAL_2="26" VAR="2.5973715651135003" WEIGHT="1.5750030049566728"/>
<DICH_DATA CI_END="237.43125050939616" CI_START="0.10529363740604411" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.375537879869564" LOG_CI_START="-0.9775978711975266" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="84724" O_E="0.0" SE="1.4987174003640065" STUDY_ID="STD-Jawad-1989" TOTAL_1="12" TOTAL_2="12" VAR="2.2461538461538457" WEIGHT="1.473389907862694"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="84725" O_E="0.0" SE="0.0" STUDY_ID="STD-Loiseau-1990" TOTAL_1="11" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.159591760813896" CI_START="1.076147958432397" EFFECT_SIZE="3.617391304347826" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="1.0849189944266828" LOG_CI_START="0.03187198611957947" LOG_EFFECT_SIZE="0.5583954902731311" ORDER="84726" O_E="0.0" SE="0.4706698421764966" STUDY_ID="STD-Messenheimer-1994" TOTAL_1="46" TOTAL_2="52" VAR="0.2215301003344482" WEIGHT="13.831823624833454"/>
<DICH_DATA CI_END="44.35787296341351" CI_START="0.09941865345160669" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.6469707128062498" LOG_CI_START="-1.002532123338411" LOG_EFFECT_SIZE="0.3222192947339193" ORDER="84727" O_E="0.0" SE="1.1842216652219095" STUDY_ID="STD-Schapel-1993" TOTAL_1="20" TOTAL_2="21" VAR="1.4023809523809523" WEIGHT="2.8749071372930612"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="84728" O_E="0.0" SE="0.0" STUDY_ID="STD-Schmidt-1993" TOTAL_1="11" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.195202348235357" CI_START="0.8115346007130739" EFFECT_SIZE="2.731707317073171" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.9635612906980885" LOG_CI_START="-0.09069295879719627" LOG_EFFECT_SIZE="0.43643416595044615" ORDER="84729" O_E="0.0" SE="0.4712094306421853" STUDY_ID="STD-Smith-1993" TOTAL_1="41" TOTAL_2="40" VAR="0.22203832752613245" WEIGHT="14.915799067251964"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.56315737610686" CI_END="2.6385224044658155" CI_START="1.5143816116440643" CI_STUDY="99" CI_TOTAL="99" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9989321677420453" ESTIMABLE="YES" EVENTS_1="324" EVENTS_2="95" I2="39.62503782989182" I2_Q="64.28824620593406" ID="CMP-003.02" LOG_CI_END="0.4213607862503276" LOG_CI_START="0.18023532757354363" LOG_EFFECT_SIZE="0.30079805691193556" METHOD="MH" MODIFIED="2012-10-11 17:26:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.08460660585215363" P_Q="0.06079804162427316" P_Z="1.3051796898132597E-10" Q="5.600397033237641" RANDOM="NO" SCALE="18.64" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1024" TOTAL_2="743" WEIGHT="100.00000000000001" Z="6.426566930727282">
<NAME>Dizziness</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>More in controls</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More in Lamotrigine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.79543809119499" CI_END="2.9363845975828653" CI_START="1.4864409179428582" DF="3" EFFECT_SIZE="2.0892013346406673" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="59" I2="69.37349843804672" ID="CMP-003.02.01" LOG_CI_END="0.46781293737110957" LOG_CI_START="0.17214765183807865" LOG_EFFECT_SIZE="0.31998029460459415" MODIFIED="2012-09-20 12:45:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02038749475846713" P_Z="2.4707210054879825E-8" STUDIES="4" TAU2="0.0" TOTAL_1="739" TOTAL_2="447" WEIGHT="67.75036575988238" Z="5.5753222290862725">
<NAME>Parallel studies - adults</NAME>
<DICH_DATA CI_END="2.452565930350146" CI_START="0.342509752957729" EFFECT_SIZE="0.9165302782324058" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.38962069099689683" LOG_CI_START="-0.46532705746960445" LOG_EFFECT_SIZE="-0.03785318323635384" MODIFIED="2012-09-20 12:45:16 +0100" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.3821274061513945" STUDY_ID="STD-Baulac-2010" TOTAL_1="141" TOTAL_2="140" VAR="0.1460213545319928" WEIGHT="11.713624117573689"/>
<DICH_DATA CI_END="2.7004453140706906" CI_START="0.8977138737798805" EFFECT_SIZE="1.556993006993007" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="20" LOG_CI_END="0.43143538693555694" LOG_CI_START="-0.046862062931197115" LOG_EFFECT_SIZE="0.19228666200217992" ORDER="84730" O_E="0.0" SE="0.21377980609252487" STUDY_ID="STD-Matsuo-1993" TOTAL_1="143" TOTAL_2="73" VAR="0.045701805492957534" WEIGHT="23.776472384699417"/>
<DICH_DATA CI_END="11.09680426660947" CI_START="1.1222434613718564" EFFECT_SIZE="3.5289256198347108" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="6" LOG_CI_END="1.0451979257051363" LOG_CI_START="0.05008708371201122" LOG_EFFECT_SIZE="0.5476425047085738" MODIFIED="2010-03-14 14:23:16 +0000" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.4447746959577641" STUDY_ID="STD-Naritoku-2007" TOTAL_1="121" TOTAL_2="122" VAR="0.1978245301643215" WEIGHT="5.364947615009099"/>
<DICH_DATA CI_END="4.7805080419774955" CI_START="1.6204112263441883" EFFECT_SIZE="2.7832335329341316" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="20" LOG_CI_END="0.6794740531189991" LOG_CI_START="0.2096252433503829" LOG_EFFECT_SIZE="0.444549648234691" ORDER="84731" O_E="0.0" SE="0.2100036023046339" STUDY_ID="STD-Schachter-1995" TOTAL_1="334" TOTAL_2="112" VAR="0.04410151298092284" WEIGHT="26.895321642600187"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.788762103589356" CI_START="1.2669438105098318" DF="0" EFFECT_SIZE="4.328571428571428" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="1.169931822808243" LOG_CI_START="0.10275735416785343" LOG_EFFECT_SIZE="0.6363445884880482" NO="2" P_CHI2="1.0" P_Z="0.002127164428136812" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="101" WEIGHT="4.4215866697061985" Z="3.0718782848516986">
<NAME>Parallel studies - children</NAME>
<DICH_DATA CI_END="14.788762103589356" CI_START="1.2669438105098318" EFFECT_SIZE="4.328571428571428" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="1.169931822808243" LOG_CI_START="0.10275735416785343" LOG_EFFECT_SIZE="0.6363445884880482" ORDER="84732" O_E="0.0" SE="0.47698425119429744" STUDY_ID="STD-Duchowny-1999" TOTAL_1="98" TOTAL_2="101" VAR="0.22751397588738465" WEIGHT="4.4215866697061985"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.281521074246907" CI_END="2.383596784050513" CI_START="0.8329010167112192" DF="5" EFFECT_SIZE="1.4090068079556126" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="31" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.3772327908029008" LOG_CI_START="-0.07940660777735661" LOG_EFFECT_SIZE="0.1489130915127721" NO="3" P_CHI2="0.9368216179946176" P_Z="0.09295935240767979" STUDIES="8" TAU2="0.0" TOTAL_1="187" TOTAL_2="195" WEIGHT="27.828047570411425" Z="1.6799895321920704">
<NAME>Cross-over studies</NAME>
<DICH_DATA CI_END="6.624681433501632" CI_START="0.08490974330560036" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.8211649988354383" LOG_CI_START="-1.071042472052038" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="84733" O_E="0.0" SE="0.8457409637576849" STUDY_ID="STD-Binnie-1989" TOTAL_1="16" TOTAL_2="18" VAR="0.7152777777777777" WEIGHT="2.5351137976610816"/>
<DICH_DATA CI_END="6.366773867750244" CI_START="0.5709921309114078" EFFECT_SIZE="1.9066666666666667" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.8039194250590228" LOG_CI_START="-0.2433698769122993" LOG_EFFECT_SIZE="0.28027477407336177" ORDER="84734" O_E="0.0" SE="0.46809637801869297" STUDY_ID="STD-Boas-1996" TOTAL_1="30" TOTAL_2="26" VAR="0.2191142191142191" WEIGHT="4.809925732169462"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="84735" O_E="0.0" SE="0.0" STUDY_ID="STD-Jawad-1989" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="84736" O_E="0.0" SE="0.0" STUDY_ID="STD-Loiseau-1990" TOTAL_1="11" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.5851921579228563" CI_START="0.5132643238290421" EFFECT_SIZE="1.3565217391304347" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.5545124377971423" LOG_CI_START="-0.2896589217954425" LOG_EFFECT_SIZE="0.13242675800084988" ORDER="84737" O_E="0.0" SE="0.377310791878236" STUDY_ID="STD-Messenheimer-1994" TOTAL_1="46" TOTAL_2="52" VAR="0.14236343366778154" WEIGHT="8.428822235420773"/>
<DICH_DATA CI_END="195.85731374585518" CI_START="0.050432382796923754" EFFECT_SIZE="3.142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.291939793704466" LOG_CI_START="-1.297290512088567" LOG_EFFECT_SIZE="0.4973246408079494" ORDER="84738" O_E="0.0" SE="1.6042422116354729" STUDY_ID="STD-Schapel-1993" TOTAL_1="20" TOTAL_2="21" VAR="2.5735930735930737" WEIGHT="0.4384862527931231"/>
<DICH_DATA CI_END="5.274007471200774" CI_START="0.35257897194598337" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.7221407406828556" LOG_CI_START="-0.45274359288794336" LOG_EFFECT_SIZE="0.13469857389745618" ORDER="84739" O_E="0.0" SE="0.5251262474468171" STUDY_ID="STD-Schmidt-1993" TOTAL_1="11" TOTAL_2="12" VAR="0.2757575757575758" WEIGHT="3.4352628997291466"/>
<DICH_DATA CI_END="3.469530694162172" CI_START="0.4877070218654011" EFFECT_SIZE="1.3008130081300813" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.5402707339494575" LOG_CI_START="-0.3118409915164039" LOG_EFFECT_SIZE="0.11421487121652683" ORDER="84740" O_E="0.0" SE="0.38085981744206804" STUDY_ID="STD-Smith-1993" TOTAL_1="41" TOTAL_2="40" VAR="0.1450542005420054" WEIGHT="8.180436652637841"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.157613844923462" CI_END="1.220760624274424" CI_START="0.5537368632841809" CI_STUDY="99" CI_TOTAL="99" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8221801255847517" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="76" I2="1.4126124735458032" I2_Q="47.484754273155744" ID="CMP-003.03" LOG_CI_END="0.08663051263560279" LOG_CI_START="-0.2566965637410897" LOG_EFFECT_SIZE="-0.08503302555274345" METHOD="MH" MODIFIED="2012-10-11 17:26:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4301550409726487" P_Q="0.14894053759798698" P_Z="0.2019804950960019" Q="3.808417864790945" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="881" TOTAL_2="670" WEIGHT="100.0" Z="1.2759294215866768">
<NAME>Fatigue</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>More in controls</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More in Lamotrigine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.034145849504469" CI_END="1.419082204509254" CI_START="0.461706840493297" DF="2" EFFECT_SIZE="0.8094442297306408" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="37" I2="34.08359059843362" ID="CMP-003.03.01" LOG_CI_END="0.15200755397100107" LOG_CI_START="-0.335633691040184" LOG_EFFECT_SIZE="-0.09181306853459148" MODIFIED="2012-09-20 12:46:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.21935308791209496" P_Z="0.33206942512262627" STUDIES="3" TAU2="0.0" TOTAL_1="596" TOTAL_2="374" WEIGHT="51.59868301278952" Z="0.9699540176291681">
<NAME>Parallel studies - adults</NAME>
<DICH_DATA CI_END="1.3018408335492841" CI_START="0.257687614118582" EFFECT_SIZE="0.5791962174940898" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="24" LOG_CI_END="0.11455788950345895" LOG_CI_START="-0.5889064555244786" LOG_EFFECT_SIZE="-0.2371742830105099" MODIFIED="2012-09-20 12:46:02 +0100" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.3144203911498436" STUDY_ID="STD-Baulac-2010" TOTAL_1="141" TOTAL_2="140" VAR="0.09886018237082066" WEIGHT="29.554254981739053"/>
<DICH_DATA CI_END="12.091841298090555" CI_START="0.33629195154121105" EFFECT_SIZE="2.0165289256198347" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="1.0824924385540893" LOG_CI_START="-0.4732835265095308" LOG_EFFECT_SIZE="0.3046044560222793" MODIFIED="2010-03-14 14:27:13 +0000" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.6953695534596027" STUDY_ID="STD-Naritoku-2007" TOTAL_1="121" TOTAL_2="122" VAR="0.48353881587860725" WEIGHT="3.666032686987821"/>
<DICH_DATA CI_END="2.3239265580878845" CI_START="0.3793471060326131" EFFECT_SIZE="0.9389221556886228" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="10" LOG_CI_END="0.3662223991394831" LOG_CI_START="-0.4209632247378104" LOG_EFFECT_SIZE="-0.027370412799163617" ORDER="84741" O_E="0.0" SE="0.3518404500759775" STUDY_ID="STD-Schachter-1995" TOTAL_1="334" TOTAL_2="112" VAR="0.12379170230966641" WEIGHT="18.37839534406265"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.190515031472391E-32" CI_END="6.6294065736798595" CI_START="0.5385162478176513" DF="0" EFFECT_SIZE="1.8894557823129254" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="100.0" ID="CMP-003.03.02" LOG_CI_END="0.8214746546022401" LOG_CI_START="-0.26880118887278165" LOG_EFFECT_SIZE="0.2763367328647292" NO="2" P_CHI2="0.0" P_Z="0.19164856351600895" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="101" WEIGHT="7.251372765308191" Z="1.3057177381665823">
<NAME>Parallel studies - children</NAME>
<DICH_DATA CI_END="6.629406573679857" CI_START="0.5385162478176513" EFFECT_SIZE="1.8894557823129252" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.8214746546022399" LOG_CI_START="-0.26880118887278165" LOG_EFFECT_SIZE="0.27633673286472915" ORDER="84742" O_E="0.0" SE="0.4873096406229766" STUDY_ID="STD-Duchowny-1999" TOTAL_1="98" TOTAL_2="101" VAR="0.2374706858440946" WEIGHT="7.251372765308191"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.308332251128522" CI_END="1.2310009583088302" CI_START="0.34329733032383947" DF="7" EFFECT_SIZE="0.6500764129035213" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="33" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="0.09025839102073539" LOG_CI_START="-0.4643295738831143" LOG_EFFECT_SIZE="-0.18703559143118942" NO="3" P_CHI2="0.74365722203692" P_Z="0.08231583296170773" STUDIES="8" TAU2="0.0" TOTAL_1="187" TOTAL_2="195" WEIGHT="41.14994422190229" Z="1.7374042990586118">
<NAME>Cross-over studies</NAME>
<DICH_DATA CI_END="8.69259113277354" CI_START="0.2588411171804528" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.9391492525049306" LOG_CI_START="-0.5869667343935681" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="84743" O_E="0.0" SE="0.6821127309893708" STUDY_ID="STD-Binnie-1989" TOTAL_1="16" TOTAL_2="18" VAR="0.4652777777777777" WEIGHT="3.464641489306915"/>
<DICH_DATA CI_END="2.1314637842511455" CI_START="0.11506682533722944" EFFECT_SIZE="0.49523809523809526" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.32867795793857923" LOG_CI_START="-0.9390498688088571" LOG_EFFECT_SIZE="-0.3051859554351389" ORDER="84744" O_E="0.0" SE="0.5666235708671773" STUDY_ID="STD-Boas-1996" TOTAL_1="30" TOTAL_2="26" VAR="0.32106227106227103" WEIGHT="9.202953955971493"/>
<DICH_DATA CI_END="2.2122466021308846" CI_START="0.11300729302022411" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.34483353672636335" LOG_CI_START="-0.9468935280543257" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="84745" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Jawad-1989" TOTAL_1="12" TOTAL_2="12" VAR="0.33333333333333337" WEIGHT="7.362363164777194"/>
<DICH_DATA CI_END="223.1965632325292" CI_START="0.06300500239042438" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.3486875030762966" LOG_CI_START="-1.200624967620859" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="84746" O_E="0.0" SE="1.586400537905439" STUDY_ID="STD-Loiseau-1990" TOTAL_1="11" TOTAL_2="14" VAR="2.516666666666666" WEIGHT="0.5453602344279402"/>
<DICH_DATA CI_END="12.68991466404152" CI_START="0.025175165309673276" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="1.1034587016013646" LOG_CI_START="-1.5990276690228766" LOG_EFFECT_SIZE="-0.24778448371075615" ORDER="84747" O_E="0.0" SE="1.207903183344778" STUDY_ID="STD-Messenheimer-1994" TOTAL_1="46" TOTAL_2="52" VAR="1.4590301003344481" WEIGHT="2.3038687454404827"/>
<DICH_DATA CI_END="3.449519278067271" CI_START="0.11505951061748493" EFFECT_SIZE="0.63" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.5377585763980918" LOG_CI_START="-0.9390774774909282" LOG_EFFECT_SIZE="-0.2006594505464183" ORDER="84748" O_E="0.0" SE="0.6600865744084526" STUDY_ID="STD-Schapel-1993" TOTAL_1="20" TOTAL_2="21" VAR="0.4357142857142857" WEIGHT="5.985661109574954"/>
<DICH_DATA CI_END="11.332769491311335" CI_START="0.10501251662627724" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="1.05433605530168" LOG_CI_START="-0.9787589335228806" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="84749" O_E="0.0" SE="0.9087120422650817" STUDY_ID="STD-Schmidt-1993" TOTAL_1="11" TOTAL_2="12" VAR="0.8257575757575757" WEIGHT="2.347420139494178"/>
<DICH_DATA CI_END="1.8996818281814682" CI_START="0.07045858810616491" EFFECT_SIZE="0.36585365853658536" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.27868086840749656" LOG_CI_START="-1.152066063735605" LOG_EFFECT_SIZE="-0.43669259766405427" ORDER="84750" O_E="0.0" SE="0.6394865826824627" STUDY_ID="STD-Smith-1993" TOTAL_1="41" TOTAL_2="40" VAR="0.40894308943089425" WEIGHT="9.937675382909134"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.1604746060867" CI_END="2.676402723047504" CI_START="1.219554388523293" CI_STUDY="99" CI_TOTAL="99" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8066595380282016" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="50" I2="0.0" I2_Q="19.727359313041724" ID="CMP-003.04" LOG_CI_END="0.4275514630710547" LOG_CI_START="0.08620117333267836" LOG_EFFECT_SIZE="0.2568763182018665" METHOD="MH" MODIFIED="2012-10-11 17:27:04 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6131654609886779" P_Q="0.28772384081016433" P_Z="1.0584910691291222E-4" Q="2.4915089162189923" RANDOM="NO" SCALE="23.5" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="883" TOTAL_2="603" WEIGHT="99.99999999999999" Z="3.876777420164184">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>More in controls</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More in Lamotrigine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0887683426247237" CI_END="2.778888302811211" CI_START="1.0175022089814247" DF="2" EFFECT_SIZE="1.6815246018488845" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="28" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.4438710906968972" LOG_CI_START="0.007535360744827205" LOG_EFFECT_SIZE="0.22570322572086218" MODIFIED="2010-03-14 14:29:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5801990946102984" P_Z="0.007703490290417992" STUDIES="3" TAU2="0.0" TOTAL_1="598" TOTAL_2="307" WEIGHT="64.22041722097076" Z="2.66479659037398">
<NAME>Parallel Studies - adults</NAME>
<DICH_DATA CI_END="5.124615467488788" CI_START="0.7635821648355432" EFFECT_SIZE="1.9781468531468531" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" LOG_CI_END="0.7096612830715725" LOG_CI_START="-0.1171442240761261" LOG_EFFECT_SIZE="0.2962585294977232" ORDER="84751" O_E="0.0" SE="0.36954895127186566" STUDY_ID="STD-Matsuo-1993" TOTAL_1="143" TOTAL_2="73" VAR="0.13656642738613572" WEIGHT="17.423760182748058"/>
<DICH_DATA CI_END="14.899128654258394" CI_START="0.4852052763590306" EFFECT_SIZE="2.6887052341597797" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.173160870310745" LOG_CI_START="-0.3140744850495865" LOG_EFFECT_SIZE="0.42954319263057933" MODIFIED="2010-03-14 14:29:04 +0000" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.6647346457135663" STUDY_ID="STD-Naritoku-2007" TOTAL_1="121" TOTAL_2="122" VAR="0.4418721492119405" WEIGHT="4.91439389769817"/>
<DICH_DATA CI_END="2.714737842478331" CI_START="0.7637708732164579" EFFECT_SIZE="1.4399436421275096" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="17" LOG_CI_END="0.43372789688538366" LOG_CI_START="-0.11703690768378543" LOG_EFFECT_SIZE="0.15834549460079908" ORDER="84752" O_E="0.0" SE="0.246169811601934" STUDY_ID="STD-Schachter-1995" TOTAL_1="334" TOTAL_2="112" VAR="0.06059957614413168" WEIGHT="41.882263140524536"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="39.685293909254725" CI_START="0.8096295936049205" DF="0" EFFECT_SIZE="5.668367346938775" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="1.5986296010381478" LOG_CI_START="-0.09171362586936481" LOG_EFFECT_SIZE="0.7534579875843915" NO="2" P_CHI2="1.0" P_Z="0.02165795075294244" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="101" WEIGHT="3.2402058856205054" Z="2.296313710161125">
<NAME>Parallel studies - children</NAME>
<DICH_DATA CI_END="39.68529390925474" CI_START="0.80962959360492" EFFECT_SIZE="5.668367346938775" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.598629601038148" LOG_CI_START="-0.09171362586936505" LOG_EFFECT_SIZE="0.7534579875843915" ORDER="84753" O_E="0.0" SE="0.7555157305956164" STUDY_ID="STD-Duchowny-1999" TOTAL_1="98" TOTAL_2="101" VAR="0.570804019177428" WEIGHT="3.2402058856205054"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.43782522870381" CI_END="3.291317636869147" CI_START="0.8464247963554321" DF="6" EFFECT_SIZE="1.6690874334581787" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="20" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="0.517369796995923" LOG_CI_START="-0.07241162229070183" LOG_EFFECT_SIZE="0.22247908735261063" NO="3" P_CHI2="0.6176470365046973" P_Z="0.05197704019212458" STUDIES="8" TAU2="0.0" TOTAL_1="187" TOTAL_2="195" WEIGHT="32.53937689340872" Z="1.9433238616531172">
<NAME>Cross-over studies</NAME>
<DICH_DATA CI_END="6.415748338300375" CI_START="0.021918721337697237" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.8072473201403507" LOG_CI_START="-1.6591847846849128" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="84754" O_E="0.0" SE="1.102396379610246" STUDY_ID="STD-Binnie-1989" TOTAL_1="16" TOTAL_2="18" VAR="1.2152777777777777" WEIGHT="4.644424762822189"/>
<DICH_DATA CI_END="46.929069703058424" CI_START="0.14404717678772655" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.6714419450747833" LOG_CI_START="-0.8414952491331474" LOG_EFFECT_SIZE="0.414973347970818" ORDER="84755" O_E="0.0" SE="1.1231822922119372" STUDY_ID="STD-Boas-1996" TOTAL_1="30" TOTAL_2="26" VAR="1.2615384615384613" WEIGHT="1.7623933251780628"/>
<DICH_DATA CI_END="237.43125050939616" CI_START="0.10529363740604411" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.375537879869564" LOG_CI_START="-0.9775978711975266" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="84756" O_E="0.0" SE="1.4987174003640065" STUDY_ID="STD-Jawad-1989" TOTAL_1="12" TOTAL_2="12" VAR="2.2461538461538457" WEIGHT="0.8224502184164293"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="84757" O_E="0.0" SE="0.0" STUDY_ID="STD-Loiseau-1990" TOTAL_1="11" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.634405216560261" CI_START="0.4340828800351417" EFFECT_SIZE="1.2560386473429952" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.5604333471616516" LOG_CI_START="-0.3624273421338512" LOG_EFFECT_SIZE="0.09900300251390022" ORDER="84758" O_E="0.0" SE="0.41248177104638123" STUDY_ID="STD-Messenheimer-1994" TOTAL_1="46" TOTAL_2="52" VAR="0.17014121144555927" WEIGHT="13.897730221404151"/>
<DICH_DATA CI_END="66.70045210265118" CI_START="0.2644659735267201" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.8241287776200157" LOG_CI_START="-0.5776301968242147" LOG_EFFECT_SIZE="0.6232492903979004" ORDER="84759" O_E="0.0" SE="1.0734900802433864" STUDY_ID="STD-Schapel-1993" TOTAL_1="20" TOTAL_2="21" VAR="1.1523809523809523" WEIGHT="1.6047809139832767"/>
<DICH_DATA CI_END="11.332769491311335" CI_START="0.10501251662627724" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="1.05433605530168" LOG_CI_START="-0.9787589335228806" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="84760" O_E="0.0" SE="0.9087120422650817" STUDY_ID="STD-Schmidt-1993" TOTAL_1="11" TOTAL_2="12" VAR="0.8257575757575757" WEIGHT="3.1467660530715555"/>
<DICH_DATA CI_END="10.012867197318618" CI_START="0.5941195322951753" EFFECT_SIZE="2.4390243902439024" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="1.0005584560680836" LOG_CI_START="-0.2261261695075545" LOG_EFFECT_SIZE="0.3872161432802645" ORDER="84761" O_E="0.0" SE="0.5482789035678474" STUDY_ID="STD-Smith-1993" TOTAL_1="41" TOTAL_2="40" VAR="0.3006097560975609" WEIGHT="6.660831398533057"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.760529761993109" CI_END="1.9982500177812457" CI_START="0.9608499627726629" CI_STUDY="99" CI_TOTAL="99" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3856473054841851" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="72" I2="13.79668238568589" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.3006498255064446" LOG_CI_START="-0.0173444223492054" LOG_EFFECT_SIZE="0.14165270157861956" METHOD="MH" MODIFIED="2016-05-19 02:34:44 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3092649879381548" P_Q="0.513599989931975" P_Z="0.021742216117186033" Q="1.3326212452130193" RANDOM="NO" SCALE="4.652299255077483" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1024" TOTAL_2="743" WEIGHT="100.0" Z="2.29484138228001">
<NAME>Somnolence</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>More in controls</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More in Lamotrigine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.655805049656909" CI_END="2.672377150083384" CI_START="0.9313779686602686" DF="3" EFFECT_SIZE="1.577654335251794" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="33" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.4268977497022574" LOG_CI_START="-0.030874039328387223" LOG_EFFECT_SIZE="0.19801185518693512" MODIFIED="2012-09-20 12:47:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.44779013938375967" P_Z="0.025855188711228903" STUDIES="4" TAU2="0.0" TOTAL_1="739" TOTAL_2="447" WEIGHT="49.30522703110665" Z="2.228379953778431">
<NAME>Parallel studies - adults</NAME>
<DICH_DATA CI_END="2.41528465923624" CI_START="0.40817793395390073" EFFECT_SIZE="0.9929078014184397" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.38296832293437083" LOG_CI_START="-0.3891504768886546" LOG_EFFECT_SIZE="-0.0030910769771418803" MODIFIED="2012-09-20 12:47:04 +0100" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.3451061830928503" STUDY_ID="STD-Baulac-2010" TOTAL_1="141" TOTAL_2="140" VAR="0.11909827760891589" WEIGHT="19.210710204339595"/>
<DICH_DATA CI_END="7.6171216275351625" CI_START="0.662350865234156" EFFECT_SIZE="2.246153846153846" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="5" LOG_CI_END="0.8817908903112057" LOG_CI_START="-0.1789118920280426" LOG_EFFECT_SIZE="0.3514394991415815" ORDER="84762" O_E="0.0" SE="0.4740916665841662" STUDY_ID="STD-Matsuo-1993" TOTAL_1="143" TOTAL_2="73" VAR="0.22476290832455217" WEIGHT="8.448734438107191"/>
<DICH_DATA CI_END="6.746414908834456" CI_START="0.3857587972573968" EFFECT_SIZE="1.6132231404958677" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.8290730470631149" LOG_CI_START="-0.4136841610346691" LOG_EFFECT_SIZE="0.2076944430142229" MODIFIED="2010-03-14 14:25:51 +0000" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.5554627043093058" STUDY_ID="STD-Naritoku-2007" TOTAL_1="121" TOTAL_2="122" VAR="0.3085388158786072" WEIGHT="6.354603679943872"/>
<DICH_DATA CI_END="4.964609197633498" CI_START="0.7488481023066382" EFFECT_SIZE="1.9281437125748504" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="8" LOG_CI_END="0.6958850675360886" LOG_CI_START="-0.1256062664395933" LOG_EFFECT_SIZE="0.28513940054824766" ORDER="84763" O_E="0.0" SE="0.3671737286764445" STUDY_ID="STD-Schachter-1995" TOTAL_1="334" TOTAL_2="112" VAR="0.13481654703016327" WEIGHT="15.291178708715991"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.80988135828109" CI_START="0.6720167320015723" DF="0" EFFECT_SIZE="1.3741496598639455" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.44868798306109015" LOG_CI_START="-0.17261991366419485" LOG_EFFECT_SIZE="0.13803403469844766" NO="2" P_CHI2="1.0" P_Z="0.2524047929374059" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="101" WEIGHT="22.624806483785044" Z="1.1445279010208902">
<NAME>Parallel studies - children</NAME>
<DICH_DATA CI_END="2.80988135828109" CI_START="0.6720167320015723" EFFECT_SIZE="1.3741496598639455" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" LOG_CI_END="0.44868798306109015" LOG_CI_START="-0.17261991366419485" LOG_EFFECT_SIZE="0.13803403469844766" ORDER="84764" O_E="0.0" SE="0.2776997488125606" STUDY_ID="STD-Duchowny-1999" TOTAL_1="98" TOTAL_2="101" VAR="0.07711715049055926" WEIGHT="22.624806483785044"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.236913325117133" CI_END="2.1729020779354027" CI_START="0.5148081418420697" DF="6" EFFECT_SIZE="1.0576519659825234" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" I2="35.04323588611876" ID="CMP-003.05.03" LOG_CI_END="0.3370401552342204" LOG_CI_START="-0.28835459321846263" LOG_EFFECT_SIZE="0.024342781007878903" NO="3" P_CHI2="0.16068617953415987" P_Z="0.8410719894352994" STUDIES="8" TAU2="0.0" TOTAL_1="187" TOTAL_2="195" WEIGHT="28.06996648510831" Z="0.20052246618668942">
<NAME>Cross-over studies</NAME>
<DICH_DATA CI_END="4.3592047580164675" CI_START="0.07258347968586175" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.6394072689232062" LOG_CI_START="-1.1391622153564058" LOG_EFFECT_SIZE="-0.2498774732165999" ORDER="84765" O_E="0.0" SE="0.7949493345141213" STUDY_ID="STD-Binnie-1989" TOTAL_1="16" TOTAL_2="18" VAR="0.6319444444444444" WEIGHT="4.8044140219001985"/>
<DICH_DATA CI_END="18.44027963057645" CI_START="0.004570820102570831" EFFECT_SIZE="0.2903225806451613" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.2657675024603185" LOG_CI_START="-2.340005871250214" LOG_EFFECT_SIZE="-0.5371191843949478" ORDER="84766" O_E="0.0" SE="1.6116363005074998" STUDY_ID="STD-Boas-1996" TOTAL_1="30" TOTAL_2="26" VAR="2.5973715651135003" WEIGHT="2.046276554047471"/>
<DICH_DATA CI_END="300.92391323813496" CI_START="0.16283185830174968" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.478456700783326" LOG_CI_START="-0.7882606207548125" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="84767" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Jawad-1989" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="0.6380862372836201"/>
<DICH_DATA CI_END="223.1965632325292" CI_START="0.06300500239042438" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.3486875030762966" LOG_CI_START="-1.200624967620859" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="84768" O_E="0.0" SE="1.586400537905439" STUDY_ID="STD-Loiseau-1990" TOTAL_1="11" TOTAL_2="14" VAR="2.516666666666666" WEIGHT="0.567187766474329"/>
<DICH_DATA CI_END="10.924009767849103" CI_START="0.5922076051740701" EFFECT_SIZE="2.5434782608695654" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="1.0383820797980756" LOG_CI_START="-0.22752601966890043" LOG_EFFECT_SIZE="0.4054280300645876" ORDER="84769" O_E="0.0" SE="0.5658102256459839" STUDY_ID="STD-Messenheimer-1994" TOTAL_1="46" TOTAL_2="52" VAR="0.3201412114455593" WEIGHT="4.792157863681066"/>
<DICH_DATA CI_END="2.5100513116479384" CI_START="0.012200945796559667" EFFECT_SIZE="0.175" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.39968259962358066" LOG_CI_START="-1.9136065022509918" LOG_EFFECT_SIZE="-0.7569619513137056" ORDER="84770" O_E="0.0" SE="1.033947590087437" STUDY_ID="STD-Schapel-1993" TOTAL_1="20" TOTAL_2="21" VAR="1.069047619047619" WEIGHT="7.470277899905796"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="84771" O_E="0.0" SE="0.0" STUDY_ID="STD-Schmidt-1993" TOTAL_1="11" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.469050120958368" CI_START="0.19053694715592315" EFFECT_SIZE="0.8130081300813008" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.5402105745893643" LOG_CI_START="-0.7200207974681602" LOG_EFFECT_SIZE="-0.08990511143939794" ORDER="84772" O_E="0.0" SE="0.5632729558253509" STUDY_ID="STD-Smith-1993" TOTAL_1="41" TOTAL_2="40" VAR="0.31727642276422763" WEIGHT="7.75156614181583"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.736415748362649" CI_END="6.678581457294615" CI_START="2.1508181202622674" CI_STUDY="99" CI_TOTAL="99" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.7900414266861038" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.8246842273421106" LOG_CI_START="0.33260368667469453" LOG_EFFECT_SIZE="0.5786439570084025" METHOD="MH" MODIFIED="2012-10-11 17:27:46 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.4197033910387591" P_Q="1.0" P_Z="1.3790761826709326E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="618" TOTAL_2="325" WEIGHT="99.99999999999999" Z="6.057902874038314">
<NAME>Diplopia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>More in controls</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More in Lamotrigine</GRAPH_LABEL_2>
<DICH_DATA CI_END="53.4953478051478" CI_START="1.1794561644004267" EFFECT_SIZE="7.943262411347518" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.7283160154716397" LOG_CI_START="0.07168180455796386" LOG_EFFECT_SIZE="0.8999989100148017" MODIFIED="2012-09-20 12:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.7404491503645491" STUDY_ID="STD-Baulac-2010" TOTAL_1="141" TOTAL_2="140" VAR="0.5482649442755826" WEIGHT="7.1876174014242356"/>
<DICH_DATA CI_END="12.604554000409312" CI_START="1.552924524567141" EFFECT_SIZE="4.424242424242424" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="6" LOG_CI_END="1.1005274832065954" LOG_CI_START="0.19115034860650382" LOG_EFFECT_SIZE="0.6458389159065496" ORDER="84773" O_E="0.0" SE="0.4064551620627331" STUDY_ID="STD-Matsuo-1993" TOTAL_1="143" TOTAL_2="73" VAR="0.1652057987674426" WEIGHT="28.449569547028176"/>
<DICH_DATA CI_END="6.328181195899685" CI_START="1.4660700090465508" EFFECT_SIZE="3.0459081836327346" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="12" LOG_CI_END="0.8012789058961877" LOG_CI_START="0.16615470960704415" LOG_EFFECT_SIZE="0.48371680775161596" ORDER="84774" O_E="0.0" SE="0.2838750814272354" STUDY_ID="STD-Schachter-1995" TOTAL_1="334" TOTAL_2="112" VAR="0.08058506185531951" WEIGHT="64.36281305154758"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4933329461109235" CI_END="1.4467512695233884" CI_START="0.8749337175768872" CI_STUDY="99" CI_TOTAL="99" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1250828710158107" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="120" I2="0.0" I2_Q="100.0" ID="CMP-003.07" LOG_CI_END="0.1603938721289043" LOG_CI_START="-0.05802484661306116" LOG_EFFECT_SIZE="0.051184512757921574" METHOD="MH" MODIFIED="2012-10-11 17:28:09 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9741467722695101" P_Q="0.0" P_Z="0.22733742246691924" Q="2.0208010011356014E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="837" TOTAL_2="548" WEIGHT="100.0" Z="1.2072460511544578">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>More in controls</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More in Lamotrigine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0501185956297925" CI_START="0.6280912671024025" EFFECT_SIZE="1.1347517730496455" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="28" LOG_CI_END="0.31177898492786177" LOG_CI_START="-0.2019772449267719" LOG_EFFECT_SIZE="0.05490087000054491" MODIFIED="2012-09-20 12:50:18 +0100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.22962846075752083" STUDY_ID="STD-Baulac-2010" TOTAL_1="141" TOTAL_2="140" VAR="0.05272922998986829" WEIGHT="19.263858973761987"/>
<DICH_DATA CI_END="2.8167980344367916" CI_START="0.5429969363587049" EFFECT_SIZE="1.236734693877551" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4497557090113066" LOG_CI_START="-0.2652026207357616" LOG_EFFECT_SIZE="0.09227654413777253" ORDER="84775" O_E="0.0" SE="0.3195577420288222" STUDY_ID="STD-Duchowny-1999" TOTAL_1="98" TOTAL_2="101" VAR="0.10211715049055926" WEIGHT="10.12830391355443"/>
<DICH_DATA CI_END="2.2447733058808157" CI_START="0.6804709940016329" EFFECT_SIZE="1.235921972764078" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="19" LOG_CI_END="0.3511724892252721" LOG_CI_START="-0.16719038245699375" LOG_EFFECT_SIZE="0.0919910533841392" ORDER="84776" O_E="0.0" SE="0.2316874451759476" STUDY_ID="STD-Matsuo-1993" TOTAL_1="143" TOTAL_2="73" VAR="0.053679072252157733" WEIGHT="17.24679309930823"/>
<DICH_DATA CI_END="2.416794482521533" CI_START="0.5193070051972606" EFFECT_SIZE="1.120293847566575" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.3832397207834351" LOG_CI_START="-0.2845758189454884" LOG_EFFECT_SIZE="0.0493319509189733" MODIFIED="2010-03-14 14:25:06 +0000" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.29848680278056317" STUDY_ID="STD-Naritoku-2007" TOTAL_1="121" TOTAL_2="122" VAR="0.0890943714341628" WEIGHT="12.289212896673071"/>
<DICH_DATA CI_END="1.5231075579141005" CI_START="0.7209623437965496" EFFECT_SIZE="1.0479041916167664" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="40" LOG_CI_END="0.18273057317137187" LOG_CI_START="-0.1420874180939496" LOG_EFFECT_SIZE="0.02032157753871113" ORDER="84777" O_E="0.0" SE="0.1451806343676066" STUDY_ID="STD-Schachter-1995" TOTAL_1="334" TOTAL_2="112" VAR="0.02107741659538067" WEIGHT="41.07183111670227"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-06-02 12:00:49 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-06-02 12:00:49 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram for update.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAOzCAYAAACS7YBAAABp1ElEQVR42u2dDaRV2f//v4wxMkYi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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-05-29 11:39:38 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-05-29 11:39:38 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAT8AAAK+CAIAAABbwI4cAAAejUlEQVR42u3dvc4cSRnF8VdCQgQO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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-06-08 12:33:56 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-06-02 17:18:51 +0100" MODIFIED_BY="Graham Chan" NO="1">
<TITLE MODIFIED="2015-06-02 17:18:28 +0100" MODIFIED_BY="Graham Chan">Cochrane Epilepsy Group Specialized Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-06-02 17:18:51 +0100" MODIFIED_BY="Graham Chan">
<P>#1 (lamotrigine OR lamictal) AND &gt;2011:YR</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-06-02 17:19:21 +0100" MODIFIED_BY="Graham Chan" NO="2">
<TITLE MODIFIED="2010-01-29 13:13:37 +0000" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-06-02 17:19:21 +0100" MODIFIED_BY="Graham Chan">
<P>#1 lamotrigine or lamictal</P>
<P>#2 (epilep* or seizure* or convulsion*):ti,ab,kw (Word variations have been searched)</P>
<P>#3 MeSH descriptor: [Epilepsy] explode all trees</P>
<P>#4 MeSH descriptor: [Seizures] explode all trees</P>
<P>#5 (#2 or #3 or #4) in Trials</P>
<P>#6 #1 and #5 from 2012</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-06-08 12:33:56 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-01-29 13:13:45 +0000" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-06-08 12:33:56 +0100" MODIFIED_BY="[Empty name]">
<P>This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>).</P>
<P>1. (randomized controlled trial or controlled clinical trial).pt. or (randomi?ed or placebo or randomly).ab.</P>
<P>2. clinical trials as topic.sh.</P>
<P>3. trial.ti.</P>
<P>4. 1 or 2 or 3</P>
<P>5. exp animals/ not humans.sh.</P>
<P>6. 4 not 5</P>
<P>7. exp Epilepsy/</P>
<P>8. exp Seizures/</P>
<P>9. (epilep$ or seizure$ or convuls$).tw.</P>
<P>10. 7 or 8 or 9</P>
<P>11. (lamotrigine or lamictal).ti,ab.</P>
<P>12. 6 and 10 and 11</P>
<P>13. limit 12 to ed=20120701-20150528</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;14 full-text articles assessed for eligibility + 2 Classification pending&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;96 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;96 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;141 records identified through database searching (carried out 28 May 2015): Epilepsy Specialized Register - 27; CENTRAL - 62; MEDLINE - 50.&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;82 records excluded due to irrelevance&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;14 full-text articles excluded, with reasons: Not RCT (N = 4); Inelegible population (N = 5); No results available (N = 3); No LTG in add-on (N = 1); Not placebo-controlled study (N = 1)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>